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Study aims and objectives 
The aim of this study was to investigate clinical and technical factors that may 
influence patient toxicity and outcome within an oesophageal cancer clinical trial 
dataset. The objectives of the study were: 
 
1. To assess interdepartmental variation in radiotherapy treatment planning 
techniques 
2. Identify clinical factors that may influence radiotherapy treatment outcome 
3. To implement new metrics that may allow quantification of treatment 
planning variation 
4. To incorporate treatment planning variation data, dose data and other 
biological and clinical factors into a multivariate analysis linked with patient 
outcome 
5. To investigate the role of radiotherapy dose escalation in improving patient 
outcome 
6. To identify and explore new metrics that relate patient factors to outcome 
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Abstract 
The work contained within this thesis explores the relationship between clinical and 
technological parameters of radiotherapy treatment planning and patient outcome 
in patients who were treated for cancer of the oesophagus as part of the SCOPE 1 
clinical trial. However the methods and concepts of the work could also have 
applications at other tumour sites.  
By developing ideas from previous studies, a novel method of applying a conformity 
index found a significant relationship between the quality of a radiotherapy plan and 
patient outcome in terms of overall survival. Furthermore it was found that the plan 
quality could be improved by utilising a relatively new method of dose delivery. This 
dose delivery method also allowed the improving of tumour control via dose 
escalation to be explored via radiobiological modelling. The results of this work 
showed that although the probability of controlling the tumour is increased, there is 
also a significantly higher risk of increased gastric toxicity for patients with lower 
oesophageal tumours. Interfraction gastric movement was also investigated with the 
end result being a recommendation for stomach movement and toxicity to be 
minimised by using a pre-treatment protocol. This is being taken forward in a 
nationwide multicentre clinical trial. Finally a texture analysis software package was 
used to investigate whether there was relationship between the image 
heterogeneity parameters of computed tomography images and patient outcome. 
This work could potentially aid the decision making process of radiotherapy 
treatment, allowing a more informed judgement to be made on the most beneficial 
treatment for the patient. 
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Chapter 1 
 
Introduction 
 
1.1 Oesophageal Cancer 
Worldwide, oesophageal cancer is the eighth most common cancer and it has the 
fifth highest mortality rate of any tumour sites (1). The disease can present in two 
main histological sub types, squamous-cell carcinoma, more common in the 
developing world and arises from the skin cells that line the upper and middle third 
of the oesophagus, and adenocarcinoma, which is more common in the developed 
world and arises from glandular cells present in the lower third of the oesophagus. 
The main risk factors associated with squamous cell carcinomas include tobacco 
smoking, alcohol consumption and poor nutrition whilst the main risk factors for 
adenocarcinomas include smoking, obesity and gastroesophageal reflux disease (2). 
The incidence of squamous cell carcinoma in the UK remains stable or is falling whilst 
the incidence of adenocarcinomas affecting the lower oesophagus and gastro-
oesophageal junction has increased substantially over recent decades (3). Where the 
patient remains fit and healthy, surgical resection of the tumour remains the first 
choice of curative therapy. However surgery is only appropriate for 10-20% of the 
patient population and despite low postoperative mortality rates, the long-term 
outcomes from surgical-based treatment due to both systematic relapse and locally 
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advanced disease at presentation remains poor (4). Most patients will therefore 
present with in-operable disease or may not be fit enough to undergo surgery.  
Chemoradiotherapy (CRT), the combination of chemotherapy and radiotherapy, is 
used widely in combination with surgery to try and improve the low survival rates of 
surgery alone. CRT can be combined with surgery both as neoadjuvant, before 
surgery, or adjuvant, after surgery, therapy. Recent studies and trials however have 
shown definitive CRT (dCRT), where chemo-radation is the sole method of 
treatment, is not only more effective than chemotherapy (5) or radiotherapy (6) 
alone in treating oesophageal cancer, but also results in significantly higher overall 
survival rate compared to surgery alone (7) & (8).  
The majority of patients who relapse do so within the previously irradiated area (9) 
(10), with the reported local failure rate in patients treated with CRT being 45-58%. 
Therefore, although radiotherapy undoubtedly does and will continue to play an 
important part in the treatment of oesophageal cancer, it is vital that the delivery of 
radiation to the tumour sites is done in a manner that will maximise the tumour 
control whilst reducing the risk of normal tissue toxicity.  
 
1.2 Radiotherapy 
Radiotherapy, together with surgery and chemotherapy, is one of three main 
modalities used in the treatment of cancer. It uses photons, electrons or ions to 
destroy tumour cells within the body. Ionising radiation in the form of photons and 
electrons has been used in the treatment of patients since the beginning of the 20th 
century, soon after the initial discovery of x-rays. This early treatment mostly 
consisted of either kilovoltage x-ray sets or the application of radium either on or 
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near the lesions on the patient. It was not until 1956 that the first patient was 
treated with a linear accelerator, which uses the high-speed impact of electrons on a 
small piece of high-density material to produce high-energy x-ray photons that can 
be focused to enter a patient. A key step forward was the use of higher energies, 
giving skin sparing for deep seated tumours. However, tight dose distributions are 
needed to spare normal tissue of irradiation, with geometric accuracies of 2-3mm 
required for the delivery of successful treatment plans (11) and dosimetric 
differences of 5-7% known to cause significant changes in tumour control and 
normal tissue (12) & (13).  
Radiotherapy is usually performed as part of a fractionated schedule, in which the 
treatment is spread over a number of days. This is important as it allows both the 
healthy tissue to recover from some unavoidable exposure but also to ensure that 
tumour cells that may have been in the radio-resistant phase of their cell cycles to be 
in the radio-sensitive cycle when the next radiation dose is given (14). Fractionation 
schedules will vary between tumour sites and can also be changed as a result of 
clinical trials in which a particular schedule is found to be more beneficial. 
Clinical trials are an extremely important part of clinical science and research. They 
are essential in evaluating the efficacy of new treatment methods and carefully 
conducted clinical trials are the quickest and safest method of determining whether 
the new treatment should be given to the extended population. Radiotherapy can be 
prescribed to patients either as a stand-alone therapy or as part of a treatment 
schedule that includes chemotherapy. As a result, radiotherapy can be included in a 
clinical trial in two ways; as part of standard care where all patients receive the same 
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radiotherapy schedule, or as the research arm itself, where patients will receive 
different radiotherapy schedules to determine the efficacy of one over the other.  
 
1.3 Radiotherapy in practice 
1.3.1 Measuring the radiotherapy dose 
In order to safely treat a patient it is critical that the dose of radiotherapy 
administered to that patient is quantified. The SI unit for radiotherapy is the Gray 
(Gy), and it is defined as the absorption of one joule of radiation energy by one 
kilogram of matter (1Gy = 1 J/Kg) (15). This standard unit is used to prescribe 
radiotherapy to patients, with the amount of dose prescribed usually dependent on 
the tumour site. 
 
1.3.2 How does radiotherapy work? 
It is the interaction of the x-ray radiation produced for radiotherapy with a patient’s 
tissue that enables radiotherapy to be an effective form of treatment.  
 
  
Figure 1.1 - Schematic of radiation damage to DNA (16) 
 
 
26 
 
Radiation can cause damage either via the indirect or direct route as shown in Figure 
1.1.  
The effects of radiation on tissue can be divided into four phases (17): 
 
1. The physical phase – radiation absorption in tissue leads to ionisation 
(ejection of orbital electrons) and excitation (raising electrons to higher 
energy levels within the atom). 
2. The chemical phase – these damaged atoms and molecules react with other 
cellular components leading to the breakage of chemical bonds and the 
formation of ‘free-radicals’. These free radicals are highly reactive oxygen 
species that go on to interact with the DNA. 
3.  The biological phase – this includes all subsequent processes, beginning with 
enzymatic reactions that act on the residual chemical damage. The vast 
majority of DNA damage is repaired successfully but some lesions fail to 
repair and this leads to cell death. In most tissues, several cell divisions 
may occur prior to cell death. 
4. The clinical phase – this covers the clinical effects of the delivered radiation. 
Tumour effects are thought to be generally due to cell death caused 
directly by DNA damage, although indirect effects such as reduction of 
tumour vascularity or enhanced immune recognition may also be 
important. Normal tissue effects may be acute due to direct cell death to 
mucosal surface or late, thought to be due to indirect effects on the 
vasculature or on the stem cell component, reducing the capacity to 
 
 
27 
repair future damage. Radiation is also potentially carcinogenic and there 
is a risk of radiation-induced second malignancies, especially in younger 
patients and those expected to live a further 10 years. 
 
The maximum radiation dose that can be tolerated at any given tumour site within 
an individual is largely unknown. This is mostly due to the difficulty of carrying out 
studies that are not limited by the toxicity of the surrounding normal tissue. As a 
result, the commonly accepted maximum doses that are prescribed to any particular 
area have been derived empirically during the history of radiation therapy and these 
will be based on limited retrospective data and clinical observations. There are 
published guidelines that have been used as reasonable estimates of the risk of 
developing a particular toxicity (18), however these are based on small populations 
of patients, treated with out-dated techniques.  A major consideration when 
prescribing radiation to patients is the type of tissue exposed and the impact of 
uncontrolled cancer, as this may influence the decision on how much radiation is 
necessary and tolerable. For example in some tissues such as the lung, quite a lot of 
damage after irradiation may be acceptable if the probability of tumour control is 
reasonably high. However, the consequences of a high dose to the central nervous 
system can be severe, and it must therefore be tailored to minimise the likelihood of 
damage. 
 
1.3.3 The linear accelerator 
Linear accelerators are the most widely used machine for producing x-rays in a 
radiotherapy department. The megavoltage x-rays are produced by the deceleration 
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of electrons in a tungsten target and the energy spectrum of the photons will be 
determined by the electron energy, target and filter composition. Electrons 
produced by an electron gun are accelerated up to relativistic velocities along a 
waveguide by a magnetic field generated by microwaves. The microwaves are 
produced in either a klystron or magnetron. Typically electrons will enter the 
waveguide at around 0.4c and will leave having been accelerated up to 0.995c 
(where c = speed of light). It is important that the electron beam is steered so that it 
enters and leaves the waveguide correctly, and that it also strikes the target or 
scattering foil in such a way that it creates the required high quality beam. There are 
therefore usually two steering coils either side of the waveguide and then a bending 
magnet in order to focus the beam on to the target. 
Electrons lose their energy as they pass through the target via three primary 
interaction mechanisms, the most important of which for the production of clinically 
useable x-ray photons is the bremsstrahlung mechanism. Bremsstrahlung X rays 
result from Coulomb interactions between the incident electron and the nuclei of 
the target material. During the Coulomb interaction between the incident electron 
and the nucleus, the incident electron is decelerated and loses part of its kinetic 
energy in the form of bremsstrahlung photons. A range of photon energies is 
produced, with the maximum energy being equal to the energy of the electrons 
incident on the target. However the x-rays are transmitted in a very non-uniform 
beam that is unsatisfactory for x-ray therapy. The beam is therefore passed through 
a flattening filter, which will produce a flat x-ray beam at a certain depth, usually 5 or 
10cm, in water.  
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Fig 1.2 – Schematic of linear accelerator head for (a) photon beam treatment (b) electron beam 
treatment (19) 
 
After the flattening filter the beam will move through an ionisation chamber to 
measure the dose output of the linac followed by a set of collimators to shape the 
beam (see Figure 1.2). A set of primary collimators determines the maximum field 
size, usually (40×40)cm2 at the isocentre with secondary collimators then being used 
to define the photon beam as required. The secondary collimators can also be used 
to provide an enhanced dynamic wedge. In this mode the collimator is driven across 
the field whilst the beam is still on, mimicking the effect of placing a metal wedge 
block in the beam.  
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Fig 1.3 – Graphic of linear accelerator head (20) 
 
Most modern Linacs will also have a set of Multi Leaf Collimators (MLCs) to further 
collimate the beam (See Figure 1.3). These are independent blades that are in a set 
either side of the beam. They can be moved independently and by utilising these 
millimetres wide adjustable metal leaves close to the point at which the x-rays are 
generated, they allow the beam of x-rays to be shaped and focused to a high degree, 
thereby improving the precision at which the dose to the patient can be delivered. 
 
Dose delivery techniques 
Initially, the only way to conform the radiation beam created from a linear 
accelerator to the required treatment area or volume on the patient was by utilising 
the secondary collimators, blocks and wedges. However the addition of the MLCs to 
most modern day linear accelerators has resulted in the advent of more advanced 
MLC position 
Steering coils 
Waveguide 
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dose delivery techniques such as 3D conformal radiotherapy (3D-CRT), intensity 
modulated radiotherapy (IMRT) and volume modulated arc therapy (VMAT).  
 
3D-CRT 
 In essence this type of radiotherapy delivery is simply the utilisation of all the 
available ‘blocking’ tools in the linear accelerator. Before the MLC, radiotherapy 
would be administered by trying to simply match the height and width of the tumour 
within the patient. In fact, the earliest linear accelerators would administer 
radiotherapy treatments with only a relatively low quality x-ray to guide the 
oncologist and physicist as to the location and size of the tumour.  The MLC, 
together with Computed Tomography (CT) based imaging, allows a much better 
match to be made between the shape of the tumour and the x-ray field delivered 
from the linac, hence the term ‘conformal’. Typically administered using 2-5 beams, 
3D-CRT is still used widely to treat breast, lung, rectum and oesophageal tumours. 
 
IMRT 
As the name implies, this method allows the user to modulate the intensity of each 
radiation beam. This results in each field having areas of high and low intensity (or 
fluence) within the same field, allowing for a greater degree of control of the dose 
distribution within the target. By modulating the fluence across some or all of the 
fields, the high dose volume created by the superposition of the beams can have 
areas of convexity. Treatment would therefore be planned so that the area of high 
dose wraps around the tumour, and by arranging the areas of normal tissue within 
 
 
32 
the convex areas, it allows them to receive a relatively lower dose to that of the 
tumour.  
 
 
 
Figure 1.4 – Illustrating the principles of IMRT (21) 
 
Figure 1.4 is an illustration of the principles of IMRT, in this case when treating the 
prostate. It can be seen how the prostate has a concave outline and how the use of 
modulated fluence on each beam allows the high dose area to be sculpted around 
the rectum and bladder, both of which should ideally receive as little dose as 
possible. IMRT treatments will generally use a larger number of beams than 3D-CRT 
with 9 sometimes being used for some tumours located in the head and neck region 
where there are many sensitive organs to consider. 
 
VMAT 
The basic concept of arc therapy is the delivery of radiation from a continuous 
rotation of the radiation source and allows the patient to be treated from a full 360o 
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angle (22). Essentially an alternative form of IMRT, VMAT is an extremely conformal 
form of radiotherapy administration, and allows the simultaneous variation of three 
parameters during treatment delivery i.e. gantry rotation speed, treatment aperture 
shape and dose rate. Another major advantage of VMAT is the improvement in 
treatment delivery time as a result of treatment being delivered faster in a 
continuous arc compared to multiple stationary beam positions (23). 
 
1.4 Treatment planning 
Successful radiotherapy delivery depends on the patient receiving a high dose of 
radiation to the tumour cells whilst ensuring that sensitive healthy cells nearby do 
not receive the same dose. It is therefore imperative that any dose delivered to the 
patient is done so in a manner that will meet this clinical objective. As a result, an 
essential part of radiotherapy treatment is the planning of the dose delivery. Each 
treatment plan must be individually designed for each patient taking into account 
the location of the tumour and their individual anatomy. The plans are prepared on 
specific computer software that model the behaviour of the treatment machine and 
simulate the effect of the applied radiation fields within the patient, thereby giving 
the clinical and physics staff the best possible approximation of the treatment 
delivery. Plans are generated on diagnostic quality computed tomography (CT) 
images acquired for each patient. These are used to both visually deduce the area 
where treatment is required and to correct for tissue inhomogeneities by quantifying 
the relationship between CT Hounsfield units and electron densities (24).  When 
designing the radiation therapy fields, the clinical and physics staff must take into 
account several important biological and technical factors (25). These include: likely 
 
 
34 
patterns of regional tumour spread, to ensure coverage of local tumour extensions 
not detectable with current imaging techniques; uncertainties in positioning the 
patient for each treatment; and tumour and organ movement during and between 
treatments. In order to accurately and safely plan the delivery and take into account 
these factors amongst other there are specific structures that will be created in each 
treatment plan. 
 
1.4.1 Target volumes 
Target volumes are used when planning to outline any relevant volumes within the 
patient that should be taken into consideration when administering dose. The 
International Commission on Radiation Units and Measurements (ICRU) reports 50 
and 62 give specific definitions of volumes to which the dose should be restricted as 
well as those in which it should be maximised. These are shown in Figure 1.5  
 
 
Figure 1.5 – Schematic of treatment volumes 
 
Gross Tumour Volume 
Clinical Target Volume 
Planning Target Volume 
Treated Volume 
Irradiated Volume 
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Gross Tumour Volume (GTV) 
The GTV is defined as ‘The gross palpable or visible/demonstrable extent and 
location of malignant growth’. Clinical examination, imaging or both can determine 
the size and extent of the GTV.  
 
Clinical Target Volume (CTV) 
The CTV is defined as ‘A tissue volume that contains a demonstrable GTV and/or 
subclinical microscopic malignant disease, which has to be eliminated. This volume 
thus has to be treated adequately in order to achieve the aim of the radiotherapy, 
cure or palliation.’ This margin is added to the GTV but can also be created without a 
GTV present should the original tumour have been removed.  
 
Planning Treatment Volume (PTV) 
The PTV is defined as ‘A geometrical concept used for treatment planning, and it is 
defined to select appropriate beam sizes and beam arrangements, to ensure that the 
prescribed dose is actually delivered to the CTV.’ A margin is added to the CTV 
primarily to account for uncertainties that arise as a result of patient movement and 
set up errors within the CTV. Specifically, an Internal Margin (IM) accounts for 
movement of the CTV with respect to the internal or external reference points used 
for aligning patients, and a Set-up Margin (SM) accounts for uncertainty in the 
position of the beam relative to the reference points/structures on the patient. 
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Treated Volume (TV) 
The treated volume is defined as ‘The volume enclosed by an isodose surface, 
selected and specified by the radiation oncologist as being appropriate to achieve the 
purpose of treatment.’  The TV is the volume that is receiving dose in order to ensure 
that the PTV receives the required dose. It is a region enclosed by the 95% isodose 
line on the treatment plan.  
 
Irradiated volume (IV) 
The irradiated volume is defined as ‘The tissue volume which receives a dose that is 
considered significant in relation to normal tissue tolerance.’ This volume should be 
kept as small as possible in order to minimise the damage to normal tissue. 
 
Organs At Risk (OAR) 
‘Normal tissues whose radiation sensitivity may significantly influence treatment 
planning and/or dose.’  These are specific organs that due to their location, function 
and radiosensitivity will have an influence on how the tumour volume is treated. 
They are usually contoured within the Treatment Planning System (TPS) and will 
have specific dose constraints dependent on the particular organ. An additional 
volume known as the Planning Organ at Risk Volume (PRV) is also used. This is a 
margin added to the OAR to account for movements and changes in shape and/or 
size of the OAR, as well as set-up uncertainties.   
 
For a more extensive description of the target volumes and OARs relevant to this 
thesis, please refer to appendix A2 Sections 3 and 4. 
 
 
37 
1.4.2 Dose analysis and homogeneity 
When the necessary structures and OARs have been outlined, the dose can be 
calculated and optimised. There are important considerations that should be met to 
ensure that the plan is optimal, both in terms of delivering dose to the tumour and 
sparing normal tissue. Although the distribution of the dose in the plan can be 
visualised on the CT images using isodose lines, the most common method of 
quantifying the distribution is by using a Dose Volume Histogram (DVH). 
 
Dose Volume Histogram – A DVH is a histogram relating radiation dose to tissue 
volume (26). They are extensively used in treatment planning to graphically 
summarize the radiation distribution within a volume of interest that would result 
from a proposed radiation treatment plan.   They can also be used as input to 
modelling techniques such as Tumour Control Probability (TCP) and Normal Tissue 
Complication Probability (NTCP) (see Section 4.1).   
 
Within the PTV – It is aimed that 99% of the PTV volume receives 95% of the 
dose. Analysing the DVH can ensure this is met. The dose within PTV should 
also be made to be as homogeneous as possible, following the -5% and +7% 
homogeneity as set out in ICRU 50. 
 
Outside the PTV – Areas outside the PTV that have a minimum diameter of 
15mm and exceed the prescribed dose are known as ‘hot spots’. They should 
be minimised as much as possible. 
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Maximum Dose (Dmax) – This is the maximum dose to a volume of 1.8cc and 
should not exceed 107% within the PTV. 
 
1.4.3 Treatment plan optimisation 
As mentioned, an objective of successful radiotherapy treatment is the delivery of a 
high dose to the tumour whilst minimising dose to healthy tissue. In order to achieve 
this, a patient will usually be irradiated from several directions with beams that 
overlap at the tumour site to maximise the dose relative to the surrounding area. 
There are two main sets of parameters that require configuration in radiotherapy 
planning; the directions from which to irradiate the patient and the shapes and 
intensity profiles of the beams. Optimising these parameters is a significant 
mathematical challenge using complex algorithms and techniques that are 
automated using computer programs. Although these will usually be carried out 
using specific radiotherapy planning software with a graphical interface that makes 
the implementation of these techniques relatively easy, it is still essential that the 
user have a good understanding of the underlying methods in which a radiotherapy 
plan is designed and implemented.   
 
There are two types of radiation treatment planning process; forward planning and 
inverse planning (27). In forward planning, plans are constructed largely using a trial 
and error method, albeit one utilising the knowledge and experience of the planner. 
In a clinical setting, the initial stages of a standard radiotherapy plan will follow a pre 
determined set of beam arrangements that have been developed to provide a good 
starting point. The plan can therefore be improved by following an iterative process 
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where the user will adjust numerous parameters, re-calculate the dose and repeat 
until they are confident that the optimal plan for that patient has been generated. 
Although this process is used widely in clinical practice, it is generally very time 
consuming and does not necessarily create the best plans. This may be due to the 
lack of the planner’s experience and knowledge or from time constraints before the 
plan has to be reviewed by an oncologist and delivered.  
Due to considerable advances in technology, both computational and engineering, a 
new method of planning known as inverse planning is now becoming more 
widespread. In contrast to forward planning, where a plan will be generated and 
dose objectives to selected structures and OARs are taken into consideration 
towards the end of the planning process, the inverse planning process begins with 
specific dose objectives and constraints relating to the relative importance of each 
structure. An optimisation process is then run within the treatment planning system 
to find the treatment plan which best matches all the input criteria.  
 
Two treatment planning systems are used extensively in this investigation. These are 
Oncentra MasterPlan (OMP) (Elekta AB, Stockholm, Sweden), and Eclipse (Varian, 
Palo Alto, USA).  
 
1.5 Statistical analysis 
The nature of this whole study requires various statistical tests to be conducted. This 
section gives a brief introduction to all the tests used within this thesis. 
 
 
 
40 
1.5.1 Mann-Whitney U test 
The Mann-Whitney U test is essentially a test for assessing whether two 
independent samples come from the same distribution. For example, a possible use 
would be to test whether the toxicity values of a set of patients are dependent on 
the gender of the patients. The logic behind the test is to rank the data for each 
condition, and then see how different the two rank totals are. If there is a systematic 
difference between the two conditions, then most of the high ranks will belong to 
one condition and most of the low rank will belong to the other. As a result, the rank 
total will be different. A p value is calculated to inform whether this difference is 
significant. 
 
1.5.2 Kaplan-Meier plots and the log-rank test 
The Kaplan-Meier method combined with the logrank test is the most commonly 
used method for displaying and statistically testing the comparison in survival 
distributions of two or more groups.  
 
In analysing survival data, two functions that are dependent on time are of particular 
interest: the survival function and the hazard function (28). The survival function S(t) 
is defined as the probability of surviving at least to time t. The hazard function h(t) is 
the conditional probability of dying at time t having survived to that time. Plotting 
S(t) against t results in a survival curve and the Kaplan-Meier method can be used to 
estimate this curve from the observed survival times. The method is based on the 
idea that the probability of surviving k or more periods from entering the study is a 
product of the k observed survival rates for each period, given by 
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S(k)= p1´ p2 ´ p3 ´...´ pk  (1.0) 
 
Where p1 is the proportion surviving the first period, p2 the proportion surviving the 
second period etc.  
To plot a Kaplan-Meier curve the survival times, including the censored values 
(indicating missing data), must be ordered in increasing duration. Plotting the 
cumulative proportion surviving against the survival times then gives the stepped 
survival curve as seen in any Kaplan-Meier plot. 
 
The log rank test is used to test the null hypothesis that there is no difference 
between the groups in the probability of an event (usually death) at any time point. 
The test statistic is calculated as follows: 
 
x2 logrank( ) =
O1 -E1( )
E1
2
+
O2 -E2( )
2
E2
 (1.1) 
 
where the O1 and O2 are the total numbers of observed events in groups 1 and 2, 
respectively, and E1 and E2 the total numbers of expected events. The test is widely 
used however it does not allow other explanatory variables to be taken into account. 
In these instances the Cox proportional hazard test should be used. 
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1.5.3 Cox proportional hazard 
The Cox proportional hazard enables the difference between survival times of 
particular groups of patients to be tested whilst allowing for other explanatory 
factors. In this model, the response (dependent) variable is the ‘hazard’. The hazard 
is the probability of dying (or experiencing the event in question) given that the 
patients have survived up to a given point in time, or the risk for death at that 
moment. The hazard ratio calculated in the cox model does not depend on time, as it 
is assumed that if the risk of dying at a particular point in time in one group is for 
example twice that in the other group, then at any other time it will still be twice 
that in the other group. The hazard ratio is therefore a method of quantifying the 
difference between two groups. 
 
1.6 Clinical trials 
A clinical trial is a research study done to evaluate new treatments. They are 
essential in growing our understanding of potential new treatment methods and can 
be considered gateways through which these new treatment methods become the 
standard method of care. Not only do they allow us to test the efficacy of new 
protocols but also to test existing protocols that may be being applied in a different 
setting under new circumstances. If a particular protocol is found to be successful 
there is a high probability that it may become standard procedure, especially if the 
positive outcome can be confirmed via other clinical trials. However, whether the 
protocol is new or that the trial is re examining an existing one, it is essential that 
there should be precise, thorough and systematic evaluation of the protocol being 
tested. If the protocol is well designed and followed precisely by everyone involved, 
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the resulting data will be a true representation of the patient cohort included. 
Although clinical trials aren’t the only form of research in which new treatment 
methods can be implemented, their ability to provide high quality evidence based 
conclusions from often large databases means that they are considered the gold 
standard of clinical study.   
A clinical trial will be conducted to answer a specific question and to address a 
specific hypothesis. It is therefore imperative that the hypothesis is clear, well 
thought out and preferably backed by scientific theory or evidence. It is also 
important that the data or evidence produced by the trial is adequate in answering 
the initial question. If this is achieved, then the trial will be able to show that the 
clinical protocol alone was responsible for the observed results, which is the main 
aim of any trial. Trial design is therefore potentially extremely complex, requiring a 
large amount of scientific understanding and rigour. In addition, they can be 
expensive to run and often require external funding and specific teams or 
institutions to run them. Clinical trials of the highest quality, where data are acquired 
over a number of years are therefore a specialised undertaking. As a result there are 
institutions where their sole undertaking is the preparation, organisation and 
analysis of trial data. In the case of this thesis and the investigation included within it 
using the SCOPE 1 trial data, this institution was the Wales Cancer Trials Unit (WCTU) 
based within Cardiff University. WCTU is responsible for running a number of clinical 
trials within the UK and provided me with the data from the SCOPE 1 trial in order to 
conduct the investigations within this thesis. 
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1.6.1 Phases of a clinical trial 
 
Phase I Phase II Phase III Phase IV 
Number of 
participants 
20-80 100-300 1000-3000 1000+ 
Time Up to several months 
Up to 2 
years 
1-4 years 1+ years 
Purpose 
Studies the safety of 
medication/treatment 
Studies the 
efficacy 
Studies 
the safety, 
efficacy 
and 
dosing 
Studies the 
long term 
effectiveness 
Phase 
Success Rate 
70% 33% 25-30% 70-90% 
Table 1.0 – Outline of typical phases of clinical trials 
 
Table 1.0 shows the typical phases within a clinical trial. Trials can be split into 4 
main phases: 
 
Phase I: Researchers test a new drug or treatment in a small group of people for the 
first time to evaluate its safety, determine a safe dosage range, and identify side 
effects. 
 
Phase II: The drug or treatment is given to a larger group of people to see if it has 
some level of efficacy and to further evaluate its safety. 
 
Phase III: The drug or treatment is given to large groups of people to confirm its 
effectiveness, monitor side effects, compare it to commonly used treatments, and 
collect information that will allow the drug or treatment to be used safely. 
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Phase IV: These studies are done after the drug or treatment has been marketed to 
gather information on the drug’s effect in various populations and any side effects 
associated with long-term use. 
 
Due to the stringent requirements of clinical trials and the analysis of the data they 
produce, many will not reach phase III and IV. It is only when the efficacy of the new 
drug or technique is proved that the trial may move on to the next phase. Indeed, 
trials may also be stopped mid phase if the incoming results show that it would be 
un-ethical to proceed.  
 
1.7 The SCOPE 1 clinical trial 
The SCOPE 1 trial was a National Cancer Research Institute and Cancer Research UK 
funded Phase II/III two arm trial of dCRT with and without cetuximab in oesophageal 
cancer (29). See Figure 1.6 for a schematic of the trial. 
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Figure 1.6 – Schematic of SCOPE 1 clinical trial 
 
Cetuximab is a monoclonal antibody and epidermal growth factor receptor (EGFR) 
inhibitor that has been shown to prevent radiotherapy induced growth stimulation. 
For example Bonner et al reported improved local control and overall survival in the 
Patients with oesophageal carcinoma chosen 
to receive definitive chemo-radiation 
Consent prior to randomisation 
RANDOMISE 
Arm A (Control Arm) 
n=210 
 
Cisplatin 
+ 
Capecitabine 
Arm B (Research Arm) 
n=210 
 
Cisplatin 
+ 
Capecitabine 
+ 
Cetuximab 
Cisplatin 
+ 
Capecitabine 
 
 
+ 
5 weeks Conformal 
Radiotherapy 
Cisplatin 
+ 
Capecitabine 
+ 
Cetuximab 
+ 
5 weeks Conformal 
Radiotherapy 
Endoscopic assessment, biopsy and CT scan 
FOLLOW UP: Every 3 months during 1st year, 4 monthly during 
2nd year and yearly thereafter for a minimum of 5 years from 
randomisation 
 
isation. 
Weeks 
1-6 
Weeks 
7-12 
Week 
24 
 
 
47 
cetuximab arm of a trial of 424 randomised patients receiving 70-76.8Gy of 
radiotherapy for locally advanced squamous cell carcinoma of the head and neck 
(30). However, although head and neck cancer is a disease with many similarities to 
oesophageal cancer, the results of the SCOPE 1 trial were not as positive in terms of 
cetuximab administration.  258 patients were recruited from 36 UK centres between 
February 7, 2008 and February 22, 2012 with patients being randomly assigned via a 
central computerised system using stratified minimisation to receive CRT alone or 
CRT with cetuximab (see Figure 1.6). CRT consisted of cisplatin 60mg/m2 (day 1) and 
capecitabine 625mg/m2 twice daily (days 1-21) for four cycles with cycles three and 
four being given concurrently with 50Gy in 25 fractions of radiotherapy. The primary 
endpoint was the proportion of patients who were treatment failure free at week 24 
for the phase 2 trial and overall survival for the phase 3 trial. The results showed that 
the 24 week failure free survival was significantly better in the CRT only arm 
compared to the CRT plus cetuximab arm (76.9% (90% confidence interval 69.7-83.0) 
vs 66.4% (58.6-73.6)). The CRT plus cetuximab group also had shorter median overall 
survival (22.1 months (95% confidence interval 15.1-24.5) vs 25.4 months (20.5-
37.9)). However, despite this, the trial showed relatively low rates of acute and late 
toxicity (defined according to CTCAE grading) and the two year overall survival was 
56% in the control arm, higher than previously published studies.  
 
1.8 Relating radiotherapy treatment to outcome 
Whether the aim of treatment is curative or palliative, it is clear that the purpose of 
radiotherapy is to improve the well being of patients. Depending on the condition 
and health of a patient, a course of radiotherapy treatment will be prescribed that to 
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the best knowledge of the clinical staff is most likely to achieve the desired outcome. 
With the now widespread use of three-dimensional (3D) treatment planning, 
volumetric-based radiotherapy datasets that can be used to directly relate treatment 
to outcome are becoming increasingly available (31). However with so many 
variables and factors both clinical and technological involved in radiotherapy 
treatment, the analysis of these datasets quickly becomes complex. Yet the ability to 
utilise these datasets and further our knowledge of the relationship between 
treatment factors and outcome has the potential to greatly enhance the treatment 
of cancer. Importantly, this may open the way for patient-specific, individualised 
treatment planning decisions based on estimates of the risks of complications vs 
increases in local control (32). This type of highly individualised treatment however 
can only be achieved by validating predictions against relevant outcome datasets 
(33).  
 
Broadly speaking, the relating of treatment to outcome falls into two fields; a.) the 
correlation of patient and treatment factors to toxicity and outcome via statistical 
tests, and b.) the approximation of toxicity and tumour control resulting from 
treatment via radiobiological modelling. There is a significant amount of work in the 
literature in both these fields. The correlation of treatment and predictive factors to 
outcome via statistical testing is mostly concentrated on the retrospective analysis of 
clinical data sets, and these studies have been carried out on a wide number of 
tumour sites. The type of patient specific predicting factor that is investigated also 
varies widely and have increased in number in recent years due to progress in 
genetics and imaging technology (34). They include predictors such as tumour length 
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((35)-(36)) and volume (37) and the number of counted metastasis (38), variations in 
treatment administration that may increase toxicity (39), metabolic imaging (40) and 
dosimetric predictors (41).  El Naqa (31, 33, 42-46) together with Deasy (47-50) have 
made a significant contribution to both these fields and their work in multivariable 
modelling of radiotherapy outcomes (33) in particular was important.  
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Chapter 2 
 
 
Database and software preparation 
 
 
2.1 Clinical data management 
Clinical data management (CDM) is an essential part of any clinical trial. CDM is the 
process of collection, cleaning, and management of subject data in compliance with 
regulatory standards. The process should start with the end goal in mind and 
conducted correctly, it leads to generation of high-quality, reliable, and statistically 
sound data (51). The main objective is keeping the amount of errors and missing 
data to a minimum, therefore maximising the amount of analysable data (52). If this 
objective is achieved, the main research question posed by the clinical trial will be 
answerable. High quality data should be accurate and be ready for statistical 
analysis. It should be decided from the outset what to do with any data that deviates 
from the initial protocol. It may be decided to exclude all such data or that there is a 
set number or value of allowed deviations before they are excluded. Although it is 
important to maximise the amount of analysable data within the database, it is also 
important that these data are consistent and that any deviations from the protocol 
will not affect the statistical outcome of the original research question. The inclusion 
or exclusion of these patients should therefore be given serious consideration in 
every clinical trial.  
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2.2 Data preparation in the SCOPE 1 analysis 
The main data set for this thesis was the result of a nationwide clinical trial of the 
effect of including cetuximab in the chemotherapy regimen of dCRT for oesophageal 
cancer. Named ‘SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal 
cancer plus or minus cetuximab.’, the trial data were collated and organised by 
WCTU.  
 
2.2.1 Radiotherapy trial data 
The radiotherapy planning data were stored on a network drive in the exact format 
in which it was received from the Radiotherapy centres participating in the trial. 
Depending on the centre from which the data were received this was either in Digital 
Imaging and Communications in Medicine (DICOM) (53) or Radiation Therapy 
Oncology Group (RTOG) format (54), both of which are standard for handling, storing 
and transmitting information in medical imaging. In order to use these data within 
the Matlab based programs in which most of the analysis would be undertaken, it 
was required that all the DICOM and RTOG data be converted into Matlab files 
(.mat). This was carried out for the entire database using the ‘import’ function within 
the Computational Environment for Radiotherapy Research (CERR) program and 
saving each case into a separate folder. 
 
DICOM data format 
DICOM is a standard for handling, storing, printing and transmitting information in 
medical imaging. It is used in all modern medical imaging systems like x-rays, 
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ultrasound, CT and Magnetic Resonance Imaging (MRI). The core of DICOM is a file 
format and networking protocol: 
 
DICOM file format: DICOM files contain more than just images. Every DICOM 
file holds patient information (name, ID, sex and birth date), important 
acquisition data (type of equipment used and its settings), and context of the 
imaging study that is used to link the image to the medical treatment it was 
part of. 
 
DICOM network protocol: All medical imaging application that are connected 
to the hospital network use the DICOM protocol to exchange information, 
mainly images but also patient and procedure information. The network 
protocol is used to search for imaging studies in the archive and restore 
imaging studies to the workstation in order to display it. More advanced 
network commands are also available to control and follow the treatment 
schedule procedures, report statuses and share the workload between 
imaging devices.  
 
Uniform data 
It is becoming increasingly apparent that there is a need for a standardised naming 
convention in radiation oncology in order to facilitate comparison of dosimetry 
across patient datasets (55). This is important, as variations can lead to confusion 
when analysing datasets, where the analysis of the correct information is critical. 
Although the SCOPE 1 trial required a radiotherapy plan to be made for each patient, 
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and the analysis of these plans was known from the outset, there was no naming 
convention for the essential SCOPE 1 structures and dose sets decided upon when 
the trial started.  As there were 34 centres involved in the trial, with each centre and 
potentially each individual radiotherapy planner within each centre having a 
different method of naming each structure and dose set, they were originally not 
uniformly named across the database. In order for the data analysis within Matlab to 
work successfully, it was essential that the same structures and dose sets from one 
patient to the next across the data database were named exactly the same.  
 
Structure naming 
The first task was therefore ensuring that the names of each structure with the 
radiotherapy plans were uniform across the database.  
 
 
 
 
 
Figure 2.1 – Gold Standard structure naming 
Structures 
GTV 
PTV 
CTV A 
CTV B 
Heart  
Rt Lung 
Lt Lung 
Cord 
Cord PRV 
Liver 
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It was decided that all patients have their structures named according to the SCOPE 
1 protocol. An example is shown in Figure 2.1 showing the treatment plan and 
structures of a Velindre Cancer Centre patient (this particular patient was used as 
the ‘Gold Standard’ in terms of naming structures). Figure 2.2 shows an example of a 
patient file with the structure names as they were received from another centre 
participating in the trial. There were 34 separate structures that required identifying 
and renaming. 
 
 
Figure 2.2 – Example of non-uniform naming of patient structures 
 
All 207 patients in the database were uniformed by individually loading each patient 
into the CERR program and utilising the ‘renaming’ function to rename all structures 
as required. In some instances there were multiple version of the same structure 
with slight variations in name (as shown in figure above). Which version of the 
Structures 
CTV A 
GTV-KG 
Both Lung 
Lungs-PTV 
Lungs-GTV 
SC 
SC+0.5 
Body 
Contrast 
AAC GTV 
AAC GTV +2 
AAC CTV 
HEART 
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structure to use for analysis was discussed with a member of the original 
Radiotherapy Trial Quality Assurance (RTTQA) team from the SCOPE 1 trial. In order 
to ensure that uniformity across the database had been achieved, a Matlab script 
was written that exported the name of each structure attributed to each patient 
kept within a specific folder on the computer’s hard drive. Viewing this information 
in an excel spreadsheet allowed all the structures to be analysed simultaneously and 
any corrections made quickly. 
 
Uniform dose structure 
The DICOM format stores dose information in an RTDose file. However, for a 
complete patient plan, the number of RTDose files included can vary depending on 
the export method used by the treatment planner on the specific treatment planning 
system in use at their centre. As a result, there were some patients in the database 
that had multiple dose files (one for each beam position), and some with one dose 
file (containing the dose information for all the beam positions combined). 
Furthermore, the combined dose value for the beams were in some instances the 
full dose over the course of the treatment (i.e. 50Gy) where as in some patients the 
combined dose would be normalised to 1Gy per fraction. Using the dose 
management tools available in CERR it was ensured that the dose values for the 
entire patient database were uniform in nature. For manipulation of the dose 
information at a later date it was important that the names of the dose files were 
uniform, the dose files created for each patient were therefore all named 
‘Dose_Sum’.  
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2.2.2 Outcome data preparation 
The WCTU is responsible for collating all the data that are generated within the 
SCOPE 1 trial, and this includes the toxicity and outcome data. These data is 
collected via Case Report Forms (CRF) that are filled in by the Doctor or Nurse 
examining the patient at the centre where they are receiving treatment. Baseline 
assessments include overall length of tumour and stage. The Common Terminology 
Criteria for Adverse Events (CTCAE) system is used to report toxicities and include 
pulmonary, gastrointestinal and vascular disease. Recorded grade 3 and 4 toxicity 
rates in the SCOPE 1 trial were very low. This made any meaningful analysis of this 
data statistically unsound therefore it is not explored in this thesis. 
CRFs were completed at baseline, at end of treatment, and followed up at months 6, 
9, 12, 16, 20, 24, 36, 48, and 60. A substantial amount of data were therefore 
recorded that required cleaning up and formatting. For ease of use it was requested 
that the data were received from WCTU in Microsoft Excel format, this would also 
allow easy integration into the EUCLID software for analysis.  
An important part of this process was matching the outcome database to the 
radiotherapy database, i.e. making sure that a patient’s radiotherapy plan had the 
same identification number as that referred to in the outcome dataset.  
The survival time was calculated in days from when the patient’s treatment finished 
to their death date using a formula in Excel. 
There was also a large amount of data included in the outcome database on which 
analysis would not take place therefore these were removed. 
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2.3 Testing the data pathway 
With the data uniform and formatted as required, an important next step was 
testing the data pathway. This consisted of taking the raw DICOM/RTOG data as 
received from the centres, importing into CERR, creating a test database of 
information within EUCLID (including dose and outcome data) and producing end 
results such as Kaplan Meier and Dose Volume Histogram plots. Testing this process 
on a small test database would minimise problems that may arise when dealing with 
the full clinical database. 
 
Computational Environment for Radiotherapy Research (CERR) 
CERR is a software platform for developing and sharing research results in radiation 
therapy treatment planning (57). The software package, based in Matlab, addresses 
four broad needs in treatment planning research 
a. It provides a convenient and powerful software environment to develop and 
prototype treatment planning concepts 
b. It serves as a software integration environment to combine treatment 
planning software written in multiple languages (e.g. Matlab, Java etc), 
together with treatment plan information (CT scans, outlines structures, 
dose distributions) 
c. It provides the ability to extract and analyse treatment plans from disparate 
treatment planning systems  
d. It provides a convenient and powerful tool for sharing and reproducing 
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treatment planning research results 
 
CERR data format: PlanC 
All treatment plan information is contained in a Matlab cell-array named planC. The 
different cells of the planC cell array contain data objects according to the value of 
the structure indexS. They are as follows: 
indexS.header = 1; 
indexS.comment = 2; 
indexS.scan = 3; 
indexS.structures = 4; 
indexS.structuresArray = 5; 
indexS.beamGeometry = 6; 
indexS.dose = 7; 
indexS.DVH = 8; 
indexS.digital Film = 9; 
indexS.CERROptions = 10; 
indexS.indexS = 11; 
This means that the scan information is all contained in the 3rd element of the scan, 
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the dose information is all contained in the 7th element, etc. 
 
EUCLID 
EUCLID is an outcome analysis tool developed to be used by radiation oncologists 
and medical physicists (58). The software package, based in Matlab, can provide a 
fast statistical snapshot of a population and perform univariate, multivariate and 
dose-volume analysis on a large data set with a large number of physiological, 
clinical, biological and dosimetric factors. An advantage of EUCLID is its capability of 
importing clinical information in Excel spreadsheet format. Figure 2.3 shows a 
spreadsheet that was created in order to test the data pathway and the type of 
information that can be included. (note - the information contained within the 
spreadsheet is not clinically accurate and is purely for demonstrating purposes). 
 
Figure 2.3 – Spreadsheet for testing of data pathway 
 
The data contained within the Excel spreadsheet is then saved in a Matlab file format 
specific to EUCLID, which can be opened to give the options for analysis.  
 
 
 
60 
 
Figure 2.4 – EUCLID interface 
 
It was decided to simulate the analysis of the development of radiation induced 
pneumonitis as a result of the dose received by the lungs.  The appropriate variables 
were chosen for the input as clinical and outcome factors and the lung dose 
information imported for each patient, allowing the V20, V30 and mean-dose to be 
analysed (Figure 2.4). The user is then given the option of the type of statistical 
analysis to be carried out on the data (Figure 2.5).  
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Figure 2.5 – Statistical analysis options in EUCLID 
A DVH analysis was generated dependent on pneumonitis grade (Figure 2.6). 
 
Figure 2.6 – Test DVH analysis with pneumonitis grade 
 
A Kaplan-Meier curve was plotted showing overall survival time and Lung V30 with 
the best cut off in terms of low p-value (Figure 2.7).  
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Figure 2.7 – Test Kaplan Meier split by Lung V30 values 
 
Although the data produced here are not clinically relevant, the data pathway was 
shown to be successful. As a result, the process of importing data from the centres 
and the analysis of these data could be widened to include the whole SCOPE 1 data 
set using this method. 
 
2.4 Program and script development 
Another aspect of the project is program and script development. The majority of 
this thesis’s data preparation and analysis was undertaken in programs based within 
the Matlab environment, namely CERR and EUCLID. Although these programs are 
published in the literature, can be thought of as finished and fully working packages, 
and in the case of CERR have a strong and wide ranging user community, the fact 
that they are open source and written in the Matlab environment also allow for a 
large degree of customisation. The code within these programs, especially CERR, can 
also be utilised and customised to undertake tasks outside of the program itself. 
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Along with introducing and explaining Matlab scripts that were written from scratch, 
this section outlines these customised scripts and their use.  
 
2.4.1 Automatic dose volume histogram calculation 
In order to analyse the dose received by each individual patient, and specifically the 
dose received to each structure and OAR within each patient, it was necessary to 
calculate the DVH’s of the structures and OARs of interest. CERR has the capability of 
calculating DVHs for structures manually on an individual basis, however for a 
database as large as that being used in this study, calculating DVHs for all the 
required structures would be extremely time consuming. As a result, it was decided 
to write a script in Matlab that would be able to automatically calculate the DVHs 
required for any investigation within this thesis. 
 
trialInterCalcDVH(filelist, pathname, struct_name, dose_name) 
The backbone of this script, the part that actually calculates the DVH of a specific 
structure within a planC of a patient, was easily available within CERR. Additional 
scripting was required in order to direct the application of this script in the right 
place of the patient’s planC structure and to carry this out automatically for a list of 
patients kept within a specific folder. 
 
1. The first part of the script opens the filelist/pathname structure that has to 
be created for all in house scripts of this nature.   
2. The name of the first file within the filelist structure to be opened (i.e. the 
specific patient) is gathered. 
 
 
64 
3. The structure number within planC that matches the structure_name input is 
recorded. 
4. The dose number within planC that matches the dose_name input is 
recorded. 
5. The DVH matrix is calculated for the requested structure_name and 
dose_name using the same script that is used in the CERR manual version. 
6. The planC of the patient is updated and saved with the new DVH data. 
7. Steps 2-6 are repeated for all patients within the filelist/pathname structure.  
 
trialInterCalcIso(filelist, pathname, dose_name, isodoseLevel, assocScanNum, 
PrescDose) 
In addition to calculating DVHs, there was a requirement in this project to analyse 
structures that correspond to particular isodose levels. Computing isodoses is easily 
carried out within CERR itself, together with converting these isodoses to structures 
saved within planC, however as with the DVHs this has to be done manually for each 
patient. This script was therefore also automated in a similar fashion to those 
outlined previously utilising the filelist/pathname structure and was also modified to 
calculate the isodose level in percentage format dependent on the PrescDose input 
i.e. the isodose level could be requested as ‘95% of a prescribed dose of 50Gy’ rather 
than an isodose level expressed in Gy. As isodose levels are clinically usually 
expressed in percentages this was less likely to cause confusion at a later stage. 
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2.4.2 DVH import in EUCLID 
A significant amount of work was carried out in developing the EUCLID program to 
be more useful when dealing with large data sets such as those found in nationwide 
multicentre clinical trials. Originally the program was written for dealing with 
relatively small databases (<50 patients) therefore the ability to import DVHs of 
various structures was a manual process. This required that the user manually 
located each file where the DVHs of the particular patient were kept in order that 
the program is able to extract this information and include it in the database. This 
would be an extremely time consuming process when dealing with a database of 
over 200 patients such as that in this study. A script was therefore written in Matlab 
that would allow this process to be automated. The goal was to add a function to the 
EUCLID program that would find the folder in which the patients CERR files were 
kept, before exporting the DVH data of the structure selected in EUCLID from each 
specific patient and adding to the EUCLID database.  In order for this to be achieved, 
it required both the modifying of existing scripts already in use by EUCLID in addition 
to some new scripts being written.   
 
EUCLID database structure 
In order to add this functionality it was important to fully understand how the 
EUCLID database is built up from patient data and information when using the 
standard program (58). 
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Microsoft Excel data input 
As Matlab converts Excel sheets into arrays, this spreadsheet must be formatted in a 
particular way for it to be read correctly by EUCLID. Figure 2.8 is an example of how 
the data must be formatted in Excel. 
 
Figure 2.8 – Formatting of data in Excel spreadsheet 
 
The first line contains the variable name whilst the second line contains a description 
of the variable. The first column must contain the patient name with the remaining 
columns containing clinical factors and outcomes.  
 
Import into EUCLID and database creation 
The Excel sheet is imported into EUCLID using the inbuilt xlsread.m function in 
Matlab. This converts the .xls excel file into a .mat matlab file by creating an array 
that holds all the required information. 
 
 
 
There are multiple elements in the array created by EUCLID to hold specific 
information in the database. They are: 
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dBase: a structure array that is constructed for each patient and holds all the clinical 
factors and outcomes.  
 
 
varlist: a structure array that holds the name and description of each clinical factor 
or outcome 
 
 
patientlist: a cell array that holds all the patient names (not real names) 
 
 
savename: the name of the file and the directory where the database file is saved in 
the computer’s system 
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structlist: a cell that holds the names of any structures that are created for DVH 
analysis. 
 
 
The elements described above, specifically the structlist cell, are created individually 
for each patient when the user modifies or adds information to the database. The 
next section describes what was modified in order to automate the process. 
 
Modifying the EUCLID script 
Creating an automatic way of directing the EUCLID script to where the DVHs of each 
patient are stored was achieved by adding a ‘filepath’ column to the Excel sheet 
holding the patient’s clinical and outcome information (Figure 2.9). 
 
 
Figure 2.9 – Addition of filepath column to Excel spreadsheet 
 
The filepath column holds the individual source path for each patient’s CERR file in 
which the DVH data is held.  
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The code was written to work in a loop for the length of the filepath column. There 
are a number of steps in this loop to extract the correct DVH from each patient and 
save them in the EUCLID database: 
 
1. The name of the patient and the DVH structure is stored in the form of 
handles. 
2. The EUCLID database created from the Excel spreadsheet is opened. 
3. The length of the filepath column is calculated. 
4. The planC of the first patient in the list is opened. 
5. Structures (and their associated DVHs) are kept in planC using numbers. The 
number of the same DVH structure may differ from one patient to the next. 
This step therefore matches the DVH structure requested by EUCLID with the 
correct structure number within the patient’s planC. 
6. The DVH matrix is extracted. 
7. The matrix is saved in the dBase array in a newly created field for each  
patient with the prefix ‘dvh_structurename’. 
8. The loop goes to the start and steps 1-5 are repeated until the DVHs of the 
structure requested in EUCLID are extracted and saved in dBase for each 
patient in the filepath column. 
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Testing the script 
It was important to ensure that the script for extracting and saving DVHs 
automatically in the format of the EUCLID database Matlab file performed correctly.  
Fifteen patients from the SCOPE 1 database were used to create a test database by 
importing the necessary DICOM files into CERR. The trialBuildFileListGUI.m and 
trialInterCalcDVH.m scripts were used to calculate and save a DVH of the PTV 
structure in each patient’s CERR file. An excel file was also created to import in to 
EUCLID and create the dBase variable. The filepath column was included for use with 
the auto DVH feature. Two EUCLID databases were created from the same excel 
spreadsheet in order to test the feature. One database had the PTV DVH of each 
patient imported and saved using the original manual method in EUCLID, whilst the 
other database would have this repeated using the new auto import feature.   
The first test was to make sure that the DVH data were being stored correctly in the 
dBase structure array. The Figure 2.10 shows how the DVH data is stored when using 
the manual method. The 1x1 cell holds the name of the DVH, whilst the 2x213 
double holds the DVH data stored in absolute format. 
 
 
Figure 2.10 – Manual import of DVH data 
 
Figure 2.11 shows the storage of DVH data using the automatic method. It can be 
seen in this instance that only the absolute DVH data is saved in the array. 
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Figure 2.11 – Automatic import of DVH data 
 
For use in EUCLID this is not a concern as the script in EUCLID is written in a way so 
as to extract the data from the ‘last’ cell in the series. Therefore if there is only one 
cell, this is the cell that will be read and the data extracted and saved. 
 
 
Volume (cc) 
 Dose Bin (Gy) Automatic Import Manual Import 
50.00 24.11 24.11 
50.25 20.52 20.52 
50.50 18.85 18.85 
50.75 15.48 15.48 
51.00 13.50 13.50 
51.25 12.47 12.47 
51.50 9.23 9.23 
51.75 7.38 7.38 
52.00 6.62 6.62 
52.25 4.70 4.70 
52.50 2.51 2.51 
52.75 1.01 1.01 
53.00 0.06 0.06 
Table 2.0 – Dose bins for automatic and manual import of DVH 
 
To ensure that the DVH data stored within the cell is exactly the same, both DVHs 
were plotted and compared. The dose bins from 50-53Gy and their associated values 
are in Table 2.0, it can be seen that the values are exactly the same. 
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The dose volume plots (Figure 2.12) for the PTV were also identical, confirming that 
the automatic DVH import script worked correctly. 
 
 
Figure 2.12 – DVH from manual and automatic import 
This was also repeated for a DVH of the Total Lung (see Figure 2.13) 
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Figure 2.13 – DVH for TotalLung from manual and automatic import 
 
2.4.3 Addition of Hazard Ratio calculation 
Although the analysis module of EUCLID is capable of outputting a p value according 
to the log rank test, an additional test that gives useful information when analysing 
survival plots is the Cox Proportional hazard test (Section 1.5). The calculation of the 
Hazard Ratio within EUCLID required the code of the existing Kaplan Meier analysis 
module to be modified and extended. The Hazard Ratio is calculated on the last line 
of the script (See Appendix A1 - Computer coding). When undertaking Kaplan Meier 
analysis within EUCLID this value would then be given as an output.  Again, this was 
tested against the same analysis in SPSS (59), a statistical analysis program, using the 
same test database as used previously. The hazard ratio calculated using the 
customised script in EUCLID above was 0.5858 whilst the same analysis in SPSS gave 
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a hazard ratio of 0.5890. A 0.5% difference would indicate that the script was 
working correctly.  
 
2.5 Testing the survival analysis module 
As the work in this project was going to be utilising the survival analysis module of 
the EUCLID program it was important that it was tested against a known and reliable 
external piece of software. Due to its availability and reputation it was decided to 
use IBM’s SPSS software for this purpose.  
 
Using a test database, the survival analysis module was used to analyse the 
difference in survival between two groups according to the length of the tumour. 
The resulting plot is shown in Figure 2.14 
 
 
Figure 2.14 – Kaplan Meier plot from EUCLID 
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The p value obtained for the log rank test conducted between these groups was 
0.01782. The same analysis was then undertaken in SPSS (Figure 2.15).  
 
Figure 2.15 – Kaplan Meier plot from SPSS 
 
The p value obtained in SPSS using the log rank test was 0.018. 
 
2.6 Conformity Indices 
The investigation of the conformity of the dose distribution surrounding the PTV 
within this thesis requires the ability to quantify the positional relationship between 
two structures. A known method for this kind of analysis is the use of a conformity 
index, able to represent the variation in volume and spatial relationship between 
two structures in a single metric. A review of these methods was undertaken by L 
Feuvret et al (60) in which they outline the advantages and disadvantages of a 
number of conformity indexes in the context of the analysis of dose distribution. It is 
noted how the improvement in the spatial representation of dose distribution means 
that obtaining various treatment plans for the same patient is a relatively rapid 
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process but that choosing which of these plans to use remains difficult. Using a tool 
such as a conformity index could therefore aid this process as it provides a 
quantifiable score of the ratio of healthy tissue being irradiated compared to the 
target volume. A number of conformity indices were proposed and outlined in the 
RTOG report in 1993 and also included in ICRU Report 62 although their day to day 
use in a clinical setting remain limited. This may be due to an aspect of using a 
conformity index that could be seen as both advantageous and disadvantageous, 
their inherent simplicity. A tool should be simple and quick to understand, 
implement and use but it also important to remember that the consideration of dose 
conformity data alone may not be sufficient. The use of conformity indices is 
widespread in stereotactic radiotherapy (61) (62), (63) both in research and clinical 
settings, and it is unclear why this is the case in one aspect of radiotherapy whilst 
being almost unused in the remaining. It is possible that it may due to the increased 
complexity of planning in other areas of the body and the proximity of a number of 
organs at risk due to the target volume.  
 
A conformity index that takes into account critical organs has been proposed by 
Baltas et al (64). The index was proposed with a view to be implemented in 
brachytherapy but could equally used in highly conformal radiotherapy due to the 
associated high dose gradients. Named the COIN index, it takes into account the 
quality of tumour irradiation, irradiation of non-critical healthy tissue and irradiation 
of critical organs and the entire calculation is based on the volume of the reference 
isodose. It expands the application of another index known as the Van’t Riet 
Conformation Number (CN) (65), first described as a tool to compare RT plans for 
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prostate cancer using brachytherapy and external beam radiotherapy. A much 
simpler index has been used by Knoos et al (66) to study the degree of conformity 
reached in clinical routines of 57 patients treated for breast cancer. The radiation 
conformity index (RCI) is simply a ratio of the PTV volume and either the treated 
volume or the volume of the 95% isodose and therefore increases from 0 to 1 with 
increasing conformity of the two structures. Similarly, the Jaccard Conformity Index 
(JCI) was used by Mulliez et al to compare the dosimetry of different IMRT 
techniques (67). It has also been used extensively in the analysis of target volume 
delineation variation (68) & (69). First described in 1901 by Paul Jaccard as the 
‘coefficient de communaute’ as a tool for botanic comparison (68) it is perhaps the 
most commonly used index in the RT literature. It is a slight variation of the simple 
RCI index in that it is defined as the size of the intersection of two structures (circles 
A and B in Figure 2.16) divided by the size of the union of those same two structures.  
J =
AÇB
AÈB
 
 
Figure 2.16 – Schematic for Jaccard Conformity Index 
 
Similarly to when using the RCI, a JCI value of zero would be seen if there is no 
agreement and a value of one if there is complete agreement (overlap). Both of 
(2.0) 
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these indexes have the advantage of being simple to both calculate and understand, 
however neither of them provide any information about the difference in shape 
between two volumes. They are also largely confined to the study of spherical 
shapes, and can fail to function correctly when assessing more complex volumes 
(70). In addition, the data generated can be difficult to interpret when considering 
clinical significance of the dose distribution. Considering these drawbacks, Jena et al 
proposed a new conformity index known as the Mean Distance to Conformity (MDC) 
(70). The aim of this new index was the following: 
 
1. A single scoring statistic that represents the overall conformity of the two 
volumes being assessed. 
2. Additional statistics that provide information on whether the non-conformity 
is caused by over or under outlining. 
3. A method of display that would facilitate evaluation of the clinical 
significance of discrepancies. 
 
The MDC metric is a shape-based statistic that measures the mean displacement 
needed to transpose every voxel in an evaluated volume to a reference volume. It 
differs from the other indices described so far as it gives a measure of the magnitude 
of the difference between the two volumes being analysed, giving a value in cm.  
 
For calculating the MDC, Jena et al established a three-dimensional (3D) grid 
representation for processing the structure contour data. Each node within the grid 
could then adopt one of four states: 
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State 0: The node lies outside both reference and evaluation volumes. 
State 1: The node lies within the reference volume but not the evaluation volume. 
State 2: The node lies within the evaluation volume but not the reference volume.  
State 3: The node lies within both volumes. 
 
These states can be visualised in Figure 2.17, which gives a representation of two 
structures on the grid. The blue contour is the reference contour and the red 
contour the evaluation contour. The green voxels have been determined to lie within 
both outlines. The light blue voxels are within the reference volume outline but not 
within the evaluation volume outline and represent under-coverage errors (under 
MDC). The dark red voxels are within the evaluation volume outline but not the 
reference volume outline and represent over-coverage errors (over MDC). 
 
 
Figure 2.17 – Schematic of MDC showing OverMDC and UnderMDC 
Figure 2.18 shows the trendline and near exponential relationship between the MDC 
and JCI index. 
 
RED – Evaluation – 95% Isodose 
BLUE – Reference – PTV 
OverMDC 
UnderMDC 
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Figure 2.18 - Variation of MDC with change in JCI for two spherical volumes. Reproduced with 
permission from Jena et al A novel algorithm for the morphometric assessment of radiotherapy 
treatment planning volumes, BJR 83:44-51 (71) 
 
 
The MDC is simple to both calculate and interpret, yet also provides more clinically 
useful information than a simple ratio of the overlap of two volumes that is provided 
by the RCI and JCI. Following the work carried out by Dr Sarah Gwynne for her MD 
thesis (72) and discussions with her and other colleagues, it was therefore decided to 
take the JCI and MDC index forward for analysis of conformity in this thesis. 
 
2.7 Type A and Type B algorithms 
 It is widely appreciated that the choice of dose calculation algorithm for 
radiotherapy planning affects the accuracy of calculated dose distributions (73). The 
main disparity between algorithms in routine use is the extent to which they model 
 
 
81 
scattered dose transport (74), (75) & (76). In heterogeneous situations, the 
algorithms that provide approximate modelling for the variation of penumbra with 
density (known as “Type B” according to Knoos et al (74)) provide a more accurate 
representation of dose than those that do not (known as “Type A”). This is because 
the Type A algorithms use a one-dimensional density correction which does not 
accurately model the distribution of secondary electrons in media of different 
density (77). Type B algorithms meanwhile are corrected for any variation in density 
along the modelling of a photon ray. Although the limitations of Type A algorithms in 
calculating dose are well known, the clinical implementation of a Type B algorithm in 
treatment centres was limited at the start of the SCOPE 1 trial. The commissioning of 
a new dose calculation algorithm and ensuring patient safety can be time consuming 
and require significant resources. As a result, in the SCOPE 1 trial it was decided to 
allow centres to commence recruitment to the trial using their existing algorithms (if 
Type A) in order to minimize the risks associated with change and ensure that the 
trial reflected current clinical practice. The dose of radiotherapy plans in the trial 
data was therefore calculated using these two types of algorithms, dependent on the 
centre at which they were planned. Wills et al undertook an investigation as a part of 
the trial design process to assess whether the two types of algorithm needed to be 
taken into account when applying the radiotherapy protocol to each patient (78). 
The study took fifteen patient data sets that underwent CRT at Velindre Cancer 
Centre between 2007 and 2009 for carcinoma of the oesophagus. The patients had 
been planned according to the SCOPE 1 protocol using a Type A pencil beam 
algorithm. These plans were then re-calculated in OMP using a Type B collapsed 
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cone algorithm and the dose volume data for the regions of interest (See Table 2.1) 
between both sets compared.  
 
Structure Constraint 
PTV Minimum dose > 93% 
PTV Volume receiving 95% dose (V95%) > 99% 
PTV ICRU maximum dose < 107% 
Heart Volume receiving 40Gy (V40Gy) < 30% 
Liver Volume receiving 30Gy (V30Gy) < 60% 
Lung Volume receiving 20Gy (V20Gy) < 25% 
Spinal Cord PRV Maximum dose < 40Gy 
Table 2.1 – Dose Volume constraints for SCOPE 1 
 
It was found that the use of Type B algorithms during optimization results in 
improved PTV coverage by the 95% isodose. This is especially important when 
considering the dose in oesophageal cancer, due to the proximity of the treatment 
volume to the lung. The effect of algorithm type on the calculated dose in lung tissue 
can be observed in Figure 2.19a & b. 
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Figure 2.19a Plan using Type A algorithm showing PTV and 95% idodose line, b: plan using Type B 
algorithm showing PTV and 95% idodose line 
 
Figures 2.19a & b show the same plan calculated with a Type A and Type B algorithm 
respectively. It can be seen in Figure 2.19b how the 95% isodose line is modelled 
differently in the lung (marked Y) compared to that in Figure 2.19a (marked X). This 
is a direct consequence of the lateral electron transport being modelled correctly in 
Type B algorithms, which will have a large effect at the boundary of relatively dense 
matter such as the oesophagus with air filled areas such as the lung. As such Type A 
algorithms can be considered incorrect in the modelling of dose in this area. The 
analysis by Wills et al was made using only 15 patients from one centre. For 
completion it was decided to undertake an analysis of the effect of the planning 
algorithm on the JCI and MDC conformity index value using the complete SCOPE 1 
database. This was tested by comparing the JCI and MDC index value between the 
V95% and the PTV and comparing the results for patients planned with Type A and 
Type B algorithms using the Mann Whitney U test in the SPSS package. The JCI 
(Median = 0.68, Interquartile range = 0.64-0.73) was shown to have a statistically 
significant dependency with whether the plan was calculated using a Type A (n=94, 
X Y 
a b 
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Median JCI = 0.67 Interquartile range =0.63-0.71) or Type B (n=82, Median JCI = 0.71 
Interquartile range = 0.67-0.75) algorithm (Mann Whitney U test p<0.001). The test 
was repeated using the MeanMDC, OverMDC and UnderMDC metrics. The results in 
mm are shown in Table 2.2: 
 
Table 2.2 – Mann Whitney U test for MDC metrics between Type A and Type B dose algorithms 
 
These results show how the dose distribution displayed in a radiotherapy plan is 
dependent on whether the dose was calculated using a Type A or Type B algorithm. 
As a result of these tests, the prior work in this area and discussions with clinical and 
technical staff, it was decided that all dosimetric analysis on the database should be 
carried out with the database split according to those patients planned using a Type 
A and Type B algorithm. This would ensure that any conclusions reached about the 
effect of dose distribution could not be influenced by the effect of the planning 
algorithm. For this project, it was decided to concentrate on the analysis of Type B 
patients. It was felt that the results would be more relevant to the present clinical 
situation in the field due to the majority of centres having now moved to using these 
types of algorithms since the end of the SCOPE 1 trial. Figure 2.20 is a consort 
diagram showing the patient dropout rate and reasoning. Treatment and tumour 
 Median Interquartile Range 
P value of 
dependency on 
algorithm 
MeanMDC 2.1 0.9-3.1 <0.001 
OverMDC 4.0 3.3-4.7 0.002 
UnderMDC 2.1 0.9-2.7 <0.001 
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demographics of the final cohorts dependent on planning algorithm are also 
included. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.20 – Consort diagram showing patient treatment and tumour demographics 
 
 
Recruited to SCOPE 1 trial (n= 258) 
Excluded  (n=48) 
   Withdrawn completely (n=18) 
   Did not receive RT (12) 
   Data not received from centre (n=10) 
 
Type A algorithm (n=103) 
 Centres (n=18)  
 3D-CRT (n=103)  
 Age in years (Mean=71, Range=40-86) 
 Male (n=60), Female (n=43) 
 Cetuximab (Yes n=57, No n=46) 
 Adenocarcinoma (n=30) 
 Squamous Cell Carcinoma (n=73) 
 Tumour Stage I (n=5) 
 Tumour Stage II (n=17) 
 Tumour Stage III (n=67) 
 Tumour Stage IV (n=14) 
 Upper 1/3rd (n=51) 
 Middle 1/3rd (n=43) 
 Lower 1/3rd (n=9) 
Type B algorithm (n=98) 
 Analysed (n=97) 
 Centres (n=19)  
 3D-CRT (n=81) , VMAT (n=16) 
 Age in years (Mean=70, Range=44-88) 
 Male (n=57), Female (n=40) 
 Cetuximab (Yes n=44, No n=53) 
 Adenocarcinoma (n=24) 
 Squamous Cell Carcinoma (n=73) 
 Tumour Stage I (n=2) 
 Tumour Stage II (n=22) 
 Tumour Stage III (n=58) 
 Tumour Stage IV (n=15) 
 Upper 1/3rd (n=36) 
 Middle 1/3rd (n=48) 
 Lower 1/3rd (n=13) 
 
Received from WCTU (n=210) 
Excluded  (n=9) 
   Corrupt data (n=5) 
   Missing outcome data (n=4) 
 
Available for analysis (n=201) 
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Chapter 3  
 
Dose distribution and patient outcome 
 
3.1 Introduction 
It is clear that radiotherapy plays a key role in the treatment of oesophageal 
tumours, however the formulation and application of optimal radiotherapy protocols 
to these sites is not well defined (79). There is therefore a clear need to improve the 
quality and outcome of therapy. It is known that dose distribution is an important 
factor when evaluating the quality of radiotherapy plans and a plan is considered 
acceptable if 95% of the prescribed (tumoricidal) dose is delivered to 100% of the 
PTV (80) & (81). However, although this requirement will be met in the majority of 
patients undergoing radiotherapy, the quality of the dose distribution may vary 
according to factors such as PTV volume (82) or by the delivery technique (83).  It has 
been shown that adherence to a site-specific radiotherapy protocol is effective in 
improving plan quality and patient outcomes (84), and the SCOPE 1 trial provided a 
detailed radiotherapy study protocol and quality assurance programme (85).  
 
Despite a detailed radiotherapy protocol and planning guidance document, a 
rigorous RTTQA programme (73) & (86) demonstrated variation in radiotherapy 
planning practice such as planning technique across the  36 UK centres that 
participated in this study. These factors may have affected the quality of the dose 
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distribution achieved for each patient, in addition to those factors already discussed. 
A recent study by Moore et al noted that many plans may still be classed as ‘low 
quality’ even when adhering to clinical trial protocol (87). The aim of this 
investigation was two fold; Firstly to assess plan quality using a conformity index and 
analyse its influence on patient outcome. Secondly, to identify whether clinical and 
technological factors including GTV length, PTV volume, tumour location and 
treatment delivery method could be related to the conformity index value.  
 
Number of patients Reasoning 
97 
Only Type B algorithm patients analysed  
(See Figure 2.20 for demographic) 
Table 3.0 - Number of patients included in analysis in Chapter 3 
 
3.2 Correlating plan quality with outcome 
3.2.1 Quantifying plan quality 
Firstly it was hypothesised that plan quality can be objectively assessed by 
quantifying the relationship between the 95% isodose and the PTV using a 
conformity index. Secondly, that treatment and patient characteristics may influence 
plan quality.  The use of conformity indices to analyse dose distribution of 
radiotherapy plans has been carried out previously (66) & (88). However, to the best 
of my knowledge, this study is the first to explore the relationship of conformity 
index and patient outcome.  
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3.2.2 Analysis of conformity index values across the database 
The JCI and MDC (See Section 2.6) (UnderMDC and OverMDC) conformity index 
values were calculated for each patient. Figure 3.1- 3.3 show the resulting 
distribution of the conformity index values in ascending order.  
 
 
Figure 3.1 – Distribution of JCI values across the database 
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Figure 3.2 – Distribution of UnderMDC values across the database 
 
Figure 3.3 – Distribution of OverMDC values across the database 
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Figure 3.3 clearly shows an outlier in the distribution of OverMDC values. This 
patient has an over MDC value of 13.1mm, which far exceeds the average of the 
Type B patient cohort (3.7mm) outlined in Figure 2.20. This value is confirmed by 
analysing the image from the CERR screen (Figure 3.4).  
 
 
Figure 3.4 – Profile of outlier patient in CERR with dose wash 
 
Figure 3.4 shows that the 95% isodose does indeed have extremely poor conformity 
with the PTV. There is a significant area of the patient receiving 95% of the 
prescribed dose anteriorly.  The beam arrangement is unusual in the context of the 
SCOPE 1 trial, and clinical colleagues also noted that the GTV was of an unusual 
shape. Further discussion with the clinical staff concluded that the beam and dose 
distribution at least are due to a need to avoid the spinal cord. Due to the highly 
unusual nature of this plan within the context of the database, I decided to remove 
this patient from the analysis.   
 
 
91 
 
 
Figure 3.5 – Distribution of UnderMDC and OverMDC values across database 
 
Figure 3.5 shows the distribution of both UnderMDC and OverMDC for the Type B 
patients with the outlier removed.   
 
3.2.3 Comparing JCI and MDC 
In order to gain a further understanding of the relationship between the JCI and 
MDC indices they were plotted against each other. This would allow the relationship 
to be visualised and quantified. 
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OverMDC vs JCI 
 
Figure 3.6 – Plot of OverMDC vs JCI 
 
Figure 3.6 shows the correlation of the Over MDC metric with the JCI index. The 
Pearson coefficient is -0.85 and is highly significant with p < 0.01. This correlation is 
entirely expected due to the nature of both indices. For the JCI index, the conformity 
of the PTV and 95% Isodose increases as it tends towards 1. It follows therefore that 
the OverMDC value, which quantifies the extent of over outlining, should decrease 
as the JCI index increases. 
 
 
 
 
 
R = -0.85 
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UnderMDC vs JCI 
 
Figure 3.7 – Plot of UnderMDC vs JCI 
 
Figure 3.7 shows the correlation of the Under MDC metric with the JCI index. The 
Pearson coefficient is 0.03, which confirms the visual lack of correlation on the plot. 
Exactly why there should be such a lack in correlation remained unclear as it would 
be expected that similar to the OverMDC vs JCI plot, the UnderMDC metric should 
reduce as correlation according to JCI increases.  
 
 
 
 
 
 
R = 0.03 
 
 
 
94 
MeanMDC vs JCI 
 
Figure 3.8 – Plot of Mean MDC vs JCI 
 
Figure 3.8 shows the correlation of the Mean MDC metric with the JCI index. The 
Pearson coefficient is -0.75. It is clear that there is a negative correlation, similar to 
that observed with the OverMDC vs JCI plot. Again, this is to be expected due to the 
nature of both indices. As the conformity increases, the JCI index tends towards 1 
whilst the Mean MDC tends towards 0. 
 
JCI vs MDC 
The JCI and MDC indices are both able to give a quantifiable value of the relationship 
between two volumes or structures. However as noted previously (see Section 2.6) 
there are advantages and disadvantages associated to both. To streamline the 
investigation of the effect of conformity index on patient outcome I decided to 
R = -0.65 
 
 
 
 
95 
concentrate on only taking the MDC further forward. This was due to the JCI being a 
composite index and the MDC being able to give a more detailed and clinically 
meaningful values of the relationship between the two volumes under 
consideration.  
 
3.2.4 Outcome data 
Outcome data for each patient, including overall survival, was collated and prepared 
by the WCTU. Due to the adverse effect of cetuximab on survival in the SCOPE 1 trial 
(56), the cetuximab administration data for each patient was also acquired to allow 
for stratification.  Kaplan-Meier plots were generated to observe whether there was 
a clinically relevant threshold for the CI value in relation to survival. The 
demographic and prognostic data outlined in Figure 2.20 was also used for 
multivariate analysis.  
 
3.2.5 Deciding on CI breakpoint 
Using the EUCLID package, comparisons of survival for two populations 
discriminated by a given variable can be performed using a log rank test of the 
hypothesis that the curves describe the same survival function. This can also be 
extended to any end point (local control, progression etc) if the time to that 
endpoint is recorded and available. 
 
A function in EUCLID allows the option to scan the range of the variable (in this case 
the conformity index) to find the break point value that yields the lowest p-value and 
therefore best separates the low survival from the high survival population. This is 
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corrected for multiple comparisons using the Bonferroni adjustment, a method of 
dealing with multiple testing when finding an optimal break point (89) and has been 
used elsewhere in literature of other fields with survival data (90) & (91). This 
function was utilized to find the best cut off in this data set. The EUCLID script code 
was also modified to allow the data for each group above and below the break-point 
to be saved, allowing the data to be exported for further analysis in SPSS. 
 
3.4 Results 
3.4.1 OverMDC and UnderMDC and overall survival  
 
OverMDC 
For the 97 Type B patient plans in this study, the median OverMDC was 3.7mm 
(Range: 1.2-7.0mm). The break point occurs at an OverMDC value of 4.4mm with p = 
0.02 (logrank) and results in a 28 above/69 below split in the database.  (Figure 3.9) 
 
Figure 3.9 – Kaplan Meier according to OverMDC 
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The Cox Proportional Hazard ratio was calculated in SPSS to be 0.50 (95% CI: 0.28-
0.90, p=0.02). Stratifying for cetuximab administration, the log rank test between the 
two groups gave p=0.04. Therefore within this cohort, the OverMDC value for the 
conformity of the 95% isodose line and the PTV for the patient population studied is 
a predictor for overall survival in univariate analysis, independent of cetuximab 
administration; a high OverMDC is associated with worse survival.  
 
UnderMDC 
The median UnderMDC was 2.5mm (Range: 0-5.7mm). The break point occurs at an 
UnderMDC value of 2.7mm with a p = 0.05 (logrank) and results in a 32 above/62 
below split in the database (Figure 3.10). 
 
 
Figure 3.10 – Kaplan Meier according to UnderMDC 
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The Cox Proportional Hazard ratio was calculated in SPSS to be 0.53 (95% CI: 0.30-
0.97, p=0.04). Stratifying for cetuximab administration, the log rank test between the 
two groups gave p=0.14. Therefore UnderMDC cannot be considered a statistically 
significant predictor for overall survival when stratifying for cetuximab. 
 
3.5 Analysis of OverMDC values 
As only OverMDC remained clinically and statistically significant following 
stratification for cetuximab, further analysis was limited to this metric.  
 
3.5.1 Clinical factors 
Tumour site and OverMDC 
Plotting the distribution of upper, middle and lower tumours above and below the 
break point allowed us to look at the effect of tumour site on OverMDC value. 
Figures 3.11 and 3.12 show the number of patients in each location and the 
percentage of the total. 
 
Figure 3.11 – Distribution of tumour site in OverMDC >4.4mm 
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Figure 3.12 – Distribution of tumour site in OverMDC <4.4mm 
 
It can be seen that the proportion of tumours in each site above and below the 
OverMDC cutoff are similar. This would suggest that tumour site does not impact the 
OverMDC value. 
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GTV length and OverMDC 
 
Figure 3.13 – OverMDC and GTV length for patients 
 
Figure 3.13 shows the GTV length for each patient plotted with OverMDC values, 
ranked by increasing OverMDC value, with the line of best fit for the GTV lengths. 
There was no significant difference in GTV length either side of the OverMDC 
breakpoint of 4.4mm (Mann-Whitney p=0.123). The Pearson coefficient between the 
OverMDC metric and GTV length was calculated to be 0.33. 
 
PTV volume and OverMDC 
Figure 3.14 shows a similar plot only with PTV volume for each patient plotted with 
OverMDC values, again ranked by increasing OverMDC value with the line of best fit 
for the PTV volumes. Here there was a significant difference in PTV volume either 
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side of the OverMDC breakpoint of 4.4mm (Mann-Whitney p<0.001). The Pearson 
coefficient between the OverMDC metric and PTV volume was calculated to be 0.47. 
 
 
Figure 3.14 – OverMDC and PTV volume for patients 
 
3.5.2 Technological factors 
IMRT/VMAT dose delivery 
Patients were classified according to whether the dose was delivered via 3D 
conformal (81 patients) or IMRT/VMAT treatment (16 patients). 
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Figure 3.15 – OverMDC and dose delivery method for patients 
  
Figure 3.15 illustrates that IMRT/VMAT (green markers) is associated with a lower 
OverMDC value than if the patient was treated with 3D-CRT (blue markers) (mean 
VMAT = 2.1mm, 3D-CRT = 4.1mm; Mann Whitney p<0.001). To eliminate any 
unintended bias, it was found that there was no significant difference in PTV volume 
according to the treatment delivery method (Mann Whitney p=0.455). The 16 
patients whose dose was delivered using IMRT/VMAT were treated at 3 centres, 
with 14 at 1 centre and 1 each at the remaining 2 centres.  
 
3.6 Re-Planning of Type B patients in OMP 
It has been shown in the previous section that patients treated with IMRT/VMAT 
type treatments have significantly more conformal dose distributions. However, in 
order to truly understand the effect of the treatment delivery method on the 
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conformity of the dose it was decided to re plan patients who had originally been 
treated with 3D-CRT using the VMAT method. By having the same target volumes 
planned using two treatment methods, rather than comparing different treatment 
methods in different patients, it allows a direct comparison to be made. In addition, 
this work would allow an assessment to be made of whether the patients with 
relatively high OverMDC values could be improved by re-planning with VMAT.  
 
3.6.1 Obtaining a VMAT solution in OMP 
Patients who receive radiotherapy for oesophageal tumours in Velindre Cancer 
Centre are currently treated using the 3D-CRT technique. Creating VMAT plans for 
these patients would therefore require careful consideration and implementation of 
a new technique in this site. After consultation with the clinical department, it was 
decided that working towards a planning technique that could be used on all 
patients, rather than starting afresh with each patient, would be extremely beneficial 
both for this project and the clinical department. Therefore this work both allowed 
analysis of my thesis dataset and facilitated development of an advanced clinical 
service.  
 
3.6.2 Class solutions in Radiotherapy planning 
Conventional planning, although successful in obtaining clinically acceptable plans 
(92), can be a very time consuming process. This is a result of the treatment planner 
having to obtain a set of unknown relative weighting factors for each individual plan 
in an iterative manner. Although many manual iterations can be undertaken in 
designing a plan, time constraints and other factors may still result in a sub-optimal 
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plan (93) & (94). In addition, a set of factors found to work for one patient may not 
necessarily work for another. A solution to this problem lies in finding a class 
solution, where a set of dose weighting factors provides a clinically acceptable plan 
for the vast majority of patients. If a successful solution is found, the time taken 
during the planning process is therefore greatly reduced. The user can simply 
construct the required structures before applying a plan model saved in the 
database with the associated weighting factors, thereby creating a plan that meets 
the required dose constraints and objectives and can be safely delivered to the 
patient. The use of class solutions in a clinical setting has become increasingly 
prevalent with the implementation of inverse planning, and as a result, IMRT/VMAT 
dose delivery methods. There is a large amount of literature in which the term ‘class 
solution’ is used to describe a method of automating plan generation. Due to the 
number of different techniques and application of these methods there is also no 
standard definition of a class solution as applied to radiotherapy planning.  
 
3.6.3 What makes a good treatment plan? 
A class solution generated plan that meets all the dose constraint criteria may not 
necessarily be the best plan for that patient. However, meetings with clinical 
colleagues made it clear that when approving oesophageal radiotherapy plans for 
treatment, meeting the dose constraints is the primary criteria for going ahead with 
treatment. When these are met there is generally not a large amount of time and 
effort given to improving the plan further. This does not mean that meeting the dose 
constraints required by plans is easy however, and in some cases this is impossible or 
may take an unacceptable amount of time to achieve. In these instances, it is up to 
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the oncologist to decide whether the trade off between dose received by normal 
tissue compared to the treatment volume is clinically acceptable and can be 
delivered safely. Although minimising the dose received by every organ at risk whilst 
maximising the dose received in the treatment volume in each patient is the ideal 
solution, there will be small trade-offs to be made in most cases. The dose 
distribution delivered to an organ is unlikely to be uniform; being able to consider 
trade offs between organs is therefore dependent on being able to describe the dose 
delivered to each organ. Ideally parameters such as TCP and NTCP (See Section 4.1) 
would be ideally used to compare one plan to the next as they would model the 
effect of the dose delivered to the patient to a biological outcome. However the 
parameters more often used to describe the dose delivered to an organ and make a 
comparison of plans include mean dose, maximum dose, or the fraction of volume of 
a structure that receives more or less than a certain specified dose levels. It is 
managing the trade off between these parameters that will decide what plan is 
considered better than another. In most treatment planning there will be multiple 
structures to consider further increasing the time taken to plan each patient using 
conventional planning techniques.  
 
3.6.4 VMAT optimising volumes 
VMAT plans often require the creation of optimising or ‘dummy’ volumes (95). These 
are usually simple volumes that are included in a plan in addition to the usual 
GTV/PTV and OARs to assist the treatment planning system in creating a suitable 
plan by directing or limiting the dose to specific area. For example, by creating a 
dummy volume with a particular dose constraint, the TPS will attempt to limit the 
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dose received by that particular volume. The two additional structures created for 
the VMAT plan were: 
 
1. DM_PTV – This is simply the original PTV from the 3D-CRT plan grown by 
1mm in all directions. This structure is created in order to ensure that the conformity 
of the 95% isodose to the original PTV grown from the GTV is optimised. 
 
2. DM_Conf_15mm – This is a ring like structure created to achieve the required 
dose fall off from the planning PTV. 
 
3.6.5 Multicriteria Optimization and creating a Pareto curve 
One method for the creation of a class solution is that of Multicriteria Optimisation 
(MCO) (96). Here each structure is assigned one or several objectives and the end 
goal is to find a solution that is the best trade off between these objectives.  A 
solution that reaches this end goal is commonly defined as being Pareto optimal. A 
Pareto optimal solution will therefore be one where no single objective can be 
improved without deteriorating at least one of the others. The set of solutions that 
together define the Pareto optimal plan is called the Pareto set. Plotting the image of 
the Pareto set in objective space gives a 4D Pareto surface, whilst slicing through this 
surface to focus on two objectives gives a 2D Pareto curve. By analysing the 2D curve 
it allows the trade-off in coverage between two objectives to be visualised.  
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When considering the planning of oesophageal cancer treatments, the organs at risk 
constraints that are most difficult to meet are the lungs and heart. (See Table 3.1 for 
dose constraints). 
 
Region of interest/Organ at risk Dose constraint 
PTV V95% (47.5Gy) >99.0% 
Heart V80% (V40Gy) < 30Gy 
Combined Lungs V40% (V20Gy) < 25% 
Table 3.1 – Dose constraints for VMAT planning 
 
I therefore wanted to understand the relationship between these two structures 
when changing the weight of the objective given to achieving a dose constraint on 
one or the other. It was also important to understand what affect, if any, that 
changing the relative weighting on achieving dose constraints of these two 
structures may have on the coverage of the PTV. 
 
The weighting of the Cord, PTV, DM_PTV and DM_Conf_15mm structures were set 
in the Plan Optimisation Module of OMP as seen in Table 3.2. 
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Table 3.2 – Objectives and weighting of structures in VMAT plan 
 
From previous work, we know that the dose constraint for the heart is relatively easy 
to achieve using VMAT (82). Therefore in order to find the optimum lung weighting I 
set the heart weight to 0 and ran the optimising process with the lung weighting 
increasing from 5 – 20, in increments of 5.  
 
Structure Objective and weight 
  External (OAR) Max dose 60.00Gy, weight 1.0 
 Heart (OAR) Max average dose 18.00Gy, weight 10.0
Cord PRV (OAR) Max dose 38.00Gy, weight 1000.0  
 Combined Lungs 
(OAR) Max average dose 11.00Gy, weight 10.0 
PTV_RC (Target) Min dose 47.50Gy, weight 30.0 
 
 
Max dose 50.0Gy, weight 300.0 
 
 
Min dose 50.0Gy, to 50.0% volume, weight 50.0 
DM_PTV_RC (Target) Min dose 48.50Gy, weight 600.0 
 
 
Max dose 50.0Gy, weight 300.0 
 DM_Conf_15mm 
(OAR) 
Surr dose 50.00 - 47.50Gy, dist 0.5cm, weight 
1000.0 
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Figure 3.16 - % volume receiving dose constraint of each structure 
 
It can be seen from Figure 3.16 that the lung weighting of 15 gives a favourable (i.e. 
minimises) dose to the heart. This lung weighting value was therefore initially taken 
forward to explore the influence of changing the heart weighting on mean heart 
dose and mean lung dose. 
 
To analyse this aspect of plan weighting and its effect on the dose received by the 
heart and lung, I created 5 plans with a lung weighting of 15 and heart weightings of 
0.5, 5, 10, 15 and 20. The mean heart dose and mean lung dose for each plan 
created was recorded and is plotted in Figure 3.17 
 
 
 
110 
 
Figure 3.17 – Mean Lung Dose vs Mean Heart Dose 
 
Figure 3.17 shows how an increasing weight on the heart, whilst reducing the mean 
heart dose also results in an increase in mean lung dose. It can be seen how a pareto 
curve is being generated, meaning that the plan is pareto optimal. 
 
The effect of changing the weighting on the heart can also be observed in the dose 
distribution representation images of the plan itself. Figures 3.18 a-e show how as 
the weighting on the heart increases the dose deposited in the heart decreases. 
However the dose must be deposited somewhere and this can be observed by the 
spilling of the dose into the lung tissue as the weighting on the heart increases. 
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Figure 3.18: Showing spilling of dose into 
lung with increasing heart weight: 
a. Heart weighting = 0.5 
b. Heart weighting = 5 
c. Heart weighting = 10 
d. Heart weighting = 15 
e. Heart weighting = 20 
a. b. 
c. d. 
e. 
 
 
112 
I then repeated this process with a lung weighting of 10. The mean doses of the 
heart and lung were again recorded and can be seen in Figure 3.19 
 
 
Figure 3.19 –Mean Lung Dose vs Mean Heart Dose for patient 1 
 
Figure 3.20 shows how a reduced lung weighting of 10 results in an increased lung 
dose when compared to the same plan with a lung weighting of 15.  
 
Repeating with a different patient 
It was important to assess whether the weightings used on the OARs would produce 
a similar plan on another patient. I therefore repeated the previous steps of 
producing 10 plans with different combinations of weighing on the lung and heart 
organs. The plot of mean heart dose and mean lung dose can be seen in Figure 3.20. 
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Figure 3.20 – Mean Lung Dose vs Mean Heart Dose for patient 2 
 
The figure shows that in this instance, the curve of mean heart dose vs mean lung 
dose is not pareto optimal when compared to that in figure 3.19. The weightings are 
therefore not optimal for this patient.  
 
Patient dependent vs patient independent solution 
Although the weightings chosen for the first patient were shown to produce a pareto 
optimal curve in terms of heart and lung they were not replicated with the second 
patient. Therefore the solution found for the first patient is not patient independent, 
meaning that it will not produce a pareto optimal plan for each different patient.   
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3.6.6 Re-planning worst performing OverMDC patients 
The 16 worst performing patient plans according to OverMDC (plotted with square 
symbols in Figure 3.21) were re-planned from the 3D-CRT to VMAT in OMP using the 
solution. 11 patients were successfully re-planned using the class solution meeting 
all dose constraints. The 5 remaining patient plans did not meet the SCOPE 1 
protocol dose volumes constraints for the PTV initially, but in all cases acceptable 
plans were achieved after manual adjustment of the weighting on the PTV 
objectives. 
 
 
Figure 3.21 – Effect of re-planning from 3D-CRT to VMAT on OverMDC 
 
 
 
 
 
115 
Table 3.3 gives the OverMDC values before and after re-planning with the VMAT 
class solution. 
 
Patient ID 3D-CRT OverMDC (mm) VMAT OverMDC (mm) 
101003 4.7 2.7 
001023 4.9 2.7 
064002 4.9 2.8 
007003 5.1 2.3 
102009 5.2 2.7 
102003 5.3 2.1 
007002 5.3 2.7 
028003 5.4 2.8 
177004 5.4 3.7 
069009 5.5 2.3 
177003 5.6 2.5 
007001 5.8 2.3 
002004 6.0 2.2 
177005 6.6 5.1 
139003 7.0 3.0 
028001 7.0 2.9 
Table 3.3 – OverMDC after re-planning with VMAT class solution 
 
The OverMDC was reduced for all 16 patients after replanning with VMAT (Figure 
3.21 and Table 3.3), with a mean reduction of 2.8mm (Range: 1.6-4.0mm). This 
confirms that the treatment modality has a large influence on OverMDC value. 
However there are also two outliers where the OverMDC was not reduced to the 
same extent. It is known from Figure 3.14 that there is a dependency on OverMDC 
value on PTV volume and on further review it was found that these two patients had 
an above average PTV volume (441cm3 and 498cm3) when compared to the SCOPE 1 
database mean PTV volume (334cm3). The average PTV volume for the re-planned 
patients was 393cm3.  
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3.7 Multivariate analysis 
OverMDC and UnderMDC were included in a multivariate logistic regression analysis 
along with other clinical factors. They were, age, sex, tumour type, tumour stage, 
tumour site, cetuximab administration, PTV volume and disease length.  
 
Variable 
Regression 
Coefficient 
Standard 
Deviation P-value 
Age 0.0686 0.0362 0.0582 
Sex -0.8128 0.5777 0.1594 
Tumour Type 0.6688 0.6972 0.3374 
Tumour Stage 0.8288 0.4676 0.0763 
Tumour Site -0.1972 0.4755 0.6784 
UnderMDC -0.5292 2.6432 0.8413 
OverMDC 1.3680 2.3520 0.5608 
Cetuximab 0.5757 0.5263 0.2740 
PTV Volume -0.0009 0.0035 0.7887 
Disease Length -0.0351 0.1641 0.8309 
Table 3.4 – Results of multivariate analysis 
 
It was found that none of these factors were statistically significant (Table 3.4). The 
factors with the lowest p-values were found to be age and tumour staging (p=0.06 
and p=0.08 respectively).  
 
3.8 Discussion 
The aim in this piece of work was firstly to quantify plan quality using a CI and its 
effect on patient outcome. Secondly, to identify whether clinical and technological 
factors including PTV volume and treatment delivery method could be related to the 
CI value.  
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It was found that OverMDC has a statistically significant relationship with overall 
survival in univariate analysis independent of cetuximab administration, the latter 
having been shown to adversely effect survival in the SCOPE 1 trial. It was also 
shown that PTV volume was weakly correlated with the OverMDC value of each 
patient (Pearson’s correlation = 0.47), but the treatment delivery method had a 
more significant impact with the mean IMRT OverMDC being 51% of the mean 3D-
CRT OverMDC value. When OverMDC and UnderMDC were included with other 
clinical variables in a multivariate logistic regression analysis neither remained 
significant.   
 
The volume of the PTV may have an influence on dose coverage. Meeting constraints 
for larger PTVs is more difficult due to the likely increased overlap with organs at risk 
(OAR). Specifically in the case of oesophageal cancer, OARs such as the heart, lungs 
and spinal cord are in close proximity to the oesophagus and may limit the ability to 
optimise the dose distribution. In this study we hypothesized that a larger PTV 
volume would be associated with an increase in OverMDC and UnderMDC values 
due to the increased complexity of the resulting RT plan and ability to conform the 
dose to the PTV due to the need to spare adjacent OARs. Statistical tests showed 
that there was indeed a significant difference in the PTV volumes of patients either 
side of the OverMDC break point. No significant difference was found in the case of 
the UnderMDC metric.  
  
This study also confirmed that using IMRT and VMAT increase dose conformity when 
compared to 3D-conformal therapy, as shown elsewhere in the literature (97). This is 
 
 
118 
demonstrated by the significantly smaller OverMDC values between the V95% and 
PTV volumes in the IMRT/VMAT patients of the SCOPE 1 trial and furthermore by the 
re-planning of the worst performing patient plans by OverMDC value from 3D-
conformal to VMAT. A study in gastric cancers found similar results when comparing 
3D-conformal radiotherapy to IMRT (98), concluding that a better target coverage 
and therefore significant dose reduction to OARs could be achieved in IMRT plans. It 
is clear therefore that the more conformal dose delivery techniques should be used 
to administer RT wherever possible.  
 
The explanation for the improved overall survival in patients treated with a lower 
OverMDC value and therefore more conformal treatment is not clear. The 
association with IMRT/VMAT treatment is interesting as only 3 centres treated the 
16 patients with IMRT/VMAT in the original trial. In addition Figure 3.21 clearly 
shows two cases where re-planning with VMAT/IMRT did not reduce the OverMDC 
value to the same extent, but their PTV volume was higher than the average for the 
patients included in this study. It is possible that low OverMDC and/or access to 
IMRT/VMAT reflect other aspects of a high quality RT process that require further 
investigation in a future study. It is also fully acknowledged that when the OverMDC 
metric is included in a multivariate analysis it does not remain statistically significant.  
 
Nevertheless, this work suggests that IMRT/VMAT offers a potential tool for safe 
dose escalation, as the MDC analysis has shown that unnecessary irradiation of 
normal tissue can be significantly reduced without affecting PTV coverage.  This is 
consistent with the findings of Freilich et al (99) who concluded that although the 
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use of IMRT did not impact on survival, it was associated with significantly less 
toxicity, and Warren et al who have shown that IMRT allows dose escalation to 60Gy 
with the same level of normal tissue irradiation as 3D-CRT to 50Gy (82). This is being 
taken forward in the recently funded SCOPE 2 trial. Unfortunately there were an 
insufficient number of patients treated with IMRT/VMAT in this study to detect any 
impact on survival. In addition, patients treated with IMRT/VMAT may have been 
expected to have a lower rate of toxicity, however the rates were so low within the 
SCOPE 1 trial that this could not be studied. 
 
In a clinical setting, this work suggests that careful attention to the quality of RT 
planning, expressed in terms of conformity of the dose distribution to the target 
volume, may impact on overall survival. IMRT/VMAT should be considered for all 
patients when conforming the 95% isodose to the PTV is difficult.  
 
3.9 Conclusion 
I have shown using the MDC index that in univariate analysis the quality of a plan 
with respect to PTV coverage has a significant correlation with patient outcome in 
terms of overall survival, thereby meeting an initial aim of the project as set out in 
Section 1.9. It has also been shown that plan quality is also strongly related to the 
use of advanced radiotherapy delivery techniques, allowing the possibility of dose 
escalation to the tumour whilst minimising dose to OARs. This is explored further in 
Chapter 4.   
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Chapter 4 
 
 
The effect of dose escalation on gastric toxicity.  
 
 
4.1 Introduction 
The end point of true clinical interest in radiotherapy is controlling the tumour (100). 
We therefore want to convert a dose distribution in the tumour to a quantifiable 
value of tumour control.  Radiobiological modelling is a method of approximating the 
clinical outcome of radiotherapy treatment in terms of TCP and NTCP. The modelling 
of TCP and NTCP will therefore be used in this chapter to study the potential of 
VMAT dose delivery to safely dose escalate lower oesophageal tumours with a focus 
on gastric toxicity.  
 
4.1.1 Tumour control probability 
The TCP is the probability of killing all tumour cells in the defined tumour volume 
following irradiation with a certain dose distribution. Using data in the form of 
survival fraction curves (which carry information of the proportion of cells that 
survive a specified dose of radiation), as a probability model for radiation-induced 
individual clonogenic cell death, the TCP computes the probability of tumour 
eradication by taking into account factors such as cell proliferation between 
radiation treatment fractions, and natural cell death rates (101). 
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Several models have been developed to study TCP (See Zaider and Hanin et al for a 
review (102)). However modelling TCP can be split into four main methods: 
1. Binomial statistics: This is the simplest model and does not take into 
account cell proliferation between fractions or stochastic effects. 
Success is simply defined as cell death, and the TCP is defined as the 
probability that there are n0 successes where n0 is the total clonogenic 
cell population. 
2. Poisson statistics: The model also takes into account the stochastic 
process of radiation-induced cell killing. Here, deterministic 
differential equations are used that account for cell death both 
naturally and due to radiation. TCP is then given by a poisson 
distribution with a mean is the solution of the differential equations. 
3. Zaider-Minerbo model: This model also describes the stochastic 
effects of cell birth and death but with greater accuracy. A master 
equation that takes into account these effects is transformed into a 
partial differential equation that in turn can be solved to give a value 
for TCP. 
4. Monte-Carlo model: As with all Monte-Carlo methods, this method is 
capable of simulating a very large number of cells. To date, Monte-
Carlo methods are the most accurate methods of modelling but 
require specialist software packages and computing hardware.  
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The method most commonly used for quantitative predictions of dose/fractionation 
dependencies is the linear-quadratic (LQ) formalism (103) that utilises poisson 
statistics. Here the number of surviving cells following radiation is given by  
S(D)= e-(aD+bD
2
)
  (4.0) 
Where S is the number of surviving cells following a dose of D, and α and β describe 
the linear and quadratic parts of the survival curve respectively. The α and β 
constants vary between different tissues and tumours. A useful and widely used 
term is the α/β ratio, which describes the dose in Gy when the number of cells killed 
by the linear component is equal to the cell kill from the quadratic component. 
For the calculation of TCP from DVH data, the tumour volume is considered to be 
constructed from independent sub-volumes. If each sub-volume (denoted by i in 
formula 4.1) is considered small enough to receive a uniform dose then the TCP for 
the tumour is the product of the TCP values calculated in each of the sub-volumes, 
given by TCPi.  
TCP = TCPi
i=1
m
å  (4.1) 
 
4.1.2 Normal tissue complication probability 
The NTCP can be defined as the probability that otherwise normal tissue (i.e. non 
cancerous) will develop adverse late effects as a result of being irradiated. In the 
past, knowledge of the tolerance of normal tissue to irradiation was severely lacking. 
However the seminal Emami paper (104) and consequent Quantitative Analyses of 
Normal Tissue Effects in the Clinic (QUANTEC) (105) working group report have since 
vastly improved the knowledge base within this area, to the extent that NTCP 
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modelling is now a recognised and well regarded method of approximating the 
expected normal tissue toxicity resulting from irradiation. Initially, Burman et al (106) 
fitted a Lyman model (107) to the Emami data, allowing the ability to use Emami’s 
constraints for an arbitrary fraction of a whole organ uniformly irradiated. Kutcher et 
al (108) then expanded on this work to allow the analysis of NTCP via DVH data. This 
Lyman-Kutcher-Burman model is now the most widely used method of estimating 
NTCP.   
 
The specific symptom that results from the exposure to radiation is known as a 
clinical endpoint. The endpoints can be grouped into two categories; those that are 
binary and relate to functional changes (paralysis or death) and those that are scalar, 
describe physiological changes and are usually graded by increasing severity.  
 
4.1.3 Clinical derivation and use of TCP and NTCP  
Most of the models that have been developed to describe the dose response of 
different normal tissues and tumours have the following common features: 
 
 Cell survival after irradiation is binomial and obeys binomial or Poisson 
statistics 
 Response of an organ is determined by the death or survival of its target cells 
 All the target cells respond identically 
 Equal effects are obtained from equal dose fractions if sufficiently separated 
in time 
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The modelling of both TCP and NTCP requires reliable data from specific clinical 
studies. As the setting up of a suitable study for the sole benefit of producing reliable 
TCP and NTCP data is unlikely to be justified, most data used in the generation of 
models is gathered from retrospective analysis of suitable cohort studies and clinical 
trials. In order to accurately model TCP and NTCP, there must be detailed 
information on the radiation exposure and treatment outcome available for 
assessment. However, radiobiological modelling is a complicated process even with 
the use of accurate data. In general, the information available only covers a small 
part of the dose-response curve required for the model as the treatment 
administered during radiotherapy is usually at a very specific dose. As a result, the 
part of the dose-response outside the region of the clinical data is based on the 
model only and can be difficult to verify. However radiobiological modelling is an 
established field with a large body of published work. Indeed there is an increasing 
call for radiobiological modelling to be utilised in the routine treatment planning 
process (109) & (47). 
 
4.2 The need for dose escalation 
The incidence of lower third oesophagus tumours are increasing in most Western 
populations (110) and it is becoming increasingly clear that chemo-radiotherapy 
(CRT) is now a valid alternative to surgical resection in the treatment of 
gastroesophageal junction (GEJ) cancer (111). However, local in-field recurrence is 
still the main reason of treatment failure (112) following definitive CRT, with >75% of 
these occurring within the GTV when the standard radiation dose of ≈50Gy is 
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delivered. Indeed, local recurrence also contributes towards a worse prognosis in 
GEJ carcinoma (111). 
In theory, a higher radiation dose delivered to the tumour should result in higher 
local control rate. However it is only with the recent technological advances in RT 
planning and delivery that the ability to deliver increased dose to the tumour whilst 
minimising dose to normal, healthy tissue and OARs is becoming possible (113). 
Increased TCP should therefore be achievable by increasing the standard dose 
prescription beyond ≈50Gy. A retrospective study by Zhang et al (114) found that 
there was significantly higher overall survival in their patient cohort if the patient 
was treated in a high dose group (>51Gy) compared to the low dose group (<51Gy), 
whilst Geh et al found there was a dose-response relationship between increasing 
prescribed radiotherapy dose and pathological complete response in the 
neoadjuvant setting(115). Bedford et al (116) also found via radiobiological 
modelling that conformal techniques offered the potential of a 5-10Gy increase in 
dose delivered to the GTV up to 60Gy with acceptable increases in toxicity.   
The organs most at risk when planning oesophageal radiotherapy treatment, and for 
which the most stringent dose constraints are usually applied are the heart, lungs 
and spinal cord. Oesophageal cancer cases are therefore planned according to a 
combination of the achievable dose coverage of the PTV and the meeting of dose 
constraints for these organs. Work I undertook in collaboration with Oxford 
University in preparation for the forthcoming SCOPE 2 trial (82) has shown that dose 
escalation to 62.5Gy in mid oesophageal patients is feasible, with the additional dose 
able to be delivered without exceeding the OAR dose constraints in 75% of patients. 
However, dose escalation has not yet been studied in lower oesophageal cancers, 
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when the added proximity of the relatively radiosensitive stomach provides an 
added planning challenge (117).  With the role of radiotherapy dose escalation 
identified as a research priority (118) for improving outcomes and the likely increase 
in individualised RT dose prescription in the future, it is important to quantify the 
increased risk that this may pose in sites such as the lower oesophagus where clinical 
evidence for dose-toxicity correlation for adjacent organs (such as stomach) is 
lacking. This planning study therefore aims to investigate the feasibility of lower 
oesophageal dose escalation with a focus on toxicity to the stomach.  
 
4.3 Modelling the impact of dose escalation 
 
4.3.1 Study dataset 
Ten patients with tumours in the lower third region (centre of tumour at 32-40cm 
from back of teeth measured via Endoscopic ultrasound (EUS)) were selected at 
random from both arms of the SCOPE 1 database and their classification in the 
documentation as lower third tumours confirmed visually. The subset had a range of 
planning target volumes (PTV1) from 219 to 484cm3 and a mean volume of 348cm3, 
similar to that of the entire SCOPE 1 cohort (mean 327cm3). These 10 patients were 
therefore judged to give a good representation of the whole patient cohort. The 
GTVs and OARs outlined as per the SCOPE 1 protocol were re-used. 
 
 
 
 
 
 
127 
Number of 
patients 
Reasoning 
10 
Lower oesophageal patients with PTV volumes 
representative of SCOPE 1 cohort 
 
Centres = 7 
Age in years (Mean = 72, Range: 61-81) 
Male (n=4), Female (n=6) 
Cetuximab (Yes(n=4), No(n=6)) 
Adenocarcinoma (n=2) 
Squamous Cell Carcinoma (n=8) 
Tumour Stage III (n=10) 
Table 4.0 – Number of patients included in analysis in Chapter 4 
 
4.3.2 Treatment planning  
PTV1 was grown by adding 1cm isotropically to the CTV, itself grown by adding 1cm 
radially and 2cm superiorly and inferiorly (along axis of oesophagus) to the GTV and 
may include the stomach mucosa at the inferior limit. For the purpose of this specific 
study and the use of the simultaneous integrated boost (SIB) technique for dose 
escalation, additional structures were also created. A PTV2 (boost volume) was 
created for the dose escalated plans by adding an isotropic 0.5cm margin to the GTV, 
supported by a study by Hawkins et al (119) and reflecting the technique in the 
SCOPE 2 trial where margins will not be adjusted dependent on tumour position 
(82). The protocol did not address stomach filling or any dose constraints for that 
organ specifically; there were no constraints or protocol concerning the filling state 
of the stomach in the SCOPE 1 trial and therefore for the patients in this study. The 
stomach was contoured as (a) whole organ and (b) stomach wall. The stomach wall 
volume was generated by creating a ring like structure encompassing the outer 5mm 
of the whole stomach outline. This has been shown to provide a satisfactory 
approximation of stomach wall thickness (120) & (121). In addition, the stomach and 
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stomach wall structures were divided into the volume that was within PTV1 
(Stomach-In and StomachWall-In) and outside PTV1 (Stomach-Out and StomachWall-
Out) (See Figure 4.1).  
 
Figure 4.1 – Schematic of StomachWall-In and StomachWall-Out volumes 
 
Specific dose constraints were given for each for the SIB plans (Table 4.0) based on 
the recommendations of the QUANTEC paper for dose volume effects in the 
stomach and small bowel (122). An SIB dose of 60Gy in 25 fractions was considered 
to be clinically meaningful and is being taken forward within an on going prospective 
dose escalation trial (SCOPE 2). 
 
All treatment planning was undertaken in Eclipse (Version 10). The original 3D 
conformal plans were imported in DICOM format and the doses recalculated using 
the AAA algorithm with a 2.5mm grid. RapidArc (RA) plans were generated using 2 
arcs of 3600, clockwise and counter-clockwise with a collimator rotation of 100.  The 
50Gy 3D conformal plans (50Gy3D) were then compared to 50Gy RapidArc plans 
(50GyRA) and to plans with an additional simultaneously integrated boost of 60Gy to 
PTV2 (60GyRA) (See Figure 4.2).  
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Dose constraints for all the structures are listed in Table 4.1.  
Dose-volume constraints 
PTV1 (50 Gy)  V95% (47.5 Gy) > 95% 
Dmax (0.1cc) < 107% (53.5 Gy) 
PTV2 (60 Gy) V95% (57 Gy) > 95% 
Dmax (0.1cc)  < 107% (64.2 Gy) 
  
Lung Mean dose < 20 Gy 
V20Gy  < 25 % 
Heart Mean dose < 25 Gy 
V30Gy  < 45%* 
V40Gy  < 30%** 
CordPRV 
Liver 
Individual Kidneys 
StomachIn*** 
StomachOut*** 
Dmax (0.1cc) < 40 Gy (45 Gy permitted) 
V30Gy < 60% 
V20Gy < 25% 
Max dose < 60Gy 
Max dose < 45Gy 
Table 4.1 – Dose constraints for dose escalated radiotherapy plans. *Applies only to 50GyRA and 
60GyRA plans. **Applies only to 50Gy3D plans. ***Applies only to 60GyRA plans 
 
A B 
Figure 4.2 
 
A: 50Gy3D plan with GTV, PTV and 
stomach outline 
 
B: 50GyRA plan with GTV, PTV and 
stomach outline 
 
C: 60GyRA plan with GTV, PTV2, PTV 
and stomach outline  
 
Outlines: GTV – dashed 
orange  
PTV – dashed red 
PTV2 – dashed blue 
Stomach – dashed 
green 
C 
50Gy 
0Gy 0Gy 
50Gy 
0Gy 
60Gy 
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Patient 6 was originally planned using 50GyRA therefore a 50Gy3D plan was not 
created in this case. 
 
4.3.3 Radiobiological modelling 
Radiobiological modelling of TCP was undertaken using the parameters derived by 
Geh et al (115). This multivariate logistics regression model was constructed using 
data from 26 pre-operative CRT trials in oesophageal cancer and was considered a 
good representative of the SCOPE 1 patient cohort. The TCP modelling was 
undertaken bin-wise in Microsoft Excel using parameters by Geh et al found in their 
original paper (115). Differential dose-volume histograms (DVH) for each structure 
were calculated in CERR utilising Matlab scripts developed in-house (86) before 
being converted to relative DVHs in Microsoft Excel. TCP was calculated as: 
 
TCP(z) =
exp(z)
1+ exp(z)
 (4.2) 
 
where z = a0 + a1 total RT dose + a2 total RT dose × dose per fraction + a3 duration + 
a4 age + a5 5FU dose + a6 cisplatin dose. The α/β was 4.9Gy. 
 
NTCP modelling was carried out in Eclipse Biological Evaluation module using the 
whole heart volume model of Gagliardi et al (123) with an endpoint of cardiac 
mortality, and for the lung using the model parameters from De Jaeger et al (124), 
which predicts a radiation pneumonitis (RP) of grade 2 or higher. NTCP models for 
the stomach are limited therefore modelling was carried out using those judged to 
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be most relevant. The whole stomach was modelled using parameters derived by 
Burman et al (106) with the endpoint being ulceration, whilst the stomach wall 
parameters were derived by Feng et al (125), modelling the probability of ≥3 grade 
gastric bleeding.    
 
Data were analysed using the SPSS statistics package version 20.0.0 (IBM), and 
results are reported as median (range) values. Both the Z-score and the P-Values 
were calculated. 
 
4.4 Results 
Table 4.1 (Page 138) reports the dose-volume metrics and the results of the 
Wilcoxon signed rank test for all radiotherapy plans. Adequate target dose coverage 
was possible for all patients in all treatment modalities when considering the 
coverage of PTV1 (Table 4.1). Four patients failed to meet the minimum coverage of 
PTV2 with the minimum coverage being 92.4%. All OAR dose constraints for the 
heart and lung were met for all patients for all treatment plans.  6 patients failed to 
meet the Stomach-In constraint and 1 failed to meet the Stomach-Out constraint for 
the 60GyRA plans. All other dose constraints in Table 4.0 were met. 
 
There was a mean decrease 1.0% (Range: -3.0%, 0.6%) in TCP from the 50Gy3D to the 
50GyRA plans, a mean increase of 12.0% (9.9%, 13.6%) in TCP from the 50Gy3D plans 
to the 60GyRA plans and a mean increase of 13.0% (12.4%, 13.4%) in TCP from the 
50GyRA plans to the 60GyRA plans (Figure 4.3).  
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Figure 4.3 – TCP values of 50Gy3D, 50GyRA and 60GyRA radiotherapy plans 
 
For NTCP there was a mean decrease of 3.4% (-6.3%, 0%) for the heart from the 
50Gy3D to the 50GyRA plans, a mean decrease of 2.2% (-4.9%, 2.0%) from the 50Gy3D 
to the 60GyRA plans and a mean increase of 1.2% (0.5%, 2.0%) in NTCP for the heart 
from the 50GyRA to the 60GyRA plans (Figure 4.4).  
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Figure 4.4 – NTCP for heart for 50Gy3D, 50GyRA and 60GyRA radiotherapy plans 
 
For lung there was a mean increase of 0.4% (-0.8%, 2.2%) in NTCP from the 50Gy3D to 
the 50GyRA plans, a mean increase of 1.0% (-0.6%, 3.2%) from 50Gy3D to 60GyRA, and 
a mean increase of 0.6% (0.1%, 1.2%) from the 50GyRA to the 60GyRA plans (Figure 
4.5). 
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Figure 4.5 – NTCP for lung for 50Gy3D, 50GyRA and 60GyRA radiotherapy plans 
 
For the stomach and stomach wall the variation in NTCP between patients was 
considerable. Patients 1, 2, 6 & 8 all had stomach NTCP values <0.03% for all 
treatment plans whilst the largest value was 3.4% for a patient planned using the 
60GyRA technique (Figure 4.6).  
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Figure 4.6 – NTCP for stomach for 50Gy3D, 50GyRA and 60GyRA radiotherapy plans 
 
The stomach wall model, which models gastric bleeding, showed considerably larger 
absolute values of NTCP, the largest being 39.4% for a patient planned with the 
60GyRA plan. Across the whole study, there was a mean decrease in stomach wall 
NTCP of 3.1% (-6.5, 0%) from the 50Gy3D plans to the 50GyRA plans, a mean increase 
of 5.9% (-4.7, 18.7%) in NTCP from the 50Gy3D to the 60GyRA plans and a mean 
increase of 8.2% (-0.4, 21.3%) in NTCP from the 50GyRA to the 60GyRA plans (Figure 
4.7).  
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Figure 4.7 – NTCP for whole stomach wall for 50Gy3D, 50Gy3D and 60GyRA radiotherapy plans 
 
To address the fact that both part of the stomach and stomach wall are within the 
PTVs, particularly the dose escalated PTV2, I restricted the NTCP modelling to the 
volume outside the boost volume (PTV2). There was in general a smaller difference 
between the NTCP values between plans. In this case there was a mean decrease of 
3.4% (-7.4%, 0.3%) from the 50Gy3D to the 50GyRA plans, a mean decrease of 0.9% (-
4.7%, 1.0%) in NTCP from the 50Gy3D to the 60GyRA plans, and a mean increase of 
2.3% (-0.4%, 6.9%) in NTCP from the 50GyRA to the 60GyRA plans (Figure 4.8). 
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Figure 4.8 – NTCP for stomach wall minus PTV2 for 50Gy3D, 50Gy3D and 60GyRA radiotherapy plans 
 
Table 4.3 shows the Pearson correlation coefficients between the Stomach and 
Stomach Wall volumes and associated dose metrics.   
 
   
Pearson Coefficient 
 Volumes: 
  
50Gy3D 50GyRA 60GyRA 
Stomach Volume - Stomach Mean Dose 0.35 0.60 0.61 
Stomach Volume - Stomach Max Dose -0.19 0.12 0.55 
Stomach Volume - Stomach V45 0.16 0.08 -0.02 
Stomach Volume - Stomach V50 0.11 0.05 -0.04 
Stomach Wall Volume - Stomach Wall Mean Dose 0.63 0.66 0.66 
Stomach Wall Volume - Stomach Wall Max Dose -0.12 0.32 0.68 
Stomach Wall Volume - Stomach Wall V45 0.23 0.21 0.12 
Stomach Wall Volume - Stomach Wall V50 0.38 0.22 0.04 
Table 4.3 – Pearson correlation coefficients between stomach, stomach wall volumes and dose 
metrics 
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It can be seen how the strongest correlations are between the stomach wall volumes 
in each plan and the mean dose received by those volumes (0.63, 0.66 and 0.66 for 
the 50Gy3D, 50GyRA and 60GyRA respectively). 
 
Six patients had an overlap between the GTV and PTV2 and Stomach Wall structure 
whilst all patients had an overlap between the PTV1 and Stomach Wall structures. 
There was a strong correlation between the NTCP value and the Stomach Wall 
structure/PTV1 overlap structure volume for all treatment plans (Pearson’s R=0.80, 
0.77 and 0.77 for the 60GyRA, 50GyRA and 50Gy3D plans respectively). Figure 4.9 
shows the correlation between NTCP and the Stomach Wall/PTV1 overlap structure 
volume for the 60GyRA plans.  
 
 
Figure 4.9 – NTCP vs whole stomach wall/PTV1 overlap structure volume for 60GyRA radiotherapy 
plans 
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There was also a strong correlation between the NTCP value and the Stomach 
Wall/PTV2 overlap structure volume for the 60GyRA plan (R= 0.82) (Figure 4.10). 
 
 
Figure 4.10 – NTCP vs whole stomach wall/PTV2 overlap structure volume for 60GyRA radiotherapy 
plans 
 
4.5 Discussion 
This study has shown that using a VMAT delivered SIB technique it is possible to 
deliver a dose of 60Gy to the tumour whilst adhering to all standard OAR dose 
constraints for lower oesophagus tumours. In addition, this study, to my knowledge, 
is the first to specifically investigate the effect of dose escalation in lower 
oesophageal tumours on the stomach using radiobiological modelling.  
When comparing the 50GyRA to the 60GyRA plans there was a significant increase in 
TCP but also an increase in the mean dose parameter for the lung (See Table 4.2). 
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There was also a significant increase in mean TCP (≈12) going from the 50Gy3D to the 
60GyRA plan. Comparing 50Gy3D and 50GyRA, there was a statistically significant 
increase in lung V13Gy, which can be explained by the low dose wash associated 
with RapidArc type treatment plans, however V20Gy reduced and mean lung NTCP 
was reduced from 5.1% to 4.3%. There was a significant decrease in the heart 
V30/40Gy values. Although this did not result in a significant decrease in NTCP 
between the two planning methods in this study, this agrees with results from 
previous work I was involved in on mid-oesophageal cancer patients (82). For the 
60GyRA plans as a whole, the NTCP values for the heart and lung were lower than 
those found in the previous study on mid oesophageal cancer patients as would be 
expected due to the more inferior location of the tumour. However, there was still a 
similar modest increase in heart and lung toxicities when using the boost technique 
(82). This also agrees with the recently published study by Roeder et al who 
delivered 60Gy to patients with oesophageal cancer using a SIB technique and found 
acceptable acute and late overall toxicity to the lung and heart (126).  
However, when treating lower oesophageal tumours there is the added complication 
of having the stomach adjacent to the treatment volume. Here I used two models for 
the stomach and applied them to both the structure as a whole and inside and 
outside the PTV.  The model for the stomach wall by Feng et al (125) was found to 
predict a higher rate of toxicity than that for the whole stomach, most likely the 
result of the different endpoints of gastric bleeding and ulceration being modelled 
respectively. Max dose constraints of 45Gy and 60Gy were applied to the stomach 
outside (Stomach-Out) and inside (Stomach-In) the PTV respectively for the 60GyRA 
plans. The NTCP results for the 60GyRA when modelling the volume outside the PTV 
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were similar to those of the 50GyRA and 50Gy3D plans (Max NTCP of 23.0% and 23.4% 
for the 60GyRA and 50Gy3D plans respectively), suggesting that dose escalation may 
not pose any more risk to normal stomach than 3D conformal radiotherapy (Figure 
4.8). However, when considering the stomach wall structure as a whole it was found 
that there was up to 20% increase in NTCP when using the dose escalation plan 
compared to the 50GyRA plan. This value however could be considered as being the 
worst case scenario, as it is acknowledged that stomach movement and filling over 
the course of treatment may blur out any dose hot spots. Any NTCP value is also by 
nature calculated from a model that is open to interpretation therefore should only 
be used to give an approximate risk. It is fully acknowledged that radiobiological 
modelling inherently has limitations that limit its accuracy. Specifically in the case of 
this study, there is a lack of both clinical outcome data and radiobiological models 
for stomach toxicity when prescribing a dose >50Gy. However the model used was 
deemed to be the most suitable in this instance. The application of radiobiological 
modelling to partial organ irradiation is also a contentious one that may affect the 
results. However the purpose of this study was not to give definitive values of 
stomach toxicity, but to investigate and inform of the potential relative risks involved 
in dose escalation of lower oesophagus tumours both in a forthcoming trial and in 
clinical practice.  
 
I have shown that there is a strong correlation in NTCP with the volume of overlap 
between the stomach wall with both PTV1 and the high dose region PTV2. When 
more clinical data are available it may become apparent that safe delivery of the 
60Gy SIB is dependent on this volume of the overlap, which could potentially be 
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reduced by reducing the treatment margins for individual patients using techniques 
such as 4DCT, gating and breath hold protocols. However it has been reported that 
the inter-patient motion of oesophageal tumours is highly variable (127) and that 
even the use of 4DCT may not even fully account for organ motion in between 
fractions (128). A move to reduce population-based margins from those used in the 
SCOPE 1 and SCOPE 2 trials, rather than on an individual basis, may therefore 
increase the risk of failure to control the disease. The margins used in this 
investigation were taken from the SCOPE 2 protocol and therefore give an 
approximation of results from a forthcoming nationwide trial, taking into account 
the inherent errors in radiobiological modelling. 
 
An inclusion criteria for the SCOPE 1 trial was that patients were to have 
histologically confirmed carcinoma of the oesophagus with no more than 2cm of 
mucosal tumour extension into the stomach. As this patient group is also likely to be 
included in the SCOPE 2 trial, this study’s findings mean I would recommend that in 
the radiotherapy protocol that these patients be treated with caution until the safety 
of this dose escalation method is clearly defined within the SCOPE 2 trial.  
 
The results also suggest that the maximum prescribed dose achievable for each 
patient may be dependent on the volume of the stomach overlap with the treatment 
volume.  
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50Gy3D 50GyRA 60GyRA Wilcoxon signed-rank test  
 Median (range) Median (range) Median (range) 50Gy3D - 50GyRA 50Gy3D - 60GyRA 50GyRA - 60GyRA 
PTV1 
      V95% 98.2 (96.0-100) 99.1 (95.2-100) 97.0 (95.0-98.2) Z=0.53 (p=.57) Z=1.07 (p=.28) Z=1.36 (p=.17)  
PTV2 (GTV+0.5cm) 
      V95% 
  
95.1 (92.4-97.4) 
   TCP (%) Geh 38.7 (37.5-41.1) 37.8 (37.5-38.7) 50.9 (50.7-51.4) Z=2.11 (p=.04) Z=2.67 (p=.01) Z=2.81 (p=.01) 
       Lung 
      Mean dose (Gy) 9.8 (6.0-11.1) 10.2 (5.8-14.3) 10.7 (6.4-15.2) Z=1.78 (p=.07) Z=2.40 (p=.02) Z=2.80 (p=.01) 
V13Gy (%) 26.8 (20.0-35.9) 32.8 (15.1-51.6) 34.4 (18.0-54.2) Z=2.19 (p=.03) Z=2.55 (p=.01) Z=2.09 (p=.04) 
V20Gy (%) 19.7 (12.3-24.3) 11.3 (4.6-17.4) 15.6 (6.5-23.4) Z=2.55 (p=.01) Z=1.72 (p=.09) Z=2.81 (p=.01) 
NTCP (%) De Jaeger 5.1 (1.9-6.0) 4.3 (2.8-8.0) 4.7 (3.1-9.0) Z=1.49 (p=.14) Z=2.09 (p=.04) Z=2.80 (p=.01) 
       Heart 
      Mean dose (Gy) 26.8 (13.9-31.2) 21.2 (14.6-23.6) 20.2 (16.4-23.2) Z=1.68 (p=.09) Z=1.58 (p=.11) Z=0.15 (p=.88) 
V30Gy (%) 55.1 (9.7-67.9) 17.2 (8.2-25.3) 18.7 (10.3-22.6) Z=2.67 (p=.01) Z=2.55 (p=.01) Z=0.87 (p=.39) 
V40Gy (%) 16.2 (5.9-24.5) 10.1 (4.5-14.8) 10.6 (5.6-13.6) Z=2.67 (p=.01) Z=2.67 (p=.01) Z=1.58 (p=.11) 
NTCP (%) Gagliardi 8.9 (3.1-12.8) 4.9 (2.2-7.3) 6.1 (2.9-7.9) Z=1.90 (p=.06) Z=1.38 (p=.17) Z=2.80 (p=.01) 
       Stomach 
      Mean dose (Gy) 29.8 (5.5-44.2) 24.1 (5.4-40.4) 23 (6.5-36.1) Z=1.17 (p=.24) Z=0.97 (p=.33) Z=1.60 (p=.11) 
Max dose (Gy) 52.6 (49.6-53.4) 51.9 (42.4-52.9) 60.9 (51.6-61.6) Z=0.83 (p=.41) Z=2.61 (p=.01) Z=2.81 (p=.01) 
V45 (cc) 47.3 (7.3-80.4) 32.8 (0-49.8) 34.3 (5.4-25.4) Z=2.60 (p=.01) Z=2.50 (p=.01) Z=0.36 (p=.72) 
V50 (cc) 31.5 (0-23.4) 17.7 (0-14.8) 21.4 (2.2-19.2) Z=2.31 (p=.02) Z=1.78 (p=.07) Z=1.27 (p=.20) 
StomachIn max dose (Gy) 52.6 (49.6-53.4) 51.9 (42.4-52.9) 60.9 (51.6-61.6) Z=0.77 (p=.44) Z=2.61 (p=.01) Z=2.81 (p=.01) 
StomachOut max dose (Gy) 51.4 (49.4-53.1) 44.4 (36.6-43.6) 44.8 (42.3-46.1) Z=1.76 (p=.07) Z=1.79 (p=.07) Z=0.14 (p=.88) 
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NTCP (%) Burman 0.6 (0-2.5) 0.2 (0-1.3) 0.3 (0-3.4) Z=2.38 (p=.02) Z=0.35 (p=.73) Z=2.03 (p=.04) 
       Stomach wall 
      Mean dose (Gy) 29.5 (8.2-42.6) 22.9 (7.9-38.7) 22.4 (9.1-35.0) Z=0.97 (p=.33) Z=0.76 (p=.45) Z=0.87 (p=.39) 
Max dose (Gy) 52.6 (49.6-53.4) 51.9 (43.4-52.9) 61 (51.6-61.6) Z=0.77 (p=.44) Z=2.55 (p=.01) Z=2.81 (p=.01) 
V45 (cc) 28 (6.2-39.9) 17.9 (0-26.9) 17.9 (5.4-25.4) Z=2.19 (p=.03) Z=2.19 (p=.03) Z=0.46 (p=.65) 
V50 (cc) 15.8 (0-23.4) 9.1 (0-14.8) 9.2 (2.2-19.2) Z=2.31 (p=.02) Z=1.48 (p=.14) Z=1.28 (p=.20) 
NTCP (%) Feng 17.4 (3.5-24.9) 11.1 (3.6-18.9) 17.5 (3.2-39.4) Z=1.72 (p=.09) Z=1.99 (p=.05) Z=2.70 (p=.01) 
       Cord PRV 
      Dmax 0.1cc (Gy) 36.9 (16.1-41.3) 31.1 (26.2-44.1) 34.9 (28.4-39.6) Z=0.47 (p=.64) Z=0.18 (p=.86) Z=1.67 (p=.10) 
 
 
Table 4.2 – Comparison of dose volume metrics and TCP and NTCP values for all radiotherapy plans 
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4.6 Quantification of stomach movement  
The work in the previous section on approximating stomach toxicity when escalating 
the dose of lower oesophageal tumours to 60Gy was undertaken by modelling NTCP 
from RT plans constructed using the patients planning CTs.  
Although the majority of radiotherapy is delivered based on the plan from a single 
CT scan such as this, the anatomy of a patient may change over the course of 
treatment. This is mainly due to patient movement, inaccurate patient positioning, 
and organ motion (129). The first two of these factors can be minimised by patient 
and staff training and the third to a lesser extent by the use of protocols and 
specialist equipment. However there is still likely to be internal organ motion that 
cannot be accounted for without using advanced techniques such as Image Guided 
Radiotherapy (IGRT) where on set CT images are used to position the patient 
correctly and track their movement during the fraction. Nakamura et al discuss how 
large variations in stomach volume may have a detrimental effect on dose escalation 
when treating pancreatic cancer, despite using a breath hold technique (130). As a 
result, the dose distribution received by the patient during treatment will most likely 
differ slightly to what was planned. This will therefore affect the dose distribution 
around the tumour volume and also any adjacent organs at risk and in turn any TCP 
or NTCP modelling. The impact of variation in gas in the stomach on dose 
distribution should also be considered. For example, Kumagai et al found that dose 
conformation to the CTV was degraded due to bowel gas movement when treating 
pancreatic cancer using carbon ion beams (131) and consequently may also be 
applicable when using photon beams. Bouchard et al also found that changes in 
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stomach filling resulted in the boost target being missed when treating GEJ tumours 
with IMRT-SIB (132). 
 
Motion of the tumour volume is accounted for by the use of margins that encompass 
the tumour volume as set out in ICRU Reports 50 and 62 (80) & (81), and there are 
several methods reported in the literature to minimise the uncertainty of target 
localisation and reproducibility during RT for lung, liver and intrapelvic tumours. 
However there are usually no such margins added to the outline of organs at risk. 
Some trial protocols specify methods to decrease uncertainty in OAR position such 
as drinking a specific amount of water to fill bladder or stomach. According to Urie et 
al, the problem of internal organ motion is most pronounced and severe in the 
abdominal region (133), where organ motion may arise from differences in filling 
states in addition to respiratory motion. As there was no stomach filling protocol for 
the SCOPE 1 trial, a study to investigate and quantify stomach filling between 
fractions may give an indication towards what impact, if any, the inclusion of a 
stomach filling or breath hold protocol would have on stomach toxicity and dose 
distribution when treating lower oesophageal tumours. The objective of the 
following study was therefore to investigate the inter fraction movement of the 
stomach by analysing the cone beam computed tomography (CBCT) images for 
patients being treated for lower oesophageal tumours. This may then give an 
indication of how stomach movement could affect the dose distribution and 
consequent TCP and NTCP modelling when dose escalating patients. 
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4.7 Cone Beam Computed Tomography 
Compared to the now widespread multi-slice CT scanners, cone beam computed 
tomography is a relatively recent technology (134). A divergent pyramidal or cone 
shaped source of ionizing radiation is directed through the middle of the area of 
interest on to an x-ray detector on the opposite side (Figure 4.11). 
 
 
 
 
Figure 4.11 – Schematic of CBCT and conventional ‘fan’ CT. (135) 
 
Figure 4.11 shows the difference between CBCT and conventional ‘fan’ CT. In CBCT, 
multiple basis projections for the projection data from which orthogonal planar 
images are secondarily reconstructed. In fan beam geometry, primary reconstruction 
of data produces axial slices from which secondary reconstruction generates 
orthogonal images. The amount of scatter generated and recorded by cone beam 
acquisition is substantially higher, therefore reducing image contract and increasing 
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image noise.   
 
4.8 Preparing for analysis 
Patients undergoing treatment for lower oesophageal cancer at Velindre Cancer 
Centre receive a cone beam scan on the first three fractions of their radiotherapy 
treatment, and then once weekly. This follows the guidance of the National Cancer 
Action Team report published in August 2012 (136). By utilising and analysing these 
images together with the planning CT, a clearer picture of the inter-fraction 
movement of the stomach could be gained. The planning CT image and CBCTs 
images for 4 patients treated at Velindre Cancer Centre were chosen for analysis. 
Although there were a greater number of patients with CBCT images available, there 
was a large variation in image quality of the CBCT images. As a result, I was only 
confident in being able to correctly identify the stomach on these 4 patients. 
 
4.8.1 Outlining the stomach volume 
The stomach organ volumes were outlined on both the planning CT and the cone 
beam CT for each patient on the OMP treatment planning system. These were 
checked and confirmed for accuracy by an oncologist before commencing with the 
study.  
 
4.8.2 Image registration 
To assess the movement of the stomach, it was important to assign one reference 
stomach volume from which the movement over the other fractions could be 
quantified. For the purpose of this study, the volume outlined on the planning CT 
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scan was assigned as the reference volume. Another requirement was the position 
matching of the bony anatomy of the patient from one CT image to the next, this 
would ensure that any change in the stomach’s position within the patient would be 
relative. This process of matching the 3D position of the patient between images is 
known as image registration and I carried this out between the planning CT image 
and the 4 CBCT images on the Velocity (Varian Medical Systems Palo Alto) software 
package. This was largely an automatic process using specific tools within the 
software, however on some occasions some manual adjustments were required. 
Figures 4.12 and 4.13 show the before and after of the process.  
 
 
Figure 4.12 – Pre registration of planning CT and CBCT images 
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Figure 4.13 – Post registration of planning CT and CBCT images 
 
Once the CBCT image was matched to the planning CT the associated stomach 
structures were imported and all the separate registrations (CT:CBCT1, CT:CBCT2, 
CT:CBCT3 and CT:CBCT4) fused into one image set. This created one planning CT 
image set with the associated stomach volume from each registered CT:CBCT 
combination. This image set was then exported in DICOM format for analysis. 
 
4.8.3 Quantifying the stomach position 
The quantification of the change in the stomach’s position was carried out in CERR. 
The DICOM file containing all the stomach volumes was imported and a CERR .mat 
file created. A screen shot of the resulting file can be seen in Figure 4.14. It can be 
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seen how all the stomach volumes from the planning CT, CBCT1, CBCT2, CBCT3 and 
CBCT4 are all present as separate structures. 
 
 
Figure 4.14 – Screen grab from CERR showing all stomach volumes 
 
The position of each stomach structure was quantified by recording the maximum 
and minimum x, y and z coordinates of the structure using a script in Matlab. The 
coordinates for the centre of mass (COM) of each stomach structure were also 
recorded and the total volume of each stomach structure and the overlap volumes 
between the stomach and PTV and PTV2 calculated. 
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4.9 Results 
 
4.9.1 Difference in maximum and minimum XYZ coordinates and COM 
 
Patient 1 
The differences between the minimum, maximum and COM xyz coordinates and 
COM were calculated in mm. Table 4.4 shows the results for Patient 1. 
 
Difference Plan - CBCT1 Plan - CBCT2 Plan - CBCT3 Plan - CBCT4 
Min X -11.7 0 -6.8 2 
Min Y 2.9 2 13.7 8.8 
Min Z 0 3 0 -6 
Max X -1 3.9 -3.9 -4.9 
Max Y 4.9 3.9 -36.1 -19.5 
Max Z 9 6 18 9 
COM X -1.4 -1.2 -12.1 5.5 
COM Y -3.2 2.4 -5.7 -11.7 
COM Z 11.3 6.8 8.2 -0.1 
Table 4.4 – Difference in minimum, maximum and COM xyz coordinates (mm) for stomach structures 
(Patient 1) 
 
It can be seen that there is a displacement of up to 36.1mm in the maximum Y 
coordinate. 
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Patient 2 
Difference Plan - CBCT1 Plan - CBCT2 Plan - CBCT3 Plan - CBCT4 
Min X 4.9 -1 -1 5.9 
Min Y -3.9 -3.9 -4.9 -9.8 
Min Z -6 18 -3 18 
Max X 6.8 4.9 4.9 7.8 
Max Y 3.9 2 2 -1 
Max Z 6 42 12 30 
COM X 2.5 -6.7 -2.8 3.7 
COM Y 0.1 2 -0.8 -3.2 
COM Z 2.4 31.4 6.6 26.6 
Table 4.5 – Difference in minimum, maximum and COM xyz coordinates (mm) for stomach structures 
(Patient 2) 
 
The maximum displacement for patient 2 was 42mm in the Z direction. 
 
Patient 3 
Difference Plan - CBCT1 Plan - CBCT2 Plan - CBCT3 Plan - CBCT4 
Min X 8.8 4.9 2 2 
Min Y 3.9 5.9 2.9 5.9 
Min Z -3 0 -15 0 
Max X -8.8 0 -4.9 -3.9 
Max Y -10.7 6.8 2.9 2 
Max Z -12 -3 -12 0 
COM X 0.7 1.6 -1.6 0.7 
COM Y -6.3 6.4 1.5 0.8 
COM Z -7.3 0.4 -10.4 -0.8 
Table 4.6 – Difference in minimum, maximum and COM xyz coordinates (mm) for stomach structures 
(Patient 3) 
 
The maximum displacement for patient 3 was 15mm in the Z direction. 
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Patient 4 
Difference Plan - CBCT1 Plan - CBCT2 Plan - CBCT3 Plan - CBCT4 
Min X -3.9 -3.9 6.8 -2 
Min Y -1.27 0 0.2 -1.37 
Min Z -1.5 0 -0.3 -1.8 
Max X -2.9 -12.7 -9.8 23.4 
Max Y 2 -2 0 19.5 
Max Z 18 9 15 27 
COM X 1.3 -4.1 2.9 14.6 
COM Y -3.2 -2.5 2.1 -1.1 
COM Z 6.1 4.1 6.6 9.3 
Table 4.7 – Difference in minimum, maximum and COM xyz coordinates for stomach structures 
(Patient 4) 
 
The maximum displacement for patient 4 was 27mm in the Z direction. 
 
4.9.2 Average displacement of XYZ and COM coordinates 
The average displacement, regardless of direction, across all patients is shown in 
Table 4.8 
 
Average Plan - CBCT1 Plan - CBCT2 Plan - CBCT3 Plan - CBCT4 
Min X 7.3 2.4 4.2 2.9 
Min Y 5.9 2.9 5.9 9.5 
Min Z 6 5.3 5.3 10.5 
Max X 4.9 5.4 5.9 10 
Max Y 5.4 3.7 10.3 10.5 
Max Z 11.3 15 14.3 16.5 
COM X 1.5 3.4 4.9 6.1 
COM Y 3.2 3.3 2.5 4.2 
COM Z 6.8 10.7 8 9.2 
Table 4.8 – Average displacement of minimum, maximum and COM xyz coordinates 
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The average and range of displacement across all image sets, for both the maximum 
and minimum xyz coordinates of the structures are shown in Table 4.9: 
Average XYZ 
 X 5.4 (0.0-23.4) 
Y 6.7 (0.0-36.1) 
Z 10.5 (0.0-42.0) 
Table 4.9 – Average xyz coordinates across all image sets 
The average and range of displacement for the COM coordinates across all image 
sets are shown in Table 4.10: 
Average COM 
 X 4.0 (7.0-14.6) 
Y 3.3 (1.0-11.7) 
Z 8.7 (1.0-31.4) 
Table 4.10 – Average COM coordinates across all images 
 
4.9.3 Difference in total volume 
I also calculated the total volume of the stomach for each patient in each image. This 
would allow a clearer picture of the change in the stomach structure. Figure 4.15 
shows the change in absolute stomach volume for each CT scan. Table 4.11 shows 
the percentage difference in volume recorded with the CBCT scan compared to the 
planning scan. 
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Figure 4.15 – Absolute volume of stomach across treatment 
 
 
Plan Volume CBCT1 CBCT2 CBCT3 CBCT4 
Patient 1 166.30 -29.47 +0.43 +22.48 +14.69 
Patient 2 379.45 -20.94 -45.38 -24.65 -24.27 
Patient 3 128.78 +52.19 -3.34 +1.59 +0.38 
Patient 4 473.88 -27.06 5.57 +1.86 -64.86 
Table 4.11 – Percentage difference in stomach volume between CBCT and planning image 
 
4.9.4 Difference in overlap volumes 
The change in overlap volume between the stomach and PTV is shown in Figure 
4.16. Table 4.12 shows the percentage difference in volume recorded with the CBCT 
scan compared to the planning scan. 
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Figure 4.16 – Absolute volume of PTV/Stomach overlap across treatment 
 
 
Plan Volume CBCT1 CBCT2 CBCT3 CBCT4 
Patient 1 48.77 -26.51 +32.17 -26.58 +6.03 
Patient 2 195.92 -9.38 -74.87 -19.63 -53.26 
Patient 3 49.40 +18.93 +12.53 -26.30 +13.68 
Patient 4 108.94 -17.84 -2.08 +38.99 -33.85 
Table 4.12 - Percentage difference in PTV/stomach overlap volume between CBCT and planning image 
 
The change in overlap volume between the stomach and PTV2 is shown in Figure 
4.17. Table 4.13 shows the percentage difference in volume recorded with the CBCT 
scan compared to the planning scan. 
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Figure 4.17 – Absolute volume of PTV2/Stomach overlap across treatment 
 
 
Plan Volume CBCT1 CBCT2 CBCT3 CBCT4 
Patient 1 5.32 -70.45 48.52 -37.72 42.77 
Patient 2 93.12 -0.90 -83.13 -7.83 -62.64 
Patient 3 1.84 -99.38 -4.05 -100.00 -16.67 
Patient 4 42.23 -18.04 -15.27 30.86 -30.50 
Table 4.13 - Percentage difference in PTV2/stomach overlap volume between CBCT and planning 
image 
 
4.10 Discussion 
This study quantified the inter-fraction movement of the stomach by utilising the 
planning CT and CBCT images. It is well recognised that the stomach continually 
changes volume and position during radiotherapy (137). Previous work has used 
endoscopically placed clips to try to quantify gastric movement, however these 
proved problematic by displacement during the course of RT (138). Fluoroscopy has 
also been used to identify the most superior, inferior, anterior, posterior and lateral 
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site of mucosal surface on film (139). In this study however I outlined the stomach 
on a treatment planning system and used a Matlab script to record the maximum 
and minimum xyz coordinates of the stomach structure in CT images taken across 
the course of radiotherapy treatment. It is clear that stomach movement is a 
combination of translations, rotations and changes in morphology (size and shape) 
therefore the difference in the maximum and minimum xyz coordinates of the outer 
limit of the structure together with the difference in COM coordinates gives a good 
indication of any change. The change in total volume of the stomach in each patient 
was also recorded. It was found that there was on average a 5.4mm, 6.7mm and 
10.5mm displacement in the outer border (maximum) of the stomach for the x y and 
z coordinates respectively. For the COM there was a 4.0mm, 3.3mm and 8.7mm 
displacement in the x y and z coordinates respectively. In their study of six patients, 
Watanabe et al also found that there was increased movement in the z direction, 
recording an average inter fractional movement of 1.9mm, 1.5mm and 4.1mm in the 
x y z directions respectively for the COM.  It is unclear why the movement recorded 
in their study should be larger than in this thesis, however a possible reason is the 
differing techniques in outlining the stomach. It is unclear from their publication how 
the COM was calculated for instance, and they also make assumptions that the 
stomach was rectangular parallel piped in shape.  
In order to further ascertain the influence any change in stomach volume may have 
on the dose it receives and the plan in general, the change in total volume and 
overlap volumes between the stomach and PTV and PTV2 (high dose 60Gy) regions 
was calculated. For the total volume there was an average percentage change of 
21.20% (0.38-64.86) between the volume of the stomach on the planning CT and 
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over the course of the CBCT images. The same average change was 29.38% (2.08-
74.87) for the PTV/Stomach overlap volume and 41.80% (0.90-100) for the 
PTV2/Stomach overlap volume. Although the change in absolute volume for the 
overlap volumes may be small, Figures 4.8 & 4.9 show how a small change in volume 
can have an effect on NTCP value.  This would indicate that the risk of toxicity to the 
patient is highly variable from one fraction to the next for the same patient 
dependent on the filling state of the stomach. In order to minimise the risk of 
toxicity to the patient it would be beneficial to reduce the volume of the stomach 
receiving a high dose and to keep this condition constant over the course of 
treatment. A stomach filling protocol could therefore aid the minimisation of risk of 
toxicity to the patient. 
 
4.11 Conclusion 
One aim of the overall project was to investigate the role of radiotherapy dose 
escalation in improving patient outcome. In this chapter, radiobiological modeling 
suggests that although increasing the prescribed dose to 60Gy is likely to improve 
tumour control, it may also be associated with a significantly increased risk of 
toxicity to the stomach within the boost volume. Results also suggest that the 
maximum prescribed dose safely achievable for each patient in the future may be 
dependent on the volume of the stomach within the treatment volume. This implies 
that the volume of the stomach is a clinical parameter that may affect patient 
outcome by increasing the risk of toxicity. By analysing the position of the stomach 
on CBCT images during treatment and comparing to that on the planning CT image 
the study was therefore extended to show that the position and volume of the 
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stomach of a patient is also highly variable. In order to minimise the risk of toxicity of 
the stomach during treatment using high dose regimes (>50Gy), and thereby 
improve treatment outcome a stomach filling protocol is recommended before each 
fraction. This has been taken forward in the SCOPE 2 trial, with the patient being 
required to fast for 2 hours and the drink 200mls of liquid prior to CT planning and 
treatment in an attempt to reproduce the same anatomical position of the stomach. 
As radiotherapy becomes more individualised, dose escalation may be more likely to 
be administered to a high-risk patient group, therefore any information that may aid 
the identification of a patient as having high or low risk of recurrence or spread will 
be beneficial. In the next chapter, an investigation in the emerging field of CT image 
texture analysis aims to contribute to this aspect of radiotherapy. 
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Chapter 5 
 
Exploring the link between tumour heterogeneity and 
patient outcome 
 
5.1 Introduction 
Heterogeneity is a well recognised feature associated with adverse tumour biology 
(140). It has also been shown how heterogeneity is associated with variations in 
genomic subtypes, expression of growth and angiogenic factors and the tumoral 
microenvironment, which also result in regional variations within individual tumours 
in proliferation, cell death, metabolic activity and vascularity (141). Combining this 
information, tumour heterogeneity has also been associated with tumour grades 
(142).  
Tumour heterogeneity can be assessed by imaging or biopsy, however the latter is 
invasive and can be difficult to obtain, while the former being until recently was 
limited to qualitative rather than quantitative analysis. However advances in image 
processing methods and computing software have allowed heterogeneity 
information to be extracted from medical images that may not be visible to the 
naked eye. Because of its availability and ease of use, the analysis of CT images is 
one relatively easy method of gaining heterogeneity information. In addition, as CT 
images are routinely taken as part of radiotherapy treatment, there should also not 
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be any further burden on the patient in acquiring this information. Other advantages 
include the relatively high levels of spatial resolution and reproducibility as well as 
the important consideration that the individual pixel intensity within a CT image 
directly reflects the physical density of the organs. Heterogeneity on CT can be 
assessed using texture analysis (TA), which quantifies the distribution of pixel values 
within a lesion. Using different filters, the two most important CT texture features 
that may be extracted are entropy and uniformity (143). Entropy is a measure of 
texture irregularity, whilst the uniformity is a measure of the gray level distribution 
within the tumour. A heterogeneous lesion would therefore be expected to show 
high entropy and low uniformity. According to a review paper by Alobaidli et al, the 
initial implementation of TA to predict patient survival was suggested by Ganeshan 
et al in 2007 (144). The method proposed has since resulted in a number of 
published studies from single centres investigating the role of TA in a range of 
tumour sites including non-small cell lung cancer and colorectal cancer ((145) & 
(146)).  
Clinically, the ability to identify high-risk patients according to the heterogeneity of 
their planning CT images could be extremely beneficial. For example it could result in 
alternative treatment such as individualised radiotherapy dose escalation. The 
purpose of this study was therefore to analyse the CT heterogeneity of the planning 
CT images from the SCOPE 1 trial, and using the available outcome data, identify 
which heterogeneity parameters if any could be used to determine whether a 
patient was in a high or low risk group in terms of overall survival. To the author’s 
knowledge this is the first investigation of its type to analyse data from a nationwide 
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multicentre clinical trial, rather than from a single centre. 
Number of 
patients 
Reasoning 
179 
Contrast administration data not available for 22 
patients 
 
Centres = 34 
Age in years (Mean = 70, Range: 40-88) 
Male (n=93), Female (n=86) 
Cetuximab (Yes(n=83), No(n=96)) 
Adenocarcinoma (n=46) 
Squamous Cell Carcinoma (n=133) 
Tumour Stage 1 (n=6) 
Tumour Stage II (n=37) 
Tumour Stage III (n=117) 
Tumour Stage IV (n=19) 
Table 5.0 – Number of patients included in analysis in Chapter 5 
5.2 Texture analysis of the SCOPE 1 data 
The planning CT images of 179 patients from the SCOPE 1 database were analysed 
using a software package named TexRAD (TexRAD Ltd, Somerset, England, United 
Kingdom). This package was chosen due to it being the only commercially available 
software able to conduct the work required and work using the programme that had 
been published previously.  
  
5.2.1 TexRAD software package 
TexRAD is a sophisticated imaging risk stratification research tool that analyses the 
textures in existing radiological scans. Using a novel algorithm, it allows the user to 
analyse a region of interest (ROI) on a CT image, generating a number of parameters 
from that particular slice that may be associated with any aspect of patient outcome. 
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In addition to entropy, these parameters are shown in Table 5.1: 
 
Table 5.1 - TexRAD image analysis parameters 
 
Parameter Definition 
Mean  The average value of all the pixels within the region of interest  
Mean 
Positive 
Pixel 
(MPP) 
The average value of all the positive pixels within the region of interest 
SD  
A measure of how much variation or "dispersion" exists from the 
average (mean value). A low standard deviation indicates that the data 
points tend to be very close to the mean; high standard deviation 
indicates that the data points are spread out over a large range of 
values.  
Skewness  
A measure of the asymmetry of the histogram. The skewness value can  
be positive or negative. A negative skew indicates that the tail on the 
left side of the histogram is longer than the right side. A positive skew  
indicates that the tail on the right side is longer than the left side.  
A zero value indicates that the values are evenly distributed on both  
sides of the mean.  
Kurtosis  
A measure of the "peakedness" of the histogram. The kurtosis value  
can be positive or negative. A positive kurtosis indicates a histogram 
that is more peaked than a Gaussian (normal) distribution. A negative  
kurtosis indicates that histogram is flatter than a Gaussian (normal)  
distribution.  
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All the parameters shown in Table 5.1 can be acquired on a range of filters that are 
classified by the Spatial Scaling Factor (SSF). This approach uses the Laplacian of 
Gaussian band pass filters to highlight and enhance different spatial scales between 
fine and coarse textures (147) in a CT image, therefore providing a means of 
highlighting different aspects of tumour biology if required. In the TexRAD package 
the SSF range is from fine (2.0mm) to coarse (6.0mm). A lower SSF value (e.g. 2 mm) 
extracts and enhances features of a “finer” texture scale, whereas an SSF value of 3, 
4 or 5 mm extracts and enhances features of a “medium” texture scale and a higher 
SSF value (e.g. 6 mm) extracts and enhances features of a “coarser” texture scale 
(148). 
In addition to the texture analysis module, TexRAD has a separate ‘data miner’ 
module that allows the user to find and quantify relationships between the acquired 
heterogeneity parameters and patient outcome. There are a range of statistical 
analyses that can be undertaken on the data including correlations (Pearson) and 
Kaplan-Meier survival curve plotting.  
The Kaplan-Meier plotting module has a function that finds the lowest p-value in the 
log rank test between two groups. This function was used in the analysis of 
heterogeneity parameters with survival data.  
 
5.2.2 Considering contrast and cetuximab 
An important consideration when analysing CT images is whether the image is 
acquired using a contrast-enhancing agent. Radio contrast agents, such as iodine or 
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barium, are a type of medical contrast medium used to improve the visibility of 
internal bodily structures. The SCOPE 1 radiotherapy protocol suggests that using an 
intravenous contrast agent may be useful in distinguishing the GTV from the 
surrounding structures. Typically between 75cc and 150cc of contrast is used 
depending on the patient’s age, weight, cardiovascular health and the area being 
imaged.  Once the agent has been injected it circulates through the blood stream 
and increases the attenuation of the x-rays creating the image, thereby making the 
areas in which contrast is present show up better on the recorded image. However, 
the resulting image will have different pixel gray values and therefore heterogeneity 
when compared to the same scan acquired without contrast. This would therefore 
have an impact on the values of the parameters being recorded. When analysing the 
SCOPE 1 database it was important therefore to take the administration of contrast 
into account. As the data miner in the TexRAD software package is unable to stratify 
any survival data analysis according to a particular variable, the only way to 
compensate for contrast was to split the database into patients with and without 
contrast.  
In addition, as with previous analysis involving survival data in Chapter 3, the 
administration of cetuximab to each patient must be considered due to its effect on 
a patient’s outcome.  
 
5.2.3 Importing GTV outlines 
The TexRAD package allows a user to either manually outline a ROI or import from 
 
 
168 
an external source as an extensible markup language (XML) file. This study was an 
analysis of the SCOPE 1 database where a suitable ROI, the GTV, had already been 
outlined by the clinicians treating the patients. A workflow was therefore required to 
convert the GTV outline structure from the DICOM files received by the centres to an 
XML file suitable for import into TexRAD.  
The key to this process was identifying a suitable program that allowed the user to 
export a single ROI slice as an XML file for import into TexRAD. Discussions with 
colleagues resulted in the OsiriX software package being used for this purpose, 
however there was still a substantial amount of preparation work required. 
The resulting workflow for creating a single ROI slice and importing to TexRAD was as 
follows: 
1. Import raw DICOM files into CERR 
2. Delete all structures other than GTV 
3. Identify central slice of GTV and delete all other slices 
4. Save and export as new DICOM file 
5. Delete RTDose file 
6. Import and load new DICOM file into OsiriX (CT and RTStruct only) 
7. Export single GTV slice as XML file 
8. Manually alter XML file from OsiriX format to TexRAD format in XMLSpear  
9. Find correct image slice of patient on TexRAD 
10. Import and check position of GTV on image slice 
 
 
 
169 
 
Manually altering the XML file 
Step 8 was crucial in getting the above workflow to work. This section shows this 
process in more detail. Testing was carried out on the PTV structure. 
Figure 5.1 shows the PTV structure of a patient as imported into the Osirix program. 
 
Figure 5.1 – PTV outline in OsiriX 
 
Exporting the PTV structure as an XML file results in the following XML file (Figure 
5.2) 
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Figure 5.2 – XML output from OsiriX 
 
Initially it was thought that the first set of x y z coordinates (e.g. 35.517075, -
232.447800, -548) were required for translation to the TexRAD environment. 
However using those coordinates resulted in the following orientation of the 
structure when imported into TexRAD (Figure 5.3) 
 
 
171 
 
Figure 5.3 – In correct orientation of structure in TexRAD 
 
Figure 5.3 shows how the structure is not orientated correctly when compared to 
the original structure in OsiriX. The structure is flipped and is also smaller relative to 
the original.  
Using the ‘Point_px’ coordinates (e.g. 301.461853, 231.16812) however resulted in 
the correct orientation of the structure in TexRAD. By using these coordinates and 
arranging them in the XML format required by TexRAD (Figure 5.4), it can be seen in 
Figure 5.5 how the structure is imported correctly on to the appropriate slice.  No Z 
coordinate is needed as the structure is imported manually on to the appropriate 
slice.  
 
 
172 
 
 
Figure 5.4 – TexRAD XML format 
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Figure 5.5 – Correct import of structure into TexRAD 
 
The manual manipulation of each separate XML file for a large database of patients 
such as the SCOPE 1 trial would be extremely time consuming. Therefore, once the 
correct format of the XML file required was known the process of creating the files 
was automated in MatLab.   The automated version works slightly differently by 
creating the XML files directly from the CERR file for each patient. The script writes 
an XML files for each slice of the required structure (in this case the GTV) and saves 
them in a folder on the user’s computer. The user can then select which slice to 
upload into the TexRAD software. For this study, the central slice of the GTV was 
selected however where a central slice was not possible, for consistency the most 
superior slice from the centre of the GTV was always chosen.  
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5.2.4 Texture analysis algorithm settings for oesophageal cancer 
TexRAD allows the user to specify the algorithm to analyse the ROI. The pre-set 
algorithms are as follows: 
 ‘Liver’ - Includes only pixels between 0-300 HU within ROI after erosion for 
reducing edge artefacts in the case of large organ - Liver 
 ‘Lung’ - Includes only pixels above -50HU within ROI after erosion for 
reducing edge artefacts in the case of lung tumours 
 ‘Small Tumour’ - Includes only pixels above -50HU within ROI after erosion 
for reducing edge artefacts in the case of small tumours 
 ‘Phantom’ - Includes all pixels (no thresholds) within ROI after erosion for 
reducing edge artefacts in the case of CT phantom studies 
However there was no pre-set algorithm for the analysis of oesophageal tumours 
therefore this required the creation of a ‘custom’ setting. After consultation with the 
developers of TexRAD it was decided to use the settings of analyzing Hounsfield 
Units from -50 to infinity. Setting from -50 to 200 HU may exclude calcification of the 
oesophagus but discussions with the Chief Investigator of the SCOPE 1 trial stated 
that this would not be an issue with this dataset as calcification had not be observed. 
 
5.2.5 Analysed sample size 
179 patients’ DICOM images were imported into the TexRAD database. 22 patients 
were excluded from the whole SCOPE database of 201 patients due to their contrast 
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administration data being unavailable. 
Initially, analysis was carried out on two groups; those patients who were imaged 
using contrast and those who were not. To take into account both the use of 
contrast and the administration of cetuximab, the database was then split into 4 sub 
groups (Table 5.2). 
 
Cetuximab Contrast Number of patients 
Group 1 0 1 64 
Group 2 1 1 57 
Group 3 0 0 29 
Group 4 1 0 29 
Table 5.2 – Sub Groups of patients 
5.3 Results 
5.3.1 Texture analysis in TexRAD 
All parameters in Table 5.3 including entropy were analysed for their impact on 
overall survival using SSF values of 2-6mm. Results for patients imaged with contrast 
(121 patients): 
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SSF2 Cut Off P-value Log-Rank Upper Lower 
Entropy >5.355 0.0098 6.6801 77 44 
MPP <93.485 0.0236 5.1264 95 26 
Skewness >2.63 0.0017 9.8669 12 109 
Kurtosis >10.89 0.0044 8.1287 11 110 
SSF3 Cut off P-value Log-Rank Upper Lower 
Entropy >5.445 0.0081 7.0032 78 44 
SSF4 Cut off P-value Log-Rank Upper Lower 
Entropy >5.565 0.0028 8.9124 75 47 
MPP <169.87 0.0306 4.68 94 28 
SSF5 Cut off P-value Log-Rank Upper Lower 
Entropy >5.61 0.0142 6.0089 73 49 
Kurtosis >-0.825 0.0484 3.9003 109 13 
SSF6 Cut off P-value Log-Rank Upper Lower 
Entropy >5.195 0.0187 5.5293 100 22 
Kurtosis >-0.71 0.0097 6.6847 102 20 
Table 5.3 – Statistically significant results for all patients imaged with contrast 
Table 5.3 shows the statistically significant parameters for all patients imaged using 
contrast. The cut off indicates the patient group with worse survival. For example 
using the SSF2 filter, patients with an entropy value higher than 5.355 had worse 
survival than those with a value lower than 5.355. The upper and lower columns 
refer to the number of patients either side of the cut off point. The results show how 
entropy (highlighted in blue) is significant using all SSF filters.   
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Results for patient not imaged with contrast (58 patients): 
SSF2 Cut off P-value Log-Rank Upper Lower 
SD <277.86501 0.0309 4.6625 15 43 
Skewness >2.3 0.0003 12.8114 22 36 
Kurtosis >17.85500 0.0037 8.4059 4 54 
SSF3 Cut off P-value Log-Rank Upper Lower 
Mean >30.03 0.042 4.139 47 10 
SD >386.045 0.0233 5.1516 12 45 
Skewness >1.395 0.0057 7.6476 32 25 
Kurtosis >7.7 0.0018 9.7945 9 48 
SSF4 Cut off P-value Log-Rank Upper Lower 
Mean >42.875 0.0258 4.9737 45 12 
Skewness >1.115 0.016 5.8027 28 29 
Kurtosis >5.475 0.0023 9.2726 5 52 
SSF5 Cut off P-value Log-Rank Upper Lower 
Kurtosis >3.915 0.0269 4.9018 4 53 
SSF6 Cut off P-value Log-Rank Upper Lower 
Mean <576.39499 0.0382 4.3019 9 48 
SD <459.36 0.0459 3.9899 6 51 
Table 5.4 – Statistically significant results for all patients not imaged with contrast 
Table 5.4 shows the statistically significant result for all patients not imaged with 
contrast. The key result in this table is that Kurtosis (highlighted in green) is 
statistically significant for SSF2-5 whilst Skewness (highlighted in cyan) is significant 
for SSF2-4. 
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Group 1 
SSF2 Cut Off P-value Log-Rank Upper  Lower 
Entropy >5.225 0.02 5.41 49 15 
MPP <93.485 0.04 4.07 49 15 
Skewness >2.61 0.01 5.93 8 56 
Kurtosis >10.85 0.02 5.68 6 58 
SSF3 Cut off P-value Log-Rank Upper Lower 
Mean <157.01 0.03 4.53 18 47 
Entropy >5.39 0.02 5.79 46 19 
SSF4 Cut off P-value Log-Rank Upper Lower 
Mean <145.445 0.03 4.75 25 40 
Entropy >5.575 0.02 5.49 41 24 
SSF5 Cut off P-value Log-Rank Upper Lower 
Mean <320.505 0.03 4.57 14 51 
Kurtosis >0.195 0.02 5.89 45 20 
SSF6 Cut off P-value Log-Rank Upper Lower 
Mean <347.1299 0.02 5.10 15 50 
MPP <387.58 0.02 5.19 27 38 
Kurtosis >-0.66 0.03 4.84 55 10 
Table 5.5 – Statistically significant results for patients imaged with contrast and not administered 
cetuximab 
Table 5.5 shows that entropy (highlighted in blue) is a significant predictor for SSF2-4 
for contrast enhanced patients not administered with cetuximab. 
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Group 2 
SSF2 Cut off P-value Log-Rank Upper Lower 
Entropy >5.695 0.01 6.14 12 45 
Skewness >2.26 0.04 4.43 8 49 
SSF3 Cut off P-value Log-Rank Upper Lower 
Entropy >5.955 0.00 9.54 7 50 
SSF4 Cut off P-value Log-Rank Upper Lower 
Mean >260.965 0.05 3.98 16 41 
Entropy >6.095 0.00 12.04 8 49 
SSF5 Cut off P-value Log-Rank Upper Lower 
Mean >166.22 0.04 4.34 30 27 
SD >351.535 0.04 4.27 30 27 
Entropy >6.11 0.00 8.75 9 48 
SSF6 Cut off P-value Log-Rank Upper Lower 
Mean >266.73999 0.02 5.22 20 37 
SD >355.0551 0.01 6.22 29 28 
Entropy >5.91 0.00 8.65 18 39 
Table 5.6 – Statistically significant results for patients imaged with contrast and administered 
cetuximab 
Table 5.6 shows that entropy (highlighted in blue) is a significant predictor for all SSF 
filters for contrast enhanced patients who were administered with cetuximab. 
Group 3 
SSF2 Cut off P-value Log-Rank Upper Lower 
Skewness >2.3 0.00 9.42 11 18 
Kurtosis >5.61 0.03 4.66 17 12 
SSF3 Cut off P-value Log-Rank Upper Lower 
Skewness >1.92 0.01 6.10 9 20 
Kurtosis >7.945 0.02 5.67 5 24 
SSF4 Cut off P-value Log-Rank Upper Lower 
Skewness >1.115 0.01 7.80 16 13 
Kurtosis >5.475 0.00 8.40 4 25 
SSF5 Cut off P-value Log-Rank Upper Lower 
Skewness >0.67 0.02 5.31 18 11 
Kurtosis >3.25 0.05 3.95 5 24 
Table 5.7 – Statistically significant results for patients not imaged with contrast and not administered 
cetuximab 
Table 5.7 shows that skewness and kurtosis (highlighted in cyan and green 
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respectively) are significant predictors for all SSF filters for non-contrast enhanced 
patients who were not administered with cetuximab. 
Group 4 
SSF2 Cut off P-value Log-Rank Upper Lower 
Skewness >2.535 0.03 4.62 9 20 
Kurtosis >13.38 0.02 5.05 5 24 
SSF3 Cut off P-value Log-Rank Upper Lower 
Mean >56.385 0.04 4.18 20 8 
SSF4 Cut off P-value Log-Rank Upper Lower 
Mean >51.735 0.04 4.18 20 8 
SSF5 Cut off P-value Log-Rank Upper Lower 
Mean >39.45 0.04 4.18 20 8 
Table 5.8 – Statistically significant results for patients not imaged with contrast and administered 
cetuximab 
Table 5.8 shows that skewness and kurtosis (highlighted in cyan and green 
respectively) are a significant predictor for only SSF2 for non-contrast enhanced 
patients who were administered with cetuximab. 
 
5.3.2 Multivariate analysis 
The entropy values calculated for each patient from group 1 were included with the 
clinical factors of age and tumour staging (the most statistically significant factors 
identified in Section 3.7) in a multivariate logistic regression analysis in SPSS. The 
results are shown in Table 5.9 
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Variable 
Regression 
Coefficient 
Standard 
Deviation 
P-value 
Stage 1.952 0.125 <0.001 
Age 1.032 0.01 0.002 
Entropy 0.832 0.159 0.248 
Table 5.9 – Multivariate analysis  
The results show how entropy does not remain statistically significant when included 
with tumour staging and patient age.  
 
5.4 Discussion 
The hypothesis of this study was that CT image heterogeneity parameters from a 
clinical trial based patient cohort can be used as prognostic factors for patient 
outcome.  The SCOPE 1 database was therefore uploaded to a specific texture 
analysis software package that would allow the relationship between CT 
heterogeneity parameters and patient outcome to be explored. The original GTV 
outlines were imported and the CT image heterogeneity within these structures 
analysed using a number of parameters. The use of contrast for imaging was taken 
into account by splitting the database according to whether contrast was used or 
not. It is clear from the results that contrast has an effect on the heterogeneity, as 
the statistically significant parameters are dependent on whether contrast was 
administered prior to acquiring the CT images. For patients scanned using contrast, 
entropy was statistically significant using all SSF filters (Table 5.3), whilst for patients 
scanned with no contrast, entropy was not significant using any filters, although 
kurtosis was significant for SSF levels 2, 3, 4 and 5 (Table 5.4).  Skewness was also 
statistically significant for SSF 2, 3 and 4. However as with the other studies in this 
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thesis that included survival data, it was vital to take into account the administration 
of cetuximab when undertaking the analysis. The database was therefore further 
stratified according to cetuximab administration. The results in tables 5.5-5.8 show 
that the administration of cetuximab also had an influence on the statistically 
significant heterogeneity parameters that were found. For example in the contrast 
group, entropy remained significant using all SSF filters for patients who were 
administered cetuximab but was only significant for SSF 2, 3 and 4 when cetuximab 
was not administered. Similarly for patients not imaged with contrast, skewness and 
kurtosis remained significant for all SSF levels when no cetuximab was administered, 
but was only significant for SSF 2 when cetuximab was administered. Although it is 
interesting that the administration of cetuximab has an influence on CT 
heterogeneity parameters, and may confirm its effect on the biology of the tumour 
volume, it does not appear to have a clinically meaningful beneficial effect. The 
conclusion of the SCOPE 1 trial was that cetuximab is not recommended for use in 
patients with oesophageal cancer (56), therefore it is unlikely to be used again in the 
future.  It is only the results of the patients not administered cetuximab that are 
therefore relevant for further discussion. In addition, there were considerably more 
patients scanned using contrast than without (121 compared to 58). This would 
suggest that the most clinically relevant group in this analysis is Group 1, where 
contrast is used but no cetuximab is administered. The key result of this group was 
that the entropy value of a patient’s planning CT image was a statistically significant 
predictor of the patient’s overall survival. The most statistically significant result for 
entropy was using SSF4, with a cut off value of 5.575 and p=0.0191.   Yip et al also 
found entropy to be a statistically significant predictor of survival in a similar study of 
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patients with oesophageal cancer. Their retrospective study consisted of 36 patients 
from a single centre, all of whom were imaged with a contrast enhanced CT scan 
before and after CRT treatment. The chemotherapy regime differed in that patients 
received Cisplatin and 5-Fluorouracil (5-FU) compared to Cisplatin and Capecitabine 
in the SCOPE 1 trial. These differences in CRT regime, and the number of patients 
and centres may explain why the significant entropy cut off values found in their 
study of 7.356 and 7.116 for the medium and coarse filters respectively were higher 
than those found using the larger multicentre database here. Ganeshan et al also 
found a link between CT heterogeneity parameters and patient survival, albeit only 
with uniformity (149). Again, this was a relatively small database of 21 patients and 
patients were not scanned using contrast enhanced CT.  
When included in a multivariate cox regression analysis with age and tumour staging 
data, entropy did not remain significant. This may indicate that there is a strong 
correlation between the entropy parameter and tumour staging and age. In a clinical 
setting however, TA derived heterogeneity parameters are unlikely to be used as 
singular prognostic factors of outcome. Therefore although entropy is not significant 
in a multivariate model, it may still be useful in improving the depth of information 
on which a clinical decision is made.  
A strong point of this study is that the analysed database is from a national multi-
centre clinical trial, with some standardization of the radiotherapy planning scan 
parameters. However, it should be noted that this may also have a detrimental 
effect on the results due to the number of individual CT scanners (30 centres) used 
to collect the images for the patients. It has been shown previously that there is a 
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variation in image settings between the same model of CT scanner in different 
centres (150). This may be exacerbated in this study due to the nationwide nature of 
the database and that a variety of CT scanner models will have been used across the 
centres. The study is also limited by the fact that analysis using the TexRAD package 
is limited to that of a single slice of the GTV rather than the whole volume. 
Discussions with clinical colleagues concluded that the heterogeneity of a tumour is 
likely to not be uniform across its whole volume. As such the TA parameters will also 
likely be different depending on which section of the tumour is analysed. It is 
essential that this aspect by investigated further and the influence of single slice vs 
whole volume analysis confirmed.  
The field of TA of diagnostic images is however relatively young; for example at the 
time of writing, a PubMed search of the combined words ‘CT’, ‘Texture’, ‘Analysis’ 
and ‘Outcome’ returned 23 documents. A considerable amount of work still needs to 
be carried out in order to establish the exact relationship between TA parameters 
and patient outcome. The review article by Chalkidou et al concludes that there is 
currently insufficient evidence to fully support a relationship between texture 
features and patient survival (151). In the case of the work presented in this thesis, 
the statistically significant parameters would need validating on a similar data set if 
one were to come available. The forthcoming SCOPE 2 trial may provide an 
opportunity for this work. 
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5.5 Conclusion 
Although the exact value of the cut off in entropy value may differ between studies, 
these results show the potential of texture analysis to provide clinically meaningful 
information. The results of the multivariate analysis also suggest that heterogeneity 
parameters may not be suitable as individual predictors of outcome. The application 
and use of texture analysis in clinical practice is still exploratory in nature, but the 
clinical trial nature of the database in this study adds significant weight to the 
evidence that CT heterogeneity parameters can be useful as potential predictors of 
patient outcome. This work differs slightly from those in previous chapters by 
establishing a relationship between a diagnostic element of radiotherapy and 
outcome rather than the dose delivery aspect of treatment. In the future, this may 
allow high-risk patients to be identified and their treatment modified or 
individualized.   
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Chapter 6  
 
Conclusions and further work 
 
6.1 Conclusions 
 
The work contained within this thesis has concentrated on relating quantifiable 
parameters associated with the treatment of oesophageal cancer with patient 
outcome. In all, three main original contributions to research were made that 
together succeeded in meeting the aims and objectives of the study as set out in 
Section 1.9. In Chapter 3 a conformity index was used as a quality metric of the 
planned dose distribution for each individual patient. It was shown in a univariate 
analysis that the relationship between the 95% isodose and the PTV was significantly 
associated with patient survival. In addition, it was shown how the quality of the 
dose distribution could be improved by delivering the radiotherapy dose using the 
VMAT technique rather than the 3D-CRT technique that most patients in the trial 
received. Although the relationship between dose distribution and outcome did not 
remain significant when included in a multivariate analysis with other biological and 
clinical factors, the study suggests that the quality of the dose distribution may have 
a greater impact on patient outcome than thought previously. The work also 
suggests that using the VMAT technique offers a safer tool for dose escalation, 
therefore this aspect of the study was carried forward to Chapter 4. Here, as part of 
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important preparatory work for a forthcoming clinical trial, TCP and NTCP modelling 
was used to quantify the relationship between the dose received by the tumour and 
its effect on treatment outcome in terms of both tumour control and normal tissue 
toxicity. The study was centred on dose escalation for patients suffering from lower 
oesophageal cancer as the possible increased risk to the stomach in these patients 
was unknown. By comparing three different planning methods, the results show that 
the probability of tumour control is increased with higher doses. However, 
depending on the volume of the overlap of the stomach with the high dose region of 
the plan there may also be considerable increased risk of stomach toxicity for 
patients when the prescription dose to the tumour is escalated. Although further 
work showed that the change in volume of the overlap over the course of treatment 
was small, any variation could still impact on the risk of toxicity. Including a protocol 
to minimise stomach volume during treatment may therefore improve patient 
outcome. A similar conclusion was found in the dose escalation study on mid 
oesophageal patients, where it was reported that dose escalation was feasible 
depending on the amount of overlap between the lung and the PTV. Both of these 
studies suggest that as radiotherapy moves towards dose escalation, there may be 
additional differential issues such as these to consider compared to previous 
planning techniques and dosing regimes. However in both instances, the increased 
likelihood of toxicity is almost certainly justified if the increased tumour control is 
achieved. Finally, a software package was utilised that allowed the relatively new 
found relationship between heterogeneity parameters of CT images and patient 
outcome to be explored.  Previous work in the literature has shown this relationship 
to be statistically significant however these studies were confined to single centres. 
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The study undertaken in Chapter 5 is therefore the first to expand this type of 
analysis to data from a nationwide clinical trial. By analysing the area of interest 
originally outlined for treatment during RT the results confirm and strengthen those 
found previously in the literature. Although CT heterogeneity parameters are 
unlikely to be used as independent identifiers of patient outcome in a clinical setting, 
they can be generated from images already acquired as part of routine RT 
treatment. This means they are a relatively easy method of improving the depth of 
information on which a clinical treatment decision is based and its effect on 
treatment outcome. This type of analysis is comparatively new in nature and 
confidence and certainty in the results and how to best use them will grow as the 
field matures.  
As the treatment of cancer becomes increasingly personalised, the ability to identify 
both clinical and technological parameters that affect an individual patient’s 
outcome will become progressively more important. The author hopes that the work 
contained within this thesis goes some way to contributing in this regard. 
 
6.2 Further work 
There are several areas investigated within this study that open up the possibility of 
further work. In Chapter 3, the investigation was carried out on patients whose 
radiotherapy dose was planned using Type B algorithm. This was due to the 
increased accuracy of the dose calculation in and around areas of low density tissue 
such as the lung when compared to those planned using Type A algorithms. It could 
be possible to increase the power of this study, or alternatively provide a validation 
dataset, by re-calculating the RT plans of the 109 Type A patients with a Type B 
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algorithm.  However this would mean that half the resulting database of plans was 
calculated using only the specific algorithm and TPS available at the author’s centre. 
More importantly, as the treatment planning system of each centre that participated 
in the SCOPE 1 trial is dosimetrically matched to their local linear accelerators, a re-
calculated plan at the author’s centre would not give a correct representation of the 
actual dose received by the patient. This would mean that the outcome data did not 
match the dose distribution being analysed and might skew the results and eliminate 
any confidence in the conclusions. A possible solution would be to contact the 
centres at which the patients were planned in order to gain the required information 
or to ask the centre themselves to re-calculate using a Type B algorithm and send 
the DICOM data for analysis. The work on dose escalation in Chapter 4 is being taken 
forward in the SCOPE 2 clinical trial and will go some way towards addressing the 
role of dose escalation for oesophageal cancers. As a result of the work on gastric 
movement, a stomach filling protocol is being added to the SCOPE 2 trial protocol. It 
would be beneficial to therefore explore the same movement parameters after the 
inclusion of this protocol to confirm its effect on gastric movement and positional 
consistency. The modeling work could be expanded to include an analysis of spot 
scanning proton planning similar to the work carried out by Warren et al on mid-
oesophageal patients (152). It is possible that the use of proton planning in treating 
lower oesophageal cancer patients could reduce the risk of toxicity to the stomach 
due to the nature of the Bragg peak absorption curve in the body. However the main 
limiting factor is the volume of stomach within the high dose region, therefore 
identifying or designing a suitable pre-treament planning protocol to reduce this 
should be the priority. Finally, the work in Chapter 5 was conducted on a single slice 
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of the GTV. The work will therefore be expanded to investigate how the TA 
parameters may change over the length of the tumour. It would also be extremely 
interesting to apply the CT heterogeneity analysis software used in Chapter 5 to 
CBCT images acquired during the course of RT treatment. It may be possible to 
observe a change in the biology of the tumour during treatment, which could result 
in treatment being adjusted to improve the outcome of the patient. Although the 
inferior image quality of CBCT compared to RT planning CT scans will likely need 
overcoming in a clinical setting, initial results by Fave et al and van Timmeren et al 
on lung cancer have been promising (153) & (153). This could therefore be further 
explored in oesopheageal cancer using the SCOPE 1 database. The results of this 
chapter should also be validated on a similar dataset. The forthcoming SCOPE 2 trial 
may therefore provide an opportunity for this work. Other oesophageal trials such as 
NeoScope would also be suitable. However with both of these datasets, as was the 
case with the SCOPE 1 trial in this thesis, the patient cohort would have to be split 
according to the treatment parameter that affects overall patient survival reducing 
the overall power of the analysis.  
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Dissemination of work and attended courses, seminars 
and conferences 
 
7.1 Publications 
 
Journal Papers 
Relating CT heterogeneity parameters and patient outcome in the SCOPE 1 
oesophageal cancel trial 
Rhys Carrington, Emiliano Spezi, Sarah Gwynne, John Staffurth, Thomas Crosby 
(In preparation) 
 
The influence of dose distribution on treatment outcome in the SCOPE 1 
oesophageal cancer trial 
Rhys Carrington, Emiliano Spezi, Sarah Gwynne, Peter Dutton, Chris Hurt, John 
Staffurth, Thomas Crosby 
January 2016 · Radiation Oncology 1/2016; 11(1).  
 
The effect of dose escalation on gastric toxicity when treating lower oesophageal 
tumours: a radiobiological investigation 
Rhys Carrington, John Staffurth, Samantha Warren, Mike Partridge, Chris Hurt, 
Emiliano Spezi, Sarah Gwynne, Maria A. Hawkins, Thomas Crosby 
December 2015 · Radiation Oncology 12/2015; 10(1).  
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Radiobiological determination of dose escalation and normal tissue toxicity in 
definitive chemoradiation therapy for esophageal cancer 
Samantha Warren, Mike Partridge, Rhys Carrington, Chris Hurt, Thomas Crosby, 
Maria A. Hawkins 
International journal of radiation oncology, biology, physics 10/2014; 90(2):423-429.  
 
Conference abstracts 
EP-1632: Should dose escalation in oesophageal cancer be re-visited? A 
radiobiological analysis 
S.Warren, M.Partridge, M.Hawkins, R.Carrington, T.Crosby, C.N.Hurt 
Radiotherapy and Oncology 12/2014; 111:S218.  
 
EP-1583: An analysis of the dose distribution in the SCOPE 1 oesophageal cancer trial 
data 
R.Carrington, E.Spezi, S.Gwynne, P.Dutton, C.Hurt, J.STaffurth, T.Crosby 
Radiotherapy and Oncology 12/2014: 111:S196-S197.  
 
EP-1470: Does gastric toxicity influence dose escalation in lower oesophageal 
tumours? A radiobiological investigation 
J.Staffurth, R.Carrington, S.Warren, M.Partridge, C.Hurt, E.Spezi, S.Gwynne, 
M.Hawkins, T.Crosby 
Radiotherapy and Oncology 04/2015; 115:S797-S798.  
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PO-0986: Can radiotherapy dose distribution be related to outcome? An analysis of 
the SCOPE 1 oesophageal cancer trial data 
R.Carrington, E.Spezi, S.Gwynne, P.Dutton, C.Hurt, T.Crosby, J.Staffurth 
Radiotherapy and Oncology 04/2015; 115:S526-S527.  
 
TH-AB-304-11: The influence of radiotherapy treatment method on dose distribution 
and its relation to patient outcome in the SCOPE 1 oesophageal cancer trial using 
Type B algorithms. 
R.Carrington, E.Spezi, S.Gwynne, P.Dutton, C.Hurt, T.Crosby, J.Staffurth 
Medical Physics (Impact Factor: 2.64). 06/2015; 42(6):3703.  
 
SU-E-T-69: A radiobiological investigation of dose escalation in lower oesophageal 
tumours with a focus on gastric toxicity 
R.Carrington, J.Staffurth, S.Warren, M.Partridge, E.Spezi, S.Gwynne, M.Hawkins, 
T.Crosby 
Medical Physics 06/2015; 42(6):3346.  
 
7.2 Attended courses, seminars and conferences 
 
Courses attended at Cardiff University 
 Biomedical Research Techniques (October – December 2012) 
 How to write a literature review (January 2013) 
 Endnote: An introduction (March 2013) 
 Matlab: An introduction (June 2013) 
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 Effective Researcher: Effective Progress – The Second Year 
 
Courses attended elsewhere 
 ESTRO course in Quantitative Methods in Radiation Oncology, Cambridge, UK 
(September 2013) 
 
Conferences and seminars attended 
 CRW symposium, Swalec Stadium, Cardiff, March 2013, (Poster presentation) 
 Departmental Seminar, Velindre Cancer Centre, Cardiff, May 2013 (Oral 
presentation) 
 UKRO, Nottingham, October 2013 (Poster presentation) 
 ESTRO, Vienna, April 2014 (Poster presentation) 
 MPCE, Cardiff, June 2014 (Oral presentation) 
 NCRI, Liverpool, November 2014 (Poster presentation) 
 ESTRO, Barcelona, April 2015 (Poster presentation) 
 UKRO, Coventry, June 2015 (Oral and poster presentation) 
 AAPM, Anaheim, Los Angeles, July 2015 (Oral and poster presentation) 
 ESTRO, Turin, May 2016 (Poster presentation) 
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Appendix 
A1 Computer Coding 
 
 
function p=logranktest(tA,cA,tB,cB) 
% log rank risk for survival (two variablles only) 
% written by Issam ElNaqa, 02/03 
tt=[tA,tB]; 
ct=[cA',cB']; 
lA=length(tA); lB=length(tB); 
nt = length(tt); 
[tt,ind] = sort(tt); % should in ascending order 
ct = ct(ind); 
ft = ones(1,nt); 
totcumfreq = nt-cumsum(ft)+1; 
qt=ct./totcumfreq; 
nAc=lA; 
nBc=lB; 
for i=1:nt 
    nA(i)=nAc; 
    nB(i)=nBc; 
    if (ind(i)<=lA) 
        nAc=nAc-1; 
    else 
        nBc=nBc-1; 
    end 
end 
EA=sum(nA.*qt); 
EB=sum(nB.*qt); 
OA=sum(cA); 
OB=sum(cB); 
testA=(OA-EA)^2/EA; 
testB=(OB-EB)^2/EB; 
logtest=testA+testB; 
p=1-max(min(gammainc(logtest/2,1/2),1),0); % chi2 by integrating 
gamma. 
HazardRatio=((OA/EA)/(OB/EB))/2;  
 
Figure A1 – Script for computing Hazard Ratio 
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SCOPE 1 Radiotherapy Guidance and Procedures 
 
 
Radiotherapy Treatment Planning and Delivery 
 
 
Abbreviations and Glossary 
 
CT Computerised tomography 
CTV Clinical Treatment Volume 
DVH Dose Volume Histogram 
EUS Endoscopic ultrasound 
FSD Focus to surface distance 
GOJ Gastro-oesophageal junction 
GTV Gross Tumour Volume 
ICRU International Commission on Radiation Units and Measurements 
IRMER The Ionising Radiation (Medical Exposure) Regulations 
OAR Organs at Risk 
PET Positron Emission Tomography 
PRV Planning Risk Volume 
PTV Planning Treatment Volume 
RCR The Royal College of Radiologists 
TMG Trial Management Group 
WCTU Wales Cancer Trials Unit 
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Introduction 
 
This document describes the process for radiotherapy treatment planning of 
oesophageal cancer and has been developed for the purpose of the SCOPE 
1 trial. The aim is to aid the delivery of high quality radiotherapy and to allow 
quality assurance procedures to be applied to ensure this is achieved. 
However, some aspects of the process are not explicitly defined and will vary 
according to the capabilities and characteristics of each centre and to some 
extent their local practice and experience. Guidelines for the delivery of 
concurrent chemotherapy are described elsewhere.  
 
1.1 General Requirements 
 
Conformal radiotherapy with a pixel based inhomogeneity correction is 
essential. The type of dose calculation algorithm to be used is not specified; 
the guidelines for Planning Treatment Volume (PTV) coverage are given later 
in section 5.1 and are based on use of a pencil beam algorithm. It is 
recognised however that these guidelines may not be realistic for other 
algorithms. Centres should assess dose coverage to PTV according to local 
experience in this case. Photon energy should be between 6MV and 10MV 
(but energies in excess of 10MV should only be used in exceptional cases 
due to secondary build-up depth). A combination of energies is permissible. 
Final calculation grid spacing of no greater than 0.3cm is recommended. 
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1 Patient Positioning and Computerised Tomography (CT) 
Planning Scan Acquisition 
 
2.1 Timing of the Planning Scan 
 
The planning scan should be performed within 2 weeks of starting the neo-
adjuvant phase of chemotherapy AND within 6 weeks of the staging CT scan. 
 
2.2 Treatment Position 
 
Patients should be planned and treated in the supine position with both arms 
above their heads. Immobilisation of the patient using a ‘chest board’ which 
fixes the arm positions above the head is recommended and immobilisation of 
the legs with a device similar to a ‘knee-fix’ is also encouraged. 
 
2.3 System of Reference 
 
For the CT planning scan a suitable system of reference must be used. Three 
transversely aligned tattoos marked at the right, anterior and left surfaces of 
the patient (tattoos correspond to radio-opaque markers held in place for the 
duration of the CT planning scan) enable the patient to be correctly aligned for 
treatment. A single reference mark (for example the anterior mark) may be 
used to reference the isocentre of the external beam plan.  
 
2.4 Use of IV Contrast 
 
Use of IV contrast is recommended in line with RCR Recommendations1. 
Where contrast-enhanced CT planning scans are to be used for the dose 
calculation there may be an effect on the monitor unit calculation, which will 
not be representative of the treatment situation. The magnitude of this effect 
will vary between individual patients, scanning protocols and centres. There 
are three acceptable solutions: 
1. Use of single contrast-enhanced scan only. This can be used if the 
centre is satisfied that there are no implications of using contrast, for 
example if it has performed a study to assess the dosimetric effects of 
using contrast.  
2.  Use of both contrasted-enhanced and non-contrast CT scans. The 
contrast-enhanced scan is used for target volume definition and fused 
with the non-contrast scan which is used for dose calculation. 
3. Use of single contrast-enhanced scan and assignation of unit density to 
heavily contrasted areas.  
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2.4.1 Additional issues to consider with the use of IV contrast 
enhanced radiotherapy planning scans 
 
1. Safety: It is strongly recommended that each centre develops its own 
working instructions for the delivery of IV contrast for radiotherapy 
planning scans. It is also recommended that the RCR document 
‘Standards For Iodinated Intravascular Contrast Agent Administration 
To Adult Patients’ is read and followed. The following should be 
considered: 
a. Patient identification:  
i. Ensure that the correct patient is scanned following the 
correct protocol.  
ii. Ensure consent form for this procedure is completed 
b. Allergic reaction to contrast:  
i. Awareness of features associated with increased risk of 
reaction: history of allergy or asthma. Ask if patient has 
had previous contrast-enhanced imaging 
ii. Awareness of medical support: a member of the medical 
team should be contactable throughout the duration of 
the scan and the emergency drugs trolley should be 
brought round to the scanner or be easily accessible. 
c. Effects of contrast in renal insufficiency; ensure recent creatinine 
is available and that patient is not dehydrated. Note that risks 
are increased in elderly patients, patients with cardiac failure, 
and diabetics (especially if taking oral metformin) 
i. If serum creatinine level is above 120mol/l but less than 
150micromol/l, a member of the medical team should be 
informed and contrast administered at their discretion. 
ii. If serum creatinine level is above 150mol/l, a member of 
the medical team should be informed and contrast should 
not be administered, unless patient is on dialysis that will 
take place within 24hrs. 
If in doubt, the decision should be made by a member of the 
medical team and if necessary discussed with a member of the 
TMG. Any reactions should be included in the patient’s notes, and 
reported to the WCTU.  
 
2. Practical procedure for IV contrast:  
a. Insert cannula  
b. Position patient in radiotherapy position 
c. Select correct imaging protocol; consider requirement for pre 
and post- contrast image acquisition 
d. Optimise image quality with IV contrast: These are 
recommendations based on experience from three centres, who 
have kindly allowed us to review their clinical protocols: Mount 
Vernon Hospital, Royal Marsden NHS Trust, and Velindre NHS 
Trust. Centres need to be aware that these recommendations 
are from clinical experience with their own hardware and 
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software, and that some degree of local development may be 
required. 
i. Type: Either Omnipaque or Visipaque can be used 
ii. Temperature: ensure contrast is brought to room 
temperature by placing in warm water 
iii. Volume: 100ml  
iv. Infusion rate: 2.5-3mls per sec. This may be reduced to 
as low as 1ml per sec, depending on cannula size 
v. Time between injection and CT: 35-40s 
e. Remove cannula at completion of scan 
 
 
 
2.5 Extent of the Scan 
 
To enable accurate assessment of the dose to organs at risk the scan should 
extend superiorly to at least one CT slice above the apices of the lungs and 
inferiorly to the iliac crest (L2). Scans for upper third tumours may need to 
extend superiorly to the tragus. Slice thickness should be no greater than 
0.5cm.  
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2 Organs at risk (OAR) 
 
 
3.1 Lungs 
 
The full extent of the right and left lungs are to be outlined, this should be 
done in such a way that the planning system will be able to calculate a 
combined lung Dose Volume Histogram (DVH). 
 
3.2 Spinal Cord 
 
The spinal cord should be outlined on slices which include or are within 2cm 
of the PTV in the superior and inferior directions. A Planning Risk Volume 
(PRV) for the cord is created to account for positioning error. The size of the 
margin added to the cord being commensurate with the accuracy of treatment 
delivery expected and as such, the tolerance level allowed in portal image 
verification on treatment. For example, Velindre Hospital applies a margin of 
0.5cm isotropically to generate the spinal cord PRV and allows no more than 
0.5cm movement of the isocentre on treatment before corrective action is 
taken. See section 7.1 
 
3.3 Heart 
 
The whole heart should be outlined to the extent of the pericardial sac (if 
visible). The major blood vessels (superior to the organ) and the inferior vena 
cava (towards the inferior extent of the heart) are excluded. Appendix 1 
contains an example.   
 
3.4 Liver 
 
The whole liver should be outlined if the level of its superior edge overlaps 
with the level of the inferior extent of the PTV.  
 
3.5 Kidneys 
 
Each kidney should be outlined separately if the level of its superior edge 
overlaps with the level of the inferior extent of the PTV. 
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3 Definition of Treatment Volumes 
 
 
Targets are defined following the principles of ICRU 50 and 62. The spinal 
cord and spinal cord PRV (section 3.2) should be outlined prior to definition of 
the treatment volumes. Dialogue with a specialist Upper GI radiologist 
regarding the target volume definition is encouraged. 
 
4.1 GTV Definition 
 
The Gross Tumour Volume (GTV) is the gross primary and nodal disease as 
defined on the planning CT scan with all available diagnostic information. This 
should include as a minimum: Endoscopic ultrasound (EUS) and contrast-
enhanced CT. Some centres may have access to Positron Emission 
Tomography (PET) scans and their use is encouraged. In some cases the 
EUS will not define the full extent of the disease because the scope has failed 
to pass through the stricture, in such cases information is used from the 
original endoscopy and the diagnostic CT scan. 
 
The GTV is localised on axial slices of the planning CT scan using the EUS to 
define a reference point (tracheal carina or the arch of the aorta) as well as 
the superior and inferior extent of the GTV. In principle the GTV should 
encompass the disease as defined on any of the above imaging modalities 
used (i.e. CT, EUS and/or PET), even if it’s only apparent on a single 
modality. 
 
4.2 CTV Definition  
 
The Clinical Treatment Volume (CTV) is defined differently in two clinical 
situations depending on the proximity of the GTV to the gastro-oesophageal 
junction (GOJ). Tumours that have a high risk of disease within the stomach 
have the potential to metastasise to lymph nodes that will only be included 
within the CTV if specifically outlined. Thus, two CTV definition protocols are 
defined below.   
 
4.2.1 CTV Definition for a GTV which does not extend to within 2cm of the 
gastro-oesophageal junction. 
 
The CTV will comprise the GTV plus a margin of up to 1cm laterally and 2cm 
superiorly and inferiorly (along the line of the oesophagus). It is created in 
three steps: 
 
 Step 1: The GTV is copied and labelled ‘CTVA’ (so that the GTV is 
preserved as a separate structure) and extended by 2cm superiorly 
and inferiorly by manually drawing along the line of the oesophagus.  
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 Step 2: CTVA is copied and labelled ‘CTVB’. It is grown by a margin of 
1cm in the right, left, anterior and posterior directions.  
 
 Step 3: CTVB may then be adjusted as follows. Assessment of CTVB’s 
proximity to the spinal cord PRV is made and where it is deemed that 
the spinal cord dose volume constraints will not be met, the posterior 
margin may be reduced. This reduction should be performed on a 
slice-by-slice basis and should be subject to a minimum CTVA to 
CTVB margin of 0.5cm. This is discussed in more detail in Appendix 2.  
 
 
 
 
4.2.2 CTV Definition for a GTV which involves or comes within 2cm of the 
gastro-oesophageal junction. 
 
 
The CTV will comprise the GTV plus a margin of up to 1cm laterally, 2cm 
superiorly (along the line of the oesophagus) and  2 cm inferiorly (this will 
include the mucosa of the stomach in the direction of the lymph node stations 
along the lesser curve including the para-cardial and left gastric lymph nodes). 
It is created in five steps: 
  
 Step 1: The GTV is copied and labelled ‘CTVA’ (so that the GTV is 
preserved as a separate structure) and extended by 2cm superiorly by 
manual drawing along the line of the oesophagus.  
 
 Step 2: CTVA is extended inferiorly as far as the GOJ making note of 
the length of extension from the GTV to this point. This step is not 
necessary if the GTV already extends to the level of the GOJ.  
 
 Step 3: CTVA is copied and labelled ‘CTVB’. This is grown with a 
margin of 1cm in the right, left, anterior and posterior directions.  
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 Step 4: CTVB is manually extended inferiorly such that the total inferior 
extension from GTV to CTVB is 2cm. This extension should aim to 
include the mucosa of the stomach, in the direction of the lymph node 
stations along the lesser curve including the para-cardial and left 
gastric lymph nodes.  
 
 Step 5: CTVB may then be adjusted as follows. Assessment of CTVB’s 
proximity to the spinal cord PRV is made and where it is deemed that 
the spinal cord dose volume constraints will not be met, the posterior 
margin may be reduced. This reduction should be performed on a 
slice-by-slice basis and should be subject to a minimum CTVA – CTVB 
margin of 0.5cm. This is discussed in more detail in Appendix 2.  
 
 
 
 
4.3 PTV Definition 
 
CTVB is copied and labelled ‘PTV’. It is created by the addition of the 
following margins: 
 
Superiorly and inferiorly:   1.0cm 
Laterally, anteriorly and posteriorly:  0.5cm (this margin is applied in all 
circumstances regardless of the proximity of the target to the spinal cord)  
 
The maximum treatment field length is 17cm, i.e. maximum EUS disease 
length of primary tumour and lymph nodes is 10cm (assumes approximate 
1cm extension from PTV to field length).  
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4 Dose Volume Guidelines 
 
There follows a set of ‘dose volume guidelines.’ The guidelines for the PTV 
(section 5.1) should be taken as definitive (subject to the type of dose 
calculation algorithm used), however the aim of the remaining guidelines 
(sections 5.2 – 5.6) is to assist optimisation of the plan in consideration of all 
the organs at risk. These guidelines should all be achievable in the majority of 
cases and therefore allow for the plan to be tailored to the individual case 
such that the patients’ associated co-morbidity may be considered and doses 
to organs at risk modified within the guidelines given. 
 
 
Region of Interest / Organ at 
Risk 
Dose Constraint 
PTV V95% (47.5Gy) > 99.0% 
PTV PTV min > 93% (46.5Gy) 
DMAX <107% (53.5Gy) 
GTV GTV min > 100% (50.0Gy) 
Spinal Cord PRV Cord Max <80% (40Gy) 
Combined Lungs V40% (V20Gy) <25% 
Heart V80% (V40Gy) < 30% 
Liver V60% (V30Gy) < 60% 
Individual kidneys V40% (V20Gy) <25% 
 
 
 
5.1 PTV 
  
The aim is to encompass the PTV with the 95% isodose with the best possible 
conformality of the 95% isodose to the PTV. In practice 99% of the PTV 
should be covered by the 95% isodose. The PTV maximum should be no 
more than 107% of the prescribed dose to the ICRU reference point – this 
maximum dose is determined in accordance with ICRU definitions whereby a 
region of dose is considered clinically meaningful if its minimum diameter 
exceeds 1.5cm. These requirements for the PTV are based on the use of a 
pencil beam algorithm – if any other algorithm is used centres should assess 
dose coverage to PTV according to local experience of best possible 
coverage achievable. 
 
5.2 Spinal Cord 
 
Dose to the spinal cord PRV should be increased to a level of around 38Gy 
and up to a maximum point dose of 40Gy. In practice this is achieved via a 
high posterior beam contribution and results in best possible reduction of 
doses to heart & lungs. No significant advantage is expected in attempting to 
reduce the dose to spinal cord below 38Gy, conversely increasing the dose to 
this safe level will give improved dose volume results for the remaining OARs. 
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5.3 Lungs 
 
The volume of lung (right and left combined) receiving 20Gy should be less 
than 25% i.e. V20 < 25%.  This level of dose may be achieved by judicious 
choice of gantry angle, optimised shielding and by limiting the percentage 
contribution of the lateral / lateral oblique beams. 
 
5.4 Heart 
 
The volume of heart receiving 40Gy should be less than 30% i.e.V40 < 30%. 
A proportion of the heart may overlap with the PTV – dose reduction to the 
remainder of the heart volume if required may be achieved by reducing the 
anterior beam contribution.  
 
5.5  Liver 
 
The volume of liver receiving 30Gy should be less than 60% i.e. V30 < 60%. 
 
5.6 Kidneys 
 
Volume of each kidney receiving 20Gy should be less than 25% i.e.V20 < 
25%. Where this is not  achieved the plan should aim to spare one kidney 
(subject to consideration of individual kidney function as demonstrated on a 
renogram) as far as possible and within the V20 < 25% limit. This is not 
expected to be a problem except in some with Siewert Type 3 tumours (which 
are not eligible for SCOPE 1).  
 
5.7    SCOPE 1 Radiotherapy planning using ‘Type b’ dose 
calculation algorithm  
 
It is stated in section 5.1 that the aim is to conform the 95% isodose to the 
PTV with a target volume coverage of 99%. However, with increased use of 
type b algorithms* for dose calculation in the highly inhomogeneous region as 
is the thorax, the above is proven to be an unrealistic target for 95% dose 
coverage. 
 
Recent work has been published2 which attempted to address this issue with 
respect to oesophageal planning for SCOPE. The work was instigated as a 
result of the above issue when attempting to provide guidance to centres 
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returning QA and patient cases planned using type b algorithms, in which the 
PTV coverage would ‘fail’ target dose criteria. 
 
The work included retrospectively planning 15 patients from the SCOPE trial 
using Oncentra Masterplan (OMP) [Nucletron, Veenendaal, The Netherlands] 
using the Collapsed Cone dose calculation algorithm3. The 95% dose 
coverage was compared with the percentage overlap of the PTV with low 
density tissue. 
 
From the work it was found that a correlation could be drawn between the 
achievable 95% dose coverage and the percentage volume of the PTV which 
included low density tissue such as lung. From this correlation the following 
formula was derived to provide a dose coverage target: 
 
 PTVoverlapV %4.0%99%95   
 
Also included in the published work was a short description of an approach to 
optimising a plan to achieve the above target coverage – this aspect is 
covered in more detail in this document: 
 
In planning using type b algorithms it may be observed that improved 
coverage can be achieved through increasing the field size near the region of 
poor coverage. In order to avoid unnecessary increases in filed size it is 
suggested that the initial planning is performed under full scatter conditions – 
inhomogeneity correction should be switched off or the patient outline set to 
water density. Under these conditions the plan can be quickly optimised with 
approximate wedging and relative beam weighting. In this way the field sizes 
should be set to achieve acceptable 95% isodose coverage. It is important 
that the relative weightings are representative of the final plan at this point as 
plans weighted heavily from ant post fields will result in the requirement of 
smaller field sizes from the lat fields, and larger on the A/P. 
 
Final optimisation can then be conducted with inhomogeneity correction, 
whereby no increase to the field sizes should be applied. The figure derived 
using the formula above should be used as the target volume coverage for 
95% dose. 
 
It should be noted that the formula is based on work solely using the OMP 
collapsed cone algorithm on 15 patients. In using the technique for 
prospective planning on the same system the target coverage has been easily 
achieved in all cases. In which case the plan should be optimised to improve 
the coverage further if possible without increasing field sizes, beyond the point 
where the calculated target has been achieved. 
 
Centres with an established method for planning with type b algorithms or 
those wishing to take a different approach can plan as preferred. 
 
It is intended that plans calculated with type b algorithms will be assessed 
with respect to the target derived from the formula. As such an updated 
revision of the SCOPE RT plan assessment form has been produced to 
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include the %PTV overlap, along with the calculated target, to highlight 
deviations from the protocol. 
 
Glossary 
*Type b algorithms include ‘Collapsed Cone’ in Pinnacle [Royal Phillips Electronics, Amsterdam, The Netherlands] 
and Oncentra Masterplan, ‘Multigrid Superposition’ in Xio [CMS Inc., St Louis, MO, USA], ‘Anisotropic Analytical 
Algorithm’ (AAA) in Eclipse [Varian Medical Systems Inc., Palo Alto, CA, USA]. 
 
 
 
5 Pre-Treatment Verification 
 
 
Prior to treatment commencing, centres should follow their local protocols as 
regards pre-treatment verification; this may include a simulator check of the 
treatment, where any adjustments required should also be made according to 
local practice. Where simulator checks are performed, the single phase 
technique reduces this to one rather than two procedures.  
An alternative system verifies positional accuracy on the first fraction of 
treatment. This may be done via the generation of ‘dummy’ isocentre fields 
(shown below) in the treatment planning system. These fields are prepared 
with a standard field size with zero collimator twist and are positioned at the 
anterior (gantry = 0º) and lateral (gantry = 90º or 270º) orientations to enable 
translation of any shifts seen in the comparative verification images into 
movements in the anterior-posterior, right–left and superior-inferior directions.  
 
 
 
The ‘dummy fields’ are exported to the treatment ‘record and verification’ 
software and are used as ‘reference images’ with which ‘on-treatment’ portal 
images may be compared (see section 7). As such, the treatment is verified 
on set and a pre-treatment simulator check is not performed. 
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6  On-Treatment Verification 
 
7.1 On-Treatment Verification and Adjustment of the 
Isocentre Position 
 
Accuracy of delivery should be verified on the treatment set. This may be 
managed according to local protocols and in accordance with best practice. 
Our standard protocol for treatment positional verification specifies the 
collection of electronically acquired lateral and anterior portal isocentre 
images (or films where electronic means are not available) on the first three 
days of treatment and thereafter on a weekly basis.  
 
Images are analysed via anatomical matching as shown in the images below: 
for the anterior image the vertebral bodies are outlined and matched, for the 
lateral image the process is repeated using the vertebral bodies and the 
sternum. The magnitude and direction of displacement between the 
‘reference’ and ‘on-treatment’ images is then measured in the Sup-Inf, Ant-
Post and Left-Right directions.   
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This analysis is performed and checked by suitably trained and authorised 
‘IRMER practitioners’ For images which fall outside the accepted tolerance, 
action is determined based on the extent of the mismatch - three action levels 
are defined as follows: 
 
 Level 1 
 
No action is required if a portal image is less than 0.5cm displaced 
from the reference image. 
 
 
 Level 2 
 
If any given portal image is between 0.5 and 1.0cm displaced from the 
reference image then treatment may continue but set up is monitored 
by repeating portal images on each subsequent fraction until three sets 
have been acquired. At this point the average shift is calculated and 
the set up movements of the isocentre from the patient reference point 
are adapted accordingly.  An off-line correction strategy is adopted i.e. 
a further set of images is taken on the next fraction of treatment and is 
analysed prior to the next day’s treatment.  
 
 Level 3 
 
If any given portal image is more than 1.0cm displaced from the 
reference image, then the treatment set up is reviewed prior to further 
treatment being delivered. This review may be a simulator or an on-set 
on-line correction strategy. i.e. prior to set up, new set up isocentre 
movements from the patient reference mark are calculated using the 
known displacements from the reference image and a further set of 
isocentre images must be taken and analysed before the treatment is 
delivered. 
 
All changes are fully documented within the patient treatment record. 
 
7.2 On-Treatment Verification of Patient Outline 
 
Accuracy of the patient outline should be verified on set, as changes may 
have occurred since the CT Planning scan was acquired. This may be done 
according to local protocols and will depend on the technology available at 
each centre. Our standard protocol requires the measurement of FSD for 
each treatment field for the first three fractions of treatment. The readings 
should reflect a consistent treatment set up i.e. if set up instructions are 
changed at any point during the treatment, the measurements must be taken 
for the three fractions following the change. Where the average reading for 
any field is more than 0.5cm out of tolerance, the treatment sheet is referred 
to Physics and the need for monitor unit correction is assessed. However if 
any single measurement for any given beam is more than 1.5cm different 
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from that planned, then the matter is investigated before further treatment is 
delivered.  
 
 
Where the patient’s plan is referred for possible monitor unit correction the 
following guidelines are applied: If any single beams’ average FSD reading is 
more than 1.0cm different from the planned FSD, or if any two beams’ 
average FSD is more than 0.5cm different from that planned, then a monitor 
unit correction is calculated, checked and applied. Large changes in FSD 
(>1.5cm) may be indicative of poor set up and are investigated further to 
confirm treatment accuracy before a monitor unit correction is applied. 
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4. Appendix 1: Delineation of Heart Volume 
 
The whole heart is outlined to the extent of the pericardial sac (if visible). The 
major blood vessels (superior to the organ) and the inferior vena cava 
(towards the inferior extent of the heart) are excluded. The superior extent is 
often difficult to define and may be simplified by identification of the vessels 
superior to the heart. We use the point where the pulmonary trunk and the 
right pulmonary artery are seen as separate structures as indication of the 
superior extent of the heart. Shown below are alternate CT images for a scan 
taken at 0.3cm intervals. 
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The definition of the heart is shown below on the same data set. The superior 
extent of the heart has been interpreted as the 1st section on which the right 
and left pulmonary arteries have separated. Throughout the heart is outlined 
to the extent of the pericardial sac. The inferior extent is less problematic to 
delineate as the organ appears well defined compared to the surrounding 
tissues in the abdomen. However, if possible, the inferior vena cava should be 
excluded. 
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For reference the non-delineated CT data set is also provided below. 
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8 Appendix 2: Suggested System to Reduce Posterior CTV Margin, 
Where Required 
 
 
Where the PTV is estimated to be so close to the spinal cord PRV that its 
dose volume constraints cannot be met, we recommend reducing the 
posterior extension of CTVA to CTVB (from a maximum of 1cm to a minimum 
of 0.5cm). This process may be performed according to local centres’ 
discretion yet this example gives a system of adjustment which enables the 
clinician to delineate PTVs for which the dose volume constraints are able to 
be achieved.    
 
The distance between CTVB and the spinal cord PRV that will allow the cord 
dose volume constraints to be met is estimated (NB an additional margin is 
added to CTVB during creation of the PTV). Practically this cannot be easily 
defined, but should be evaluated at a local level with a pragmatic approach.  
Once the optimal distance (for each centre) between CTVB and spinal cord 
PRV is established, it can be applied on an individual patient basis. This 
distance will then be maintained by adjusting the CTVA to CTVB posterior 
margin on a slice-by-slice basis as follows: 
 
Following the creation of CTVB, the distance between its posterior edge and 
the anterior edge of the spinal cord, PRV should be measured. At Velindre, 
we have noted that if CTVB lies no closer than 1.3cm from the spinal cord 
PRV, at any point then the CTVA to CTVB margin is kept at 1cm. However, if 
CTVB lies <1.3cm from the spinal cord PRV then its posterior margin is 
reduced on a slice-by-slice basis to a minimum 0.5cm. We recommend 
creating two guide structures (‘Min Post CTV’ and ‘Max Post CTV’). 
Min Post CTV = CTVA + 1.0cm right, left and anteriorly and a 0.5cm margin 
posteriorly.  
Max Post CTV = CTVA + 1.0cm right, left, anteriorly and posteriorly (i.e. the 
original CTVB).  
CTVB is then adjusted within the range of these guide structures on a slice-
by-slice to maintain the 1.3cm distance. An example of this process is shown 
opposite. 
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9 Appendix 3: Planning and Optimisation of the Single-Phase 
External Beam Plan  
 
A3.1: Introduction 
 
The purpose of this section is to offer guidance to centres who have not had 
working experience, of using a single phase technique and as such comprises 
a ‘walk-through’ example which is not intended to be prescriptive but aims to 
offer assistance if required. Single-phase planning had been demonstrated to 
offer significant cardiac dose reduction as compared to a two-phase approach 
(Ant-Post phase, followed by 3-field plan). Furthermore, the single-phase may 
offer a radiobiological advantage to organs at risk and a reduced resource 
requirement as compared with the two-phase approach.  
 
A3.2: Beam Orientations 
 
The exact number of beams and gantry angles are not explicitly defined – 
each patient will require an optimised arrangement. It is up to the individual 
centres to decide the beam arrangement. However, four primary beam 
orientations: anterior, posterior, right lateral (or lateral oblique) and left lateral 
(or lateral oblique), are usually satisfactory. This section describes how an 
unproblematic patient plan may be produced. Appendix 4 explores methods 
for planning more difficult cases. 
 
A3.3: Positioning of Lateral / Oblique Beams 
 
These beams should be positioned firstly to avoid the spinal cord PRV. The 
optimal gantry angle may be selected using the beams eye view to assess 
where the greatest gap between the Cord PRV and the PTV is achieved. 
Where possible, the gantry angle which gives the narrowest apparent size of 
the PTV should be considered in order to spare normal tissue. 
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Care should be taken to avoid gantry angles which may cause beams to pass 
through the dense structural parts of the treatment couch panel. We have 
experienced such problems with the use of the Varian tennis racket panel as 
the presence of the posterior beam requires that the open part of the panel be 
used – this part of the panel contains side bars which have significant 
attenuation and should be avoided during treatment. This may be avoided if 
the elements of the couch panel are visualised in the planning system as 
shown below. Here the position and size of the side bars of the treatment 
couch panel have been measured and added to the patient data set (assumes 
the patient is positioned centrally on the treatment couch). With these in 
place, the limiting posterior extent of the lateral/oblique beams can easily be 
assessed and so problems avoided. 
 
 
 
 
A3.4: Choice of Collimator Angle and Shielding Orientation for Lateral / 
Oblique Beams. 
 
The usual ‘curved’ shape of the PTV from the lateral / oblique view will mean 
that the preferred collimator orientation for MLC shielding will often be around 
0 degrees (that which enables the most conformal shielding considering the 
limitation of fixed MLC leaves and given their low resolution as compared to 
conformal shielding blocks). This position may be assessed as a starting point 
and approximate shielding added. For the single phase approach the 
lateral/oblique beams will frequently not require a wedge oriented in the ant-
post direction which (if varian EDWs are used for example) would require the 
collimator angle to be rotated by 90 degrees. For other treatment delivery 
options, such as fixed or flying wedges etc. or conformal shielding blocks, this 
situation may not arise. However, it is undesirable to extend the treatment 
delivery process by their use if EDWs and MLCs are available. Where 
dynamic wedging is needed in the ant-post direction, the example in Appendix 
4 (A4.2) shows how the loss of conformality to the PTV may be minimised. 
 
 
 
A3.5: Establishing the Contribution of Each Beam 
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With the lateral / oblique beams in place, the anterior and posterior beams are 
added with approximate shielding and a crude calculation can then be done in 
order to assist in setting initial percentage contributions from each beam. At 
this point, the balance between the four beams can be adjusted so that the 
cord dose approaches the guideline of 38Gy (76% of the prescriptive dose) 
and that the remaining dose volume guidelines are met. The guidelines, if 
easily met will then allow for the plan to be tailored to the individual case such 
that the patient’s associated co-morbidity may be considered and doses to 
organs at risk modified within the given guidelines. This is shown in the 
figures below and with reference to the dose volume guidelines given in 
section 5. For this example, the cord dose approaches the guideline as 
recommended, the lung dose volume guideline has been achieved and the 
heart and liver doses are considerably lower than the guideline level. 
  
 
 
 
By way of example, if the patient were known to have significantly poor lung 
function we have the freedom within the process to increase the dose to the 
liver and heart in favour of the lung. This scenario is shown below. 
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A3.6: Coverage of the PTV 
 
PTV coverage and the level of dose homogeneity within the PTV is assessed. 
In order to achieve the dose-volume requirements for the PTV given in section 
5.1 the inclusion of wedges (and in some cases additional beams) may be 
deemed appropriate at this point. Adjustment to the relative contributions of 
each beam may follow. The DVH should again be referenced to check 
acceptability of doses to OARs. 
 
A3.7: Fine Tuning the Plan 
 
At this point a more detailed calculation is carried out (grid spacing of no 
greater than 0.3cm is recommended) and assessment of the overall plan is 
made. Subsequently MLC positions may be adjusted in order to improve the 
conformality of the 95% isodose to the PTV, and any of the beam parameters 
previously established may be modified over a number of iterations in order to 
fully optimise the plan. 
 
A3.8: The Final Plan 
 
The final plan meets the dose volume requirements for the PTV and has also 
achieved a suitable balance of doses to normal tissue within the guidelines 
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given. The plan has also taken into account the associated co-morbidities of 
the individual patient. The table below summarises the dose-volume 
information for this plan. 
 
Region of Interest / Organ at Risk Dose Constraint Achieved 
PTV V95% (47.5Gy) > 99% 99.2% 
PTV PTV min > 93% (46.5Gy) 93.4% 
DMAX <107% (53.5Gy) 106% 
Spinal Cord PRV Cord Max <80% (40Gy) 75.1% 
Combined Lungs V40% (V20Gy) <25% 12% 
Heart V80% (V40Gy) < 30% 13% 
Liver V60% (V30Gy) < 60% 16% 
Individual kidneys V40% (V20Gy) <25% N/A 
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10 Appendix 4: Problem Examples 
 
A4.1: Introduction to Problem Examples 
 
This section is intended to provide assistance to centres who may have 
limited experience of single phase planning and as such, attempts to illustrate 
and address some issues which have been found to arise in our experience. 
In oesophageal planning the size of the treatment site, it’s proximity to 
multiple OARs and the inhomogeneous nature of the surrounding tissues 
mean that difficulties in achieving an optimal plan are often experienced. Here 
follows a series of examples which show how specific problems may be 
overcome to produce good results. 
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A4.2: Relative contribution of each beam 
 
This example illustrates how increasing the relative contribution of the 
posterior beam in favour of the anterior beam contribution will achieve 
improved heart & liver sparing with no change to the lung dose. The figures 
below show two plans whose parameters are identical in all but one respect – 
the relative contributions of the anterior and posterior beams. The plan on the 
left has anterior and posterior beam contributions of 38% and 27% 
respectively whilst the plan on the right has anterior and posterior 
contributions of 28% and 37%. 
 
 
 
The dose volume histogram below shows a reduction in heart & liver dose, no 
change to the lung dose, and the cord dose remains within tolerance. In 
practice, increasing the cord dose to the tolerance level of 38Gy will result in 
the best possible sparing to the heart. 
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A4.3: Variations in lateral beam wedging 
 
The suggested level of contribution of the posterior beam may be assisted by 
the use of ‘anteriorly pointing’ wedges on the lateral beams. However, where 
dynamic wedges are the preferred or are the only method of dose modulation 
available, their use may lead to reduced conformality of the MLCs to the PTV 
due to the need for the collimator to be positioned at 90o or 270o. Where EDW 
wedges are used, it may be possible to maintain conformality of the 95% 
isodose by increasing the wedge angle required on one of the lateral beams, 
and removing the wedge from the other. This action enables freedom of 
collimator angle and therefore optimal MLC positioning for one of the two 
lateral beams. The example below shows two plans – one having two 
anteriorly pointing 15 degree wedges on the lateral beams, and one having 
only one 30 degree wedge. The absence of the wedge on one of the lateral 
beams on the second plan has enabled more conformal MLC shielding and 
therefore improved the plan. 
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A4.4: Use of filler beams to lower hotspots within the PTV 
 
The proximity of the oesophagus to lung tissue will often mean that difficulties 
are experienced in achieving a homogeneous dose throughout the PTV. The 
coronal sections below illustrate an example where hotspots seen in the lung 
tissue contained within the PTV have been reduced with the inclusion of a low 
weighted anterior ‘filler beam’ the ‘beams eye view’ for which is also shown 
below. In this case the filler beam delivers 5% of the tumour dose - the MLCs 
have been positioned in order to shield the hotspots and so improve the dose 
inhomogeneity within the PTV. 
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A4.5: Use of opposing superior–inferior wedged beams to improve 
coverage of 95% isodose and dose homogeneity within the PTV 
 
Improvement in the coverage of the PTV with the 95% isodose may be seen 
by using a combination of two heavily wedged beams to replace a single un-
wedged beam (usually the posterior or anterior beam). To illustrate this effect 
the image below shows the distribution from two 60 degree wedged beams 
(one pointing superiorly, and one pointing inferiorly). The important thing to 
note is that the isodoses at depth are around 10% higher at the superior and 
inferior extents of the beam than at the central axis, and so the combination 
will deliver more dose to both extremes of the PTV than can be delivered with 
a single unwedged beam. Furthermore, this combination allows a greater 
degree of freedom in plan optimisation to achieve dose homogeneity across 
the PTV as the two beams can be weighted as required to achieve the best 
balancing of the plan.  
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11 A4.6: Maximising PTV coverage Vs cord dose. 
 
A common issue raised by centres planning scope patients is how to 
approach the situation where the spinal cord PRV and PTV are in close 
proximity. 
 
It was outlined in Appendix 2 how the posterior of CTVB may be modified in 
the region where it is deemed that the spinal cord PRV dose volume objective 
may not be met, subject to a minimum CTVA to CTVB margin of 0.5cm. 
 
Additional advice was given in Appendix 4 covering the use of sup-inf wedges 
and opposed sup-inf wedges, which may be used to improve target coverage 
toward the furthest extent of the volume. 
 
Further to this, the example below may be useful in optimising the posterior 
dose gradient to allow improved PTV coverage versus cord PRV maximum 
dose. The example illustrates how careful consideration of which fields to 
apply sup-inf wedging to can improve the distribution in this region. 
 
Three plans were produced for the same SCOPE 1 patient. The first is based 
on the clinical plan in which sup wedging was used on both the anterior (45° 
wedge) and left lateral (15° wedge) fields. The cord PRV volume max dose 
was increased to a maximum, but there was still some necessary compromise 
to PTV coverage due to the extreme proximity of the two ROIs. 
 
As the cord PRV and PTV are in close proximity toward the superior end of 
the volume further plans were created – Plan01 and Plan02 – in which the 
sup wedging effect was transferred from the anterior field (30° Plan01 and 15° 
Plan02) to the lateral field (30° Plan01 and 45° Plan02). The MU for each field 
was altered so that their contribution to the isocentre was constant across all 
plans. 
 
The images below show the result to the dose distribution and DVH. 
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Figure 1 
 
 
 
 
Figure 2 
 
 
 
 
Figures 1 and 2 show sagital and coronal views respectively of the three 
plans; ClinicalPlan left, Plan01 centre and Plan02 right. On the sagital view it 
can be seen that with transferring the wedging from ant to lateral there is a 
corresponding increase in the dose gradient between the PTV and cord PRV. 
In the coronal sections it can be seen that there is only a small effect on the 
overall balance of the dose distribution throughout the length of the target. 
 
In this particular case there is an additional benefit to the lung dose as the 
increased sup wedging reduces the contribution to the PTV through the lungs 
at the inf extent - with a resulting increase in dose to the healthy tissue 
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superior to the lungs and correspondingly an increase to the lower dose level 
at the inf extent of the cord PRV. 
 
These changes to the distribution are reflected in the DVH in figure 3 below. 
 
Figure 3 
 
 
 
 
The DVH shows the curves for PTV, Cord PRV and combined lungs for the 
ClinicalPlan (solid line), Plan01 (dashed line) and Plan02 (dotted line). It can 
be seen that with minimal reduction in the PTV coverage (which could be 
improved with small alteration) there is a significant reduction in the higher 
dose level to the cord and an overall increase in uniformity of the dose to the 
cord. Small additional sparing of the lungs at the 40% (20Gy) level can be 
seen, along with the more considerable sparing at the 50% (25Gy) level. 
 
In this case the increased sparing to the cord PRV is very small at the 40Gy 
level because of the extreme proximity, with associated PTV compromise. 
However, careful selection of sup-inf wedging can significantly reduce the 
maximum cord PRV dose and consequently improve the level of compromise 
in some cases. 
 
For those cases where it has been found that a compromise is 
inevitable, the advice has been given that the balance of compromise 
should be a local clinical decision whereby the issue is for the treating 
consultant to balance risks and benefits of compromising PTV and 
exceeding cord dose constraints. 
 234 
 
 
Authors 
 
Dr T Crosby 
Dr J Staffurth 
Miss L Wills 
Mr Rhydian Maggs 
 
Reviewers / Contributors 
 
Dr A Crellin 
Dr I Geh 
Dr D Tait 
Dr K Venables (NCRI Radiotherapy Clinical Studies Quality Assurance Group 
 
 235 
References 
1. Group MRCOCW. Surgical resection with or without preoperative 
chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 
2002;18:1727-33. 
2. Zhang H, Jin G, Shen H. Epidemiologic differences in esophageal cancer 
between Asian and Western Populations. Chin J Cancer. 2012;31(6):281-6. 
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer 
Statistics. CA Cancer J Clin. 2011;61:69-90. 
4. Gwynne S, Wijnhoven BPL, Hulshof M, Bateman A. Role of 
Chemoradtioherapy in Oesophageal Cancer - Adjuvant and Neoadjuvant Therapy. 
Clin Oncol. 2014;26:522-32. 
5. Cunningham D, Starling N, Rao S. Capecitabine and oxaliplatin for advanced 
esophagogastric cancer. N Engl J Med. 2008;358:36-46. 
6. J S Cooper MDG, A Herskovic et al. Chemotherapy of locally advanced 
esophageal cancer: a long term follow up of a prospective randomised trial. JAMA. 
1999;281:1623-7. 
7. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A 
comparison of multimodal therpy and surgery for esophageal adenocarcinoma. New 
England J Medicine. 1996;335:462-7. 
8. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival 
benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal 
carcinoma: a meta analysis. Lancet Oncol. 2007;8:226-34. 
9. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, et 
al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow up 
 236 
of a propspective randomized trial (RTOG 85-01). Radiation Therapy Oncology 
Group. JAMA. 1999;281(17):1623-7. 
10. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Matrenson J, Komaki R, et al. 
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-
modality therapy for esophageal cancer: high-dose versus standard-dose radiation 
therapy. J Clin Oncol. 2002;20(5):1167-74. 
11. Palta JR, Kim S, Li JG, Liu C. Intensity-Modulated Raidation Therapy. The State 
of the Art. Madison, WI: Medical Physics Publishing; 2003. 
12. Brahme A. Dosimetric precision requirements in radiation therapy. Acta 
Radiol Oncol. 1984;23:379-91. 
13. Mijnheer BJ, Batterman JJ, Wambersie A. What degree of accuracy is 
required and can be acheived in photon and neutron therapy? Radiother Oncol. 
1987;8:237-52. 
14. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to 
radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928-42. 
15. Mesures BIdPe. The International System of Units (SI). BIPM. 
16. http://altered-states.net/barry/newsletter450/dnadamage.jpg. DNA 
Damage. 
17. Owadally W, Staffurth J. Principles of cancer treatment by radiotherapy. 
Surgery (United Kingdom). 2015. 
18. Emami B, Lyman J, Brown A, Cola L, Goitein M, Munzenrider JE, et al. 
Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 
1991;21(1):109-22. 
19. http://health-7.com/imgs/20/7507.jpg. Linear accelerator schematic. 
 237 
20. Varian Linac Head. Available from: 
https://apps.varian.com/euen/oncology/radiation_oncology/clinac/clinac_dhx_high
_performance.html. 
21. Webb S. The physical basis of IMRT and inverse planning. Brit J Radiol. 
2003;76(910):678-89. 
22. Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc 
therapy: a review of current literature and clinical use in practice. Brit J of Radiol. 
2011;84(1007):967-96. 
23. McGarry CK, McMahon SJ, Craft D, O'Sullivan JM, Prise KM, Hounsell AR. 
Inverse planned constant dose rate volumetric modulated arc therapy (VMAT) as an 
efficient alternative to five-field intensity modulated radiation therapy (IMRT) for 
prostate. Journal of Radiotherapy in Practice. 2014;13(1):68-78. 
24. Schneider U, Pedroni E, Lomax A. The calibration of CT Hounsfield units for 
radiotherapy treatment planning. Phys Med Biol. 1996;41(1):111-24. 
25. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on 
normal tissue: consequences and mechanisms. The Lancet Oncology.4(9):529-36. 
26. Drzymala RE, Mohan R, Brewster L, Chu J, Goitein M, Harms W, et al. Dose-
volume histograms. Int J Radiat Oncol Biol Phys. 1991;21(1):71-8. 
27. Pardalos, M P, Romeijn, H Edwin. Handbook of optimization in medicine: 
Springer; 2009. 
28. Bewick V, Cheek L, Ball J. Statistics review 12: Survival analysis. Critical Care. 
2004;8(5):389-94. 
 238 
29. Hurt G, Nixon L, Griffiths G, Al-Mokhtar R, Gollins S, Staffurth J, et al. SCOPE1: 
a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with 
or without cetuximab, in carcinoma of the oesphagus. BMC Cancer. 2011;11:466-78. 
30. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. 
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. 
New England J Medicine. 2006;354(6):567-78. 
31. El Naqa I, Suneja G, Lindsay PE, Hope AJ, Alaly JR, Vicic M, et al. Dose 
response explorer: an integrated open-source tool for exploring and modelling 
radiotherapy dose-volume outcome relationships. Phys Med Biol. 2006;51:5719-35. 
32. Ten Haken RK, Martel MK, Lawrence TS. Use of dose-volume-response 
factors in conformal high-dose therapy studies. In: A.R. Hounsell, J.M. Wilkinson, P.C. 
Williams, editors. XIth International Conference on the Use of Computers in 
Radiaiton Therapy: Handley Printers, Ltd, Manchetser, UK; 1994. p. 22-3. 
33. El Naqa I, Bradley J, Blanco AI, Lindsay PE, Vicic M, Hope A, et al. 
Multivariable modelling of radiotherapy outcomes, including dose-volume and 
clinical factors. Int J Radiation Oncology Biol Phys. 2006;64(4):1275-86. 
34. Elshaikh M, Ljungman M, Ten Haken R, Lichter AS. Advances in Radiation 
Oncology. Annual Review of Medicine. 2006;57(1):19-31. 
35. Griffiths EA, Brummell Z, Gorthi G, Pritchard SA, Welch IM. Tumour length as 
a prognostic factor in esophageal malignancy: Univariate and multivariate survival 
analyses. J Surg Oncol. 2006;93:258-67. 
36. Wang BY, Goan YG, Hsu PK, Hsu WH, Wu YC. Tumour length as a prognostic 
factor in esophageal squamous cell carcinoma. Ann Thorac Surg. 2011;91:887-94. 
 239 
37. Chua DTT, Sham JST, Kwong DLW, Tai KS, Wu PM, Lo M, et al. Volumetric 
analysis of tumor extent in nasopharyngeal carcinoma and correlation with 
treatment outcome. Int J Radiat Oncol Biol Phys. 1997;39(3):711-9. 
38. Twine CP, Roberts SA, Rawlinson CE, Davies L, Escofet X, Dave BV, et al. 
Prognostic significance of the endoscopic ultrasound defined lymph node metastasis 
count in esophageal cancer. Dis Esophagus. 2010;23:652-9. 
39. Wang S, Liao Z, Wei X, Liu H, Tucker S, Hu C, et al. Association between 
systematic chemotherapy before chemoradiation and increased risk of treatment-
related pneumonitis in esophageal cancer patients treated with definitive 
chemoradiotherapy. J Thorac Oncol. 2008;3:277-82. 
40. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. 
Prediction of response to preoperative chemotherapy in adenocarcinomas of the 
esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-65. 
41. Maguire PD, Sibley GS, Zhou S, Jamieson TA, Light KL, Antoine PA, et al. 
Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J 
Radiat Oncol. 1999;45:97-103. 
42. Blanco AL, Chao KSC, El Naqa I, Franklin GE, Zakarian K, Vicic M, et al. Dose-
volume modeling of salivary function in patients with head-and-neck cancer 
receiving radiotherapy. Int J Radiat Oncology Biol Phys. 2005;62(4):1055-69. 
43. Bradley J, O'Deasy J, Bentzen S, El Naqa I. Dosimetric correlates for acute 
esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat 
Oncol Biol Phys. 2004;58(4):1106-13. 
44. El Naqa I, Bradley JD, Linday PE, Hope AJ, O'Deasy J. Predicting radiotherapy 
outcomes using statistical learning techniques. Phys Med Biol. 2009;54:S9-S30. 
 240 
45. El Naqa I, O'Deasy J, Mu Y, Huang E, Hope AJ, Lindsay PE, et al. Datamining 
approaches for modelling tumour control probability. Acta Oncologica. 
2010;49:1363-73. 
46. Olsen JR, Robinson CG, El Naqa I, Creach KM, Drzymala RE, Bloch C, et al. 
Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung 
cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e299-303. 
47. Li XA, Alber M, O'Deasy J, Jackson A, Jee KK, Marks LR, et al. The use and QA 
of biologically related models for treatment planning. AAPM, 2012  Contract No.: 
166. 
48. O'Deasy J, Chao C, Markman J. Uncertainties in model-based outcome 
predictions for treatment planning. Int J Radiat Oncol Biol Phys. 2001;51(5):1389-99. 
49. O'Deasy J, Niemierko A, Herbert D, Yan D, Jackson A, Haken RKT, et al. 
Methodological issues in radiation dose-volume outcome analyses: Summary of a 
joint AAPM/NIH workshop. Med Phys. 2002;29(9):2109-27. 
50. Wasik MW, Yorke E, O'Deasy J, Nam J, Marks LB. Radiation dose-volume 
effects in the Esophagus. Int J Radiat Oncol. 2009;76:S86-S93. 
51. Krishnankutty B, Bellary S, Naveen Kumar BR, Moodahadu LS. Data 
management in clinical research: An overview. Indian Journal of Pharmacology. 
2012;44(2):168-72. 
52. Gerritsen MG, Sartorius OE, vd Veen FM, Meester GT. Data management in 
multi-center clinical trials and the role of a nation-wide computer network. A 5 year 
evaluation. Proceedings of the Annual Symposium on Computer Application in 
Medical Care. 1993:659-62. 
53. National Electrical Manufacturers Association.  
 241 
Digital Imaging and Communications in Medicine (DICOM) Standard, (available free 
at http://medical.nema.org/). Rosslyn, VA, USA   
54. Koyama-Ito H, Mizoe J. The exchange of treatment planning data using RTOG 
data exchange format. Journal of JASTRO. 2003;15(1):75-9. 
55. Santanam L, Hurkmans C, Mutic S, Van Vliet-Vroegindeweij C, Brame S, 
Straube W, et al. Standardizing naming conventions in radiation oncology. Int J 
Radiat Oncol Biol Phys. 2012;83(4):1344-9. 
56. O'Deasy J, Blanco AI, Clark VH. CERR: A computational environment for 
radiotherapy research. Med Phys. 2003;30(5):979-85. 
57. Gayou O, Parda DS, Miften M. EUCLID: an outcome analysis tool for high-
dimensional clinical studies. Phys Med Biol. 2007;52:1705-19. 
58. SPSS. IBM Corp. Released 2011. IBM SPSS Statistics for Macintosh, Version 
20.0. Armonk, NY: IBM Corp. 
59. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: A review. Int J Radiat 
Oncol Biol Phys. 2006;64(2):333-42. 
60. Lomax NJ, Scheib SG. Quantifying the degree of conformity in radiosurgery 
treatment planning. Int J Radiat Oncol Biol Phys. 2003;55:1409-19. 
61. Wu QRJ, Wessels BW, Einstein DB, Maciunas RJ, Kim EY, Kinsella TJ. Quality of 
coverage: Conformity measures for stereotactic radiosurgery. J Appl Clin Med Phys. 
2003;4(4):374-81. 
62. Ohtakara K, Hayashi S, Hoshi H. The relation between various conformity 
indices and the influence of the target coverage difference in prescription isodose 
surface on these values in intracranial stereotactic radiosurgery. Brit J Radiol. 
2012;85:e223-8. 
 242 
63. Baltas D, Kolotas C, Geramani K, Mould R, Ioannidis G, Kekchidi M, et al. A 
conformal index (COIN) to evaluate implant quality and dose specification in 
brachytherapy. Int J Radiat Oncol Biol Phys. 1998;40(2):515-24. 
64. Van Riet A, Mak CA, Moerland MA, Elders LH, Van Der Zee W. A conformation 
number to quantify the degree of conformality in brachytherapy and external beam 
irradiation: Application to the prostate. Int J Radiat Oncol Biol Phys. 1997;37(3):731. 
65. Knoos T, Kristensen I, Nilsson P. Volumetric and dosimetric evaluation of 
radiation treatment plans: Radiation conformity index. Int J Radiat Oncol Biol Phys. 
1998;42(5):1169-76. 
66. Mulliez T, Speleers B, Madani I, Gersem WD, Veldeman L, Neve WD. Whole 
breast radiotherapy in prone and supine position: is there a place for multi-beam 
IMRT? Radiat Oncol. 2013;8:151-8. 
67. Hanna GG, Hounsell AR, O'Sullivan JM. Geometrical analysis of radiotherpy 
target volume delineation: a systematic review of reported comparison methods. 
Clin Oncol. 2010;22:515-25. 
68. Persson GF, Nygaard DE, Hollensen C, Munck af Rosenschold P, Mouritsen LS, 
Due AK, et al. Interobserver delinaetion variation in lung tumour stereotactic body 
radiotherapy. Brit J Radiol. 2012;85:e654-60. 
69. Jena R, Kirkby NF, Burton KE, Hoole ACF, Tan LT, Burnet NG. A novel 
algorithm for the morphometric assessment of radiotherapy treatment planning 
volumes. Brit J Radiol. 2010;83:44-51. 
70. Jena R, Kirby NF, Burton KE, Hoole ACF, Tan LT, Burnet NG. A novel algorithm 
for the morphometric assessment of radiotherapy treatment planning volumes. Brit 
J Radiol. 2010;83:44-51. 
 243 
71. Gwynne S, Spezi E, Sebag-Montefiore D, Mukherjee S, Miles E, Conibear J, et 
al. Improving radiotherapy quality assurance in clinical trials: assessment of target 
volume delineation of the pre-accrual benchmark case. Brit J Radiol. 
2013;86:20120398. 
72. Wills L, Millin A, Paterson J, Crosby T, Staffurth J. The effect of planning 
algorithms in oesophageal radiotherapy in the context of the SCOPE 1 trial. 
Radiother Oncol. 2009;93:462-7. 
73. Knöös T, Wieslander E, Cozzi L, Brink C, Fogliata A, Albers D, et al. Comparison 
of dose calculation algorithms for treatment planning in external photon beam 
therapy for clinical situations. Phys Med Biol. 2006;51(22):5785-807. 
74. Ahnesjo A, Saxner M, Trepp A. A pencil beam model for photon dose 
calculation. Medical Physics. 1992;19(2):263-73. 
75. Ahnesjo A. Collapsed cone convolution of radiant energy for photon dose 
calculation in heterogeneous media. Medical Physics. 1989;16(4):577-92. 
76. Thomas K, Otto AS. Monte Carlo- versus pencil-beam-/collapsed-cone-dose 
calculation in a heterogeneous multi-layer phantom. Phys Med Biol. 2005;50(5):859. 
77. L Wills AM, J Paterson, T Crosby, J Staffurth. The effect of planning algorithms 
in oesophageal radiotherapy in the context of the SCOPE 1 trial. Radiother Oncol. 
2009;93:462-7. 
78. Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality 
protocols for esophageal cancer - A meta-analysis of the randomized trials. Cancer 
Treatment Reviews. 2012;38(6):599-604. 
79. Measurements BICoRUa. ICRU report. Vol. 50. Bethesda: Prescribing, 
recording and reporting photon beam therapy. 1993;50. 
 244 
80. Measurements BICoRUa. ICRU report. Vol. 62. Bethesda: Prescribing, 
recording and reporting photon beam therapy (supplement to ICRU report 50). 
1993;62. 
81. Warren S, Partridge M, Carrington R, Hurt C, Crosby T, Hawkins M. 
Radiobiological determination of dose escalation and normal tissue toxicity in 
definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol 
Phys. 2014;90:423-9. 
82. Vidal M, Vieillevigne L, Izar F, Ferrand R. Dosimetric comparison of RapidArc 
and 3D-Conformal RT for esophageal cancer. Physica Medica. 2012;28, Supplement 
1(0):S2-S3. 
83. Weber DC, Tomsej M, Melidis C, Hurkmans CW. QA makes a clinical trial 
stronger: Evidence-based medicine in radiation therapy. Radiother Oncol. 
2012;105:4-8. 
84. Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TDL. Study to 
Determine Adequate Margins in Radiotherapy Planning for Esophageal Carcinoma by 
Detailing Patterns of Recurrence After Definitive Chemoradiotherapy. Int J Radiat 
Oncol Biol Phys. 2009;73(3):818-23. 
85. Gwynne S, Spezi E, Wills L, Nixon L, Hurt C, Joseph G, et al. Toward semi-
automated assessment of target volume delineation in radiotherpay trials: the 
SCOPE 1 pretrial test case. Int J Radiat Oncol Biol Phys. 2012;84(4):1037-42. 
86. Moore KL, Schmidt R, Moiseenko V, Olsen LA, Tan J, Xiao Y, et al. Quantifying 
unnecessary normal tissue complication risks due to suboptimal planning: A 
secondary study of RTOG 0126. Int J Radiat Oncol Biol Phys. 2015;92(2):228-35. 
 245 
87. Kataria T, Sharma K, Subramani V, Karrthick KP, Bisht SS. Homogeneity Index: 
An objective tool for assessment of conformal radiation treatments. Journal of 
Medical Physics. 2012;37(4):207-13. 
88. Crosby T, Hurt C, Falk S, Gollins S, Mukherjee S, Staffurth J, et al. 
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer 
(SCOPE 1): a mluticentre, phase 2/3 randomised trial. Lancet. 2013;Online 
Publication. 
89. Williams BA, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF. Finding Optimal 
Cutpoint for Continuous Covariates with Binary and Time-To-Event Outcomes. Mayo 
Foundation. 2006. 
90. Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, et al. 
Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy 
predict progression-free and overall survival in newly diagnosed glioblastoma. 
NeuroOncology. 2012;14(3):333-43. 
91. Grunewald J, Dong GS, Niessen F, Wen BG, Tsao ML, Perera R, et al. 
Mechanistic studies of the immunochemical termination of self-tolerance with 
unnatural amino acids. Proc Natl Acad Sci USA. 2009;106(11):4337-42. 
92. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stürmer T, et al. Intensity-
modulated radiation therapy, proton therapy, or conformal radiation therapy and 
morbidity and disease control in localized prostate cancer. JAMA. 
2012;307(15):1611-20. 
93. Bohsung J, Gillis S, Arrans R, Bakai A, De Wagter C, Knöös T, et al. IMRT 
treatment planning—A comparative inter-system and inter-centre planning exercise 
of the ESTRO QUASIMODO group. Radiother Oncol. 2005;76(3):354-61. 
 246 
94. Chung HT, Lee B, Park E, Lu JJ, Xia P. Can All Centers Plan Intensity-Modulated 
Radiotherapy (IMRT) Effectively? An External Audit of Dosimetric Comparisons 
Between Three-Dimensional Conformal Radiotherapy and IMRT for Adjuvant 
Chemoradiation for Gastric Cancer. Int J Radiat Oncol Biol Phys. 2008;71(4):1167-74. 
95. Xhaferllari I, Wong E, Bzdusek K, Lock M, Chen JZ. Automated IMRT planning 
with regional optimization using planning scripts. Journal of Applied Clinical Medical 
Physics. 2013;14(1):176-91. 
96. Craft DL, Halabi TF, Shih HA, Bortfeld TR. Approximating convex Pareto 
surfaces in multiobjective radiotherapy planning. Med Phys. 2006;33(9):3399-407. 
97. Nicolini G, Ghosh-Laskar S, Shrivastava SK, Banerjee S, Chaudhary S, Agarwal 
JP, et al. Volumetric Modulation Arc Radiotherapy With Flattening Filter-Free Beams 
Compared With Static Gantry IMRT and 3D Conformal Radiotherapy for Advanced 
Esophageal Cancer: A Feasibility Study. Int J Radiat Oncol Biol Phys. 2012;84(2):553-
60. 
98. Murthy KK, Shukeili KA, Kumar SS, Davis CA, Chandran RR, Namrata S. 
Evaluation of dose coverage to target volume and normal tissue sparing in the 
adjuvant radiotherapy of gastric cancers: 3D-CRT compared with dynamic IMRT. 
Biomed Imaging Interv. 2010;6:e29-36. 
99. Freilich J, Hoffe SE, Almhanna K, Dinwoodie W, Yue B, Fulpo W, et al. 
Comparative outcomes for 3D conformal versus intensity modulated radiation 
therapy for esophageal cancer. Dis Esophagus. (in press). 
100. Nahum AE, Sanchez-Nieto B. Tumour control probability modelling: Basic 
principles and applications in treatment planning. Physica Medica. 2001;17(SUPPL. 
2):13-23. 
 247 
101. Dhawan A, Kohandel M, Hill R, Sivaloganathan S. Tumour control probability 
in cancer stem cells hypothesis. PLoS ONE. 2014;9(5). 
102. Zaider M, Hanin L. Tumor control probability in radiation treatment. Med 
Phys. 2011;38(2):574-83. 
103. Brenner DJ. Point: The linear-quadratic model is an appropriate methodology 
for determining iso-effective doses at large doses per fraction. Seminars in radiation 
oncology. 2008;18(4):234-9. 
104. Bentzen SM, Constine LS, O'Deasy J, Eisbruch A, Jackson A, Marks LB, et al. 
Quantitive analysis of normal tissue effects in the clinic (QUANTEC): An introduction 
to the scientific issues. Int J Radiat Oncol. 2010;76:S3-S9. 
105. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance 
data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21(1):123-5. 
106. Lyman JT. Complication probability as assessed from dose-volume 
histograms. Radiation Research. 1985;104(2 II):S13-S9. 
107. Kutcher GJ, Burman C, Brewster L, Goitein M, Mohan R. Three-Dimensional 
Photon Treatment Planning Report of the Collaborative Working Group on the 
Evaluation of Treatment Planning for External Photon Beam RadiotherapyHistogram 
reduction method for calculating complication probabilities for three-dimensional 
treatment planning evaluations. Int J Radiat Oncol Biol Phys. 1991;21(1):137-46. 
108. Nahum AE, Uzan J. (Radio)Biological Optimization of External-Beam 
Radiotherapy. Computational and Mathematical Methods in Medicine. 
2012;2012:13. 
 248 
109. Botterweck AA, Schouten LJ, Volovics A, Dorant E, Van Den Brandt PA. Trends 
in incidence of adenocarcinoma of the oesophagys and gastric cardia in ten 
European countries. Int J Epidemiol. 2000;29(4):645-54. 
110. Buergy D, Lorh F, Baack T, Siebenlist K, Haneder S, Michaely H, et al. 
Radiotherapy for tumours of the stomach and gastroesophageal junction - a review 
of its role in multimodal therapy. Radiat Oncol. 2012;7:192. 
111. Settle SH, Bucci MK, Palmer MB, Liu H, Liengsawangwong R, Guerrero TM, et 
al. PET/CT fusion with treatment planning CT (TP CT) shows predominant pattern of 
locoregional failure in esophagea patients treated with chemoradiation in in GTV. Int 
J Radiat Oncol Biol Phys. 2008;72:S72-S3. 
112. Fakhrian K, Oechsner M, Kampfer S, Schuster T, Molls M, Geinitz H. Advanced 
techniques in neoadjuvant radiotherapy allow dose escalation without increased 
dose to organs at risk. Strahlenther Onkol. 2013;189:293-300. 
113. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, et al. Dose-Response 
relationship in locoregional control for patients with stage II-III esophageal cancer 
treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol 
Phys. 2005;61(3):656-64. 
114. Geh JI, Bond SJ, Bentzen SM, Jones RG. Systematic overview of preoperative 
(neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a 
radiation and chemotherapy dose response. Radiother Oncol. 2006;78:236-44. 
115. Bedford JL, Viviers L, Guzel Z, Childs PJ, Webb S, Tait DM. A quantitive 
treatment planning study evaluating the potential of dose escalation in conformal 
radiotherapy of the oesophagus. Radiother Oncol. 2000;57:183-93. 
116. Rubin P, Casarett GW. Clinical Radiation Pathology. Vol 1. 1968. 
 249 
117. Gwynne S, Falk S, Gollins S, Wills L, Bateman A, Cummins S, et al. 
Oesophageal Chemoradiotherapy in the UK - A Current Practive and Future 
Directions. Clin Oncol. 2013;25:368-77. 
118. Hawkins MA, Aitken A, Hansen VN, McNair HA, Tait DM. Set-up errors in 
radiotherapy for oesophageal cancers – Is electronic portal imaging or conebeam 
more accurate? Radiother Oncol. 2011;98(2):249-54. 
119. Rapaccini GL, Aliotta A, Pompili M, Grattagliano A, Anti M, Merlino B, et al. 
Gastric wall thickness in normal and neoplastic subjects: a prospective study 
performed by abdominal ultrasound. Gastrointest Radiol. 1988;13(3):197-9. 
120. Pickhardt PJ, Asher DB. Wall thickening of the gastric antrum as a normal 
finding: multidetector CT with cadaveric comparison. AJR Am J Roentgenol. 
2003;181(4):973-9. 
121. Kavanagh BD, Pan CC, Dawson LA, Das SK, Allen X, Haken RKT, et al. Radiation 
Dose-Volume Effectes in the Stomach and Small Bowel. Int J Radiat Oncol Biol Phys. 
2010;76(3):S101-S7. 
122. Gagliardi G, Lax I, Ottolenghi A, Rutqvist LE. Long-term cardiac mortality after 
radiotherapy of breast cancer - application of the relative seriality model. Br J Radiol. 
1996;69(825):839-46. 
123. De Jaeger K, Hoogeman MS, Engelsman M, Seppenwoolde Y, Damen EMF, 
Mijnher BJ, et al. Incorporatin an improved dose-calculation algorithm in conformal 
radiotherapy of lung cancer: re-evaluation of dose in normal lung tissue. Radiother 
Oncol. 2003;69(1):1-10. 
 250 
124. Feng M, Normolle D, Pan CC, Dawson LA, Amarnath S, Ensminger WD, et al. 
Dosimetric Analysis of Radiation-Induced Gastric Bleeding. Int J Radiat Oncol Biol 
Phys. 2012;84(1):e1. 
125. Roeder F, Nicolay NH, Nguyen T, Ebrahimi LS, Askoxylakis V, Bostel T, et al. 
Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as 
definitive treatment of locally advanced esophageal cancer. Radiat Oncol. 
2014;9:191. 
126. Lever FM, Lips IM, Crijns SPM, Reerink O, van Lier ALHMW, Moerland MA, et 
al. Quantification of Esophageal Tumor Motion on Cine-Magnetic Resonance 
Imaging. Int J Radiat Oncol Biol Phys. 2014;88(2):419-24. 
127. Wang J, Lin SH, Dong L, Balter P, Mohan R, Komaki R, et al. Quantifying the 
Interfractional Displacement of the Gastroesophageal Junction during Radiation 
Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):e273-e80. 
128. Langen KM, Jones DTL. Organ motion and its management. Int J Radiat Oncol 
Biol Phys. 2001;50(1):265-78. 
129. Nakamura A, Shibuya K, Nakamura M, Matsuo Y, Shiinoki T, Nakata M, et al. 
Interfractional dose variations in the stomach and the bowels during breathhold 
intensity-modulated radiotherapy for pancreatic cancer: Implications for a dose-
escalation strategy. Med Phys. 2013;40(2). 
130. Kumagai M, Hara R, Mori S, Yanagi T, Asakura H, Kishimoto R, et al. Impact of 
Intrafractional Bowel Gas Movement on Carbon Ion Beam Dose Distribution in 
Pancreatic Radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73(4):1276-81. 
 251 
131. Bouchard M, McAleer MF, Starkchall G. Impact of gastric filling on radiation 
dose delivered to gastroesophageal junction tumours. Int J Radiat Oncol Biol Phys. 
2010;77:292-300. 
132. Urie. M. Ion beams in tumor therapy. Weinheim, Germany: Chapmann & 
Hall; 1995. 
133. Scarfe WC, Farman AG. What is Cone-Beam CT and How Does it Work? 
Dental Clinics of North America. 2008;52(4):707-30. 
134. Kim D-G. Can Dental Cone Beam Computed Tomography Assess Bone Mineral 
Density? J Bone Metab. 2014;21(2):117-26. 
135. Team NCA. National Radiotherpay Implementation Group Report: Image 
Guided Radiotherapy (IGRT) Guidance for implementation and use. 2012. 
136. Watanabe M, Isobe K, Uno T, Harada R, Kobayashi H, Ueno N, et al. 
Intrafractional Gastric Motion and Interfractional Stomach Deformity Using CT 
Images. Journal of Radiation Research. 2011;52(5):660-5. 
137. Isobe K, Uno T, Kawakami H, Ueno N, Kawata T, Ito H. A case of gastric 
lymphoma with marked interfractional gastric movement during radiation therapy. 
International Journal of Clinical Oncology. 2006;11(2):159-61. 
138. Watanabe M, Isobe K, Takisima H, Uno T, Ueno N, Kawakami H, et al. 
Intrafractional gastric motion and interfractional stomach deformity during radiation 
therapy. Radiother Oncol. 2008;87:425-31. 
139. Ganeshan B, Miles KA. Quantifying tumour heterogeneity with CT. Cancer 
Imaging. 2013;13(1):140-9. 
 252 
140. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E. Hypoxia 
and defective apoptosis drive genomic instability and tumorigenesis. Genes and 
Development. 2004;18(17):2095-107. 
141. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment 
strategies. Lancet. 2007;369(9574):1742-57. 
142. Ng F, Kozarski R, Ganeshan B, Goh V. Assessment of tumor heterogeneity by 
CT texture analysis: Can the largest cross-sectional area be used as an alternative to 
whole tumor analysis? European Journal of Radiology. 2013;82(2):342-8. 
143. Alobaidli S, McQuaid S, South C, Prakash V, Evans P, Nisbet A. The role of 
texture analysis in imaging as an outcome predictor and potential tool in 
radiotherapy treatment planning. Brit J Radiol. 2014;87(1042):20140369. 
144. Miles KA, Ganeshan B, Griffiths MR, Young RCD, Chatwin CR. Colorectal 
cancer: Texture analysis of portal phase hepatic CT images as a potential marker of 
survival. Radiology. 2009;250(2):444-52. 
145. Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. Tumour 
heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: A 
potential marker of survival. European Radiology. 2012;22(4):796-802. 
146. Davnall F, Yip CP, Ljungqvist G, Selmi M, Ng F, Sanghera B, et al. Assessment 
of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights 
Imaging. 2012;3(6):573-89. 
147. Chowdhury R, Ganeshan B, Irshad S, Lawler K, Eisenblätter M, Milewicz H, et 
al. The use of molecular imaging combined with genomic techniques to understand 
the heterogeneity in cancer metastasis. Brit J Radiol. 2014;87(1038). 
 253 
148. Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour 
heterogeneity in oesophageal cancer assessed by CT texture analysis: Preliminary 
evidence of an association with tumour metabolism, stage, and survival. Clinical 
Radiology. 2012;67(2):157-64. 
149. Koller CJ, Eatough JP, Bettridge A. Variations in radiation dose between the 
same model of multislice CT scanner at different hospitals. Brit J Radiol. 
2003;76(911):798-802. 
150. Chalkidou A, O'Doherty MJ, Marsden PK. False discovery rates in PET and CT 
studies with texture features: A systematic review. PLoS ONE. 2015;10(5). 
151. Warren S, Partridge M, Bolsi A, Lomax AJ, Hurt C, Crosby T, et al. An Analysis 
of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc 
Therapy Plans and Spot Scanning Proton Planning. Int J Radiat Oncol Biol Phys. 
2016;95(1):199-207. 
152. Fave X, Mackin D, Yang J, Zhang J, Fried D, Balter P, et al. Can radiomics 
features be reproducibly measured from CBCT images for patients with non-small 
cell lung cancer? (0094-2405 (Print)). 
153. van Timmeren JE, Leijenaar RTH, van Elmpt W, Lambin P. 221 - Can we 
replace high quality simulation CT by simple kVcone-beam CT images to extract an 
externally validated radiomics signature? Radiother Oncol.118, Supplement 1:S107. 
 
